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ABSTRACT 
Complex regional pain syndrome (CRPS) is a common problem presenting to 
orthopaedic surgeons or pain therapists, most frequently encountered following 
trauma. The cardinal features are of pain, hypersensitivity, vasomotor instability 
and joint stiffness. The exact cause remains unproven, however an exaggerated 
inflammatory response and free radical induced cellular damage has been 
proposed. A small number of previous studies have highlighted a potential role for 
antioxidants in the prevention of the condition. 
Over the last three decades pain researchers have developed and agreed on a set of 
modified International Association of the Study of Pain (IASP) diagnostic criteria. 
Orthopaedic researchers have developed their own criteria that have been subject 
to much debate as to their validity. 
The diagnosis of CRPS in two hundred and sixty-two patients from a previous study 
have been reanalysed using the Atkins and modified IASP diagnostic criteria of 
Bruehl. The incidence of CRPS was similar using either criteria (Bruehl 20.61 % vs. 
Atkins 22.520/0). Using the Bruehl criteria as a gold standard, there was strong 
diagnostic agreement (K = 0.79, sensitivity = 0.87, specificity = 0.94). 
Two hundred and eleven patients who had sustained an isolated distal radial 
fracture were recruited for a prospective double-blinded randomised control trial 
to assess the efficacy of five hundred milligrams of ascorbic acid in order to prevent 
CRPS. 
Using an intention to treat analysis one hundred and ninety-six were reviewed at a 
minimum of nine weeks. There was no significant difference in the incidence of 
CRPS (chi-squared=1.196, p=0.305) or the incidence or severity of the individual 
features of the condition between the two treatment groups. 
The results of this study suggest that prophylaxis with ascorbic acid does not 
prevent the occurrence of CRPS when diagnosed with validated criteria following a 
distal radial fracture. 
Word count: 291 
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Complex regional pain syndrome (CRPS) is a disabling chronic pain condition of 
unknown aetiology. It has been the subject of much debate and research since its 
first classical description in the 19th century. Despite advances over the last few 
decades in our understanding of this condition, many elements remain 
unanswered. This study's broad aims are to further extend these advances both in 
the conundrum of diagnOSis and possible prevention of the condition in the trauma 
setting. 
CRPS is most commonly encountered following trauma to a limb and is diagnosed 
clinically by the presence of abnormal pain, sensory changes, swelling, vasomotor 
instability, joint stiffness, motor dysfunction, trophic changes and increased 
sudomotor activity. These symptoms and signs are characteristically out of 
proportion to the precipitant cause. The nature of these features inevitably has 
caused the majority of the barriers to the rapid resolution of this condition's exact 
cause and cure by virtue of the fact that until recently its diagnosis has been varied 
and the guidance for identifying it disjointed and haphazard amongst the various 
medical specialists who encounter it. 
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1.2 TERMINOLOGY 
The origins of CRPS can be traced to the 19th Century. Silas Weir Mitchell is 
credited with the first detailed report in 1864 on an intensely painful condition he 
termed with colleagues, causalgia (Mitchell et a1. 1864). The American Civil War, 
and the widespread use of low velocity high mass projectiles led Mitchell to treat 
and observe seven soldiers who had sustained nerve injuries following gunshot 
wounds. He and his colleagues observed intense burning pain recognising that the 
worst cases caused "almost unendurable anguish". Also discussed were the now 
classic skin changes and an early theory on the condition being in part due to a 
reflex phenomena within the nervous system it self. Without wish to detract from 
Mitchell's ingenuity it is possible that one of his teachers during his first few years 
after graduation may have been the first to recognise a syndrome of pain and 
irregularities of the sympathetic nervous system. The English literature is however 
sparse on the exact details of Claude Bernard's work from 19th Century Paris. 
European researchers dominated the new discoveries being made in pain research 
at the beginning of the 20th century. In 1900 Sudeck made two important 
contributions. Firstly, only five years after x-rays had been discovered, he 
described a post-traumatic pain syndrome with oedema, trophic changes and 
osteoporosis or "Knochenatrophie". Secondly, he postulated an inflammatory 
("entzundliche") cause for this observation. Nonne coined the term Sudeck's 
atrophy in 1901. This concept has turned full circle over the last one hundred years 
and an exaggerated inflammatory response remains firmly in the group of mostly 
plausible explanations for the mechanism behind CRPS today. 
In 1916, Leriche, a French vascular surgeon reported the first successful relief from 
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the pain associated with causalgia by performing a peri-arterial sympathectomy, 
thus confirming the work of others before him that the sympathetic nervous plays 
an important role in the aetiology of the condition. 
By the 1930's De Takats had described the concept of a reflex dystrophy of the 
extremities (De Takats 1937) and based on this and Leriches' work Evans 
introduced the popular term Reflex Sympathetic Dystrophy in 1947 (Evans 1947). 
Since then the condition has been described under a number of different guises 
each one having been popularised depending on the precipitating factor, the 
country concerned or by the speciality treating the patient (table 1). To avoid a 
term suggesting aetiology or site the International Association for the Study of Pain 
(IASP), in 1993, agreed on the new nomenclature of CRPS. Two types of CRPS are 
currently recognized: type 1, where there is no discernable nerve damage present 
(formerly termed Reflex Sympathetic Dystrophy) and type 2, where there is a 
discernable nerve injury (formerly termed causalgia) (Stanton-Hicks et al. 1995). 
Table 1 Previous Terms for CRPS 
CRPS type 1 (no discernable nerve injury) 
Reflex sympathetic dystrophy (RSD) 
Siideck's atrophy 
Algodystrophy 
Shoulder hand syndrome 
Painful post traumatic osteoporosis 
Minor causalgia 
Algoneurodystrophy 
Post traumatic pain syndrome 
Painful post traumatic dystrophy 
Transient migratory osteoporosis 
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CRPS type 2 (discernable nerve 




1.3 INVESTIGATIONS AND DIFFERENTIAL DIAGNOSIS 
Fortunately the severe and therefore obvious cases of CRPS are rare following 
trauma. The more common marginal case however does present a diagnostic 
challenge without a single gold standard test that can be easily utilised by clinicians. 
A carefully taken history and initial investigations in these marginal cases should be 
directed to the exclusion of the common mimickers of the condition. 
Adjunct investigations may help but in themselves are not diagnostic. CRPS does 
not cause elevation of routinely available blood and serum markers of systemic 
inflammation such as white blood cell count, C-reactive protein and interleukin-6. 
Other IIresearch-type" systemic markers such as interleukin-8, soluble tumour 
necrosis factor receptor IjII and substance P may be raised in CRPS (Schinkel et al. 
2006). All other routine biochemical indices are also unaffected. 
Plain radiography demonstrates features of rapid bone loss: visible 
demineralisation with patchy, subchondral or sub-periosteal osteoporosis, 
metaphyseal banding and profound bone loss (Kozin et al. 1976b). Bone 
involvement is universal with increased uptake on 3-phase bone scanning in early 
CRPS, this was originally thought to be peri-articular, suggesting arthralgia 
(Mackinnon et al. 1984; Atkins et al. 1993), however CRPS does not cause arthritis 
and studies have shown generalised hyperfixation (Bickerstaff et al. 1993). Later 
the bone scan returns to normal. The debate continues on the reliability of bone 
scanning with varying results on its sensitivity and specificity, particularly in 
relation to the duration of CRPS symptoms (O'Donoghue et al. 1993; Lee et al. 1995; 
Wiippenhorst et al. 2010). The specificity of contrast enhanced Magnetic 
Resonance Imaging (MRI) can be helpful to exclude other pathologies and in CRPS 
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may demonstrate skin thickening, early bone and soft tissue oedema, joint effusions 
and late atrophy with fibrosis but it is not a sensitive screening diagnostic tool in 
the early phase of post traumatic CRPS (Schurmann et al. 2007). 
Temperature difference between the limbs is greater in CRPS than other pain 
syndromes but again this is not useful screening tool in post traumatic CRPS 
(Schurmann et al. 2007). 
1.4 INCIDENCE 
CRPS may occur at any age but it is more common in middle-aged adults. It affects 
both sexes and all races, but is more common in females. 
The full-blown, severe form of CRPS is fortunately rare, reflected by the low 
prevalence following distal radial fracture in historical retrospective studies 
(Bacorn et al. 1953; PI ewes 1956; Green et al. 1956; Frykman 1967; Cooney et al. 
1980). 
Prospective studies specifically designed to identify the occurrence of CRPS have 
consistently shown that a mild form of the condition occurs commonly following 
trauma or surgical insult. Different research groups have reported an incidence of 
11-37% following distal radial fractures over the last three decades (Atkins et al. 
1989a; Roumen et al. 1991; Bickerstaff et al. 1994; Field et al. 1997; Zollinger et al. 
1999; Livingstone et al. 2002; Schurmann et al. 2007) and 30% following tibial 
shaft fractures (Sarangi et al. 1993). Following total knee replacement an incidence 
of 41 % at 3 months and 190/0 at 6 months following surgery has been reported 
(Stanos et al. 2001). Only one prospective study following distal radial fracture has 
demonstrated an incidence of 10/0 or less (Dijkstra et al. 2003). All these 
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prospective studies have employed a variety of diagnostic criteria including the 
most up to date IASP tool based on the original work by Bruehl. 
The apparent higher rate in most studies probably reflects the transient and often 
milder nature of the condition in some individuals, the term "community eRPS" has 
been suggested (Wilson et al. 2005) to represent those individuals who have a 
either a collection of very mild symptoms, or on initial clinical inspection do not 
raise any concerns but nevertheless will have signs and symptoms consistent with 
the diagnosis with careful assessment and if necessary quantitative testing. 
The evidence from contemporary retrospective population based studies from 
North America (Sandroni et al. 2003) and the Netherlands (de Mos et al. 2007) 
provides interesting yet still controversial data, perhaps underreporting the true 
incidence of eRPS and exaggerating the proportion of patients that make a 
relatively quick and full recovery (Bennett et al. 2003). De Mos reported an 
incidence of 26.2 cases per 100,000 person years, with the highest incidence found 
in females aged 61 to 70 years old. Fractures accounted for 44% of initiating 
factors, with the upper limb predominating. 
From the prospective experience of eRPS following a distal radial fracture in 
Bristol, an estimation of the population size (est. 400,000) covered by the Bristol 
Royal Infirmary and the numbers of distal radial fractures treated per year 
(approximately 300) using De Mos' figures would in this centre amount to 104 
cases of eRPS per year for all causes. Estimating 30% could be attributed to a distal 
radial fracture would amount to approximately 30 cases of eRPS following distal 
radial fracture per year (incidence 100/0). Therefore suggesting that the population 
incidence quoted from this study may well be equivalent to those previously 
reported on by researchers from Bristol. 
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1.5 CAUSATION 
Trauma to an extremity is the commonest precipitating event, accounting for up to 
77.6 % of cases (Schwartzman et al. 2009), of the traumatic cases fracture remains 
the usual precipitant (Veldman et al. 1993; Sandroni et al. 2003; de Mos et al. 2007). 
A major difficulty in the understanding of this condition has been why one fracture 
or traumatic insult should give rise to eRPS while an identical fracture or insult in 
another patient or even in a different limb in the same patient does not. In up to 
140/0 of cases no precipitant insult can be identified (de Boer et al. 2011). Whilst 
trauma is the commonest precipitant, eRPS is also reported following a wide range 
of disease processes including: cerebral vascular events (Moskowitz et al. 1958), 
myocardial ischaemia (Steinbrocker 1947), multiple sclerosis (Schwartzman et al. 
2008), brain injury (Gellman et al. 1992), cocaine use (Gay et al. 2000) and herpes 
zoster infection (Richardson 1954). 
1.6 NATURAL HISTORY 
The exact onset of eRPS following a precipitating insult is difficult to ascertain. The 
acute stages of the condition mimic those of acute inflammation, an expected 
finding in the immediate time period following either trauma or surgery. It is 
probable that the majority of cases begin within a month after the initial insult, with 
some cases apparent as early one week following a distal radial fracture (Field et al. 
1997). A minority report the onset of some cases are delayed by up to several 
months, however this questions the relevance of the reported initial insult 
(Veldman et al. 1993). 
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The clinical course and severity following onset is varied, reflected by the reported 
lower incidence following trauma in studies involving established cases. Although 
most cases resolve within a year (Bickerstaff 1990), some features, particularly 
stiffness, remain suggesting eRPS may be responsible for significant long-term 
morbidity even when mild (Field et al. 1992). 
In a detailed quality of life study of thirty-one patients with eRPS for a mean 
duration of 3.3 years, 800/0 of patients reported significant sleep disturbance and 
the majority also reported substantial interference scores in nine out of ten points 
on the modified brief pain inventory quality of life assessment tool (Galer et al. 
2000). A more recent retrospective review of six hundred and fifty-six eRPS 
patients reported that 810/0 of patients had stopped working because of pain 
following disease onset. Of this group only 27% had been able to return to work 
(Schwartzman et al. 2009). 
1.7 THE DIAGNOSTIC CONUNDRUM 
The ultimate goal amongst researchers and clinicians alike has been the discovery 
of a single diagnostic test that allows the disease to be sensitively and specifically 
identified from the extensive list of conditions that share its clinical features. In the 
acute stages of recovery from limb trauma this is a particular problem because of 
the extensive cross over with the symptoms and signs of the physiologically normal 
process of inflammation leading to tissue repair and generation. This goal will 
almost certainly remain unattainable due to the now widely excepted variability in 
the conditions clinical course, possibly more than one underlying 
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pathophysiological causative mechanism and perhaps the existence of more than 
one disease process occurring under the umbrella of the CRPS label. 
What has been achieved so far is the culmination of a process led by the 
International Association for the Study of Pain (lASP) which sort to standardize 
diagnostic criteria and taxonomy amongst researchers, improve clinical 
communication and allow comparison of results from different centres (Harden et 
al. 2001). This process began with a consensus symposia at Schloss Rettershof in 
1988, followed on by a final definitive international workshop in Orlando, Florida in 
1993 leading to this group's publication on the taxonomy and criteria of eRPS 
(table 2). Specifically the consensus agreed not only on what was considered to be 
the clinical hallmarks essential for diagnosis but also those features previously 
thought definitive but deemed to be lacking in scientific support such as motor 
dysfunction, sympathetically mediated pain and osteoporosis. From the outset the 
goals were not to produce the finished definitive article but to provide a framework 
that would evolve by way of systematic testing, fine-tuning and validation. 
Table 2 IASP diagnostic criteria for CRPS 
1) The presence of an initiating noxious event, or a cause of immobilisation. 
2) Continuing pain, allodynia, or hyperalgesia with which the pain is 
disproportionate to any inciting event. 
3) Evidence at some time of oedema, changes in skin blood flow, or abnormal 
sudomotor activity in the region of the pain. 
4) This diagnosis is excluded by the existence of conditions that would otherwise 
account for the degree of pain and dysfunction. 
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The challenge of moving these diagnostic criteria forward has not been without 
issue. The original IASP criteria were intended to be broad and sensitive and more 
recent work has confirmed a lack of specificity, which inevitably leads potentially to 
over diagnosis and unnecessary or incorrect treatment. Therefore when applied to 
a heterogeneous group of patients in the pain clinic setting, those with eRPS will be 
correctly identified, but incorrectly identified with eRPS will be those suffering not 
from eRPS but a variety other neuropathic entities such as diabetic peripheral 
neuropathy and radiculopathy. There are two main reasons for this. Firstly the 
grouping together of distinct elements of the condition into one required criterion, 
namely oedema, vasomotor and sudomotor dysfunction, compounded by the fact 
that these maybe self reported at anytime and do not have to be present at the time 
of assessment. Secondly is the lack of consideration of motor and trophic changes 
which whilst not essential may aid differentiation from other neuropathic 
conditions. 
The challenge of improving the accuracy of diagnosis, in order to maintain the near 
perfect sensitivity but greatly improve the specificity of the original IASP criteria 
has been met by use of internal and external validation techniques. 
Internal validation by factor analysis is a statistical method for identifying linked 
variables within a dataset, in the case of eRPS diagnosis this amounts to the various 
signs and symptoms that are the distinguishing features of the clinical syndrome. 
By statistically grouping related variables together researchers have identified that 
four statistically distinct essential subgroups for eRPS diagnosis exist based on the 
analysis of one hundred and twenty-three patients diagnosed with eRPS according 
to the 1993 IASP diagnostic criteria (Harden et al. 1999). 
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The fourth group contains those features originally not included in the 1993 IASP 
diagnostic criteria, but now believed to be as important as the other groups, 
forming a statistically distinct group with no significant overlap with the other 
three subgroups. This research group have also concluded differentiation between 
clinical symptoms and signs further improved the diagnostic specificity. From the 
same patient group cluster analysis of the symptom/sign subgroups in relation to 
duration of CRPS has shed doubt on the previously described theorem of three 
distinct sequential stages involved in the evolution of the disorder (De Takats 




Early acute phase characterised by pain and sensory dysfunction, 
vasomotor disorder, oedema and excessive sweating. This phase may 
be short or last up to 3 months. 
Dystrophic phase characterised by increasing pain and sensory 
dysfunction, continued vasomotor disorder and the onset of motor 
and trophic changes. 
Atrophic phase characterised by decreasing pain and sensory 
dysfunction, continued vasomotor disorder and marked motor and 
trophic changes with joint stiffness due to contractures. 
Cluster analysis is a pattern recognition tool that enables patients with a similar 
subset of symptoms to be grouped together. Grouping patients and correlating the 
overall duration of CRPS symptoms allowed comparison to the classical three 
stages model. The results of the cluster analysis were mixed; increased duration of 
CRPS did in deed correlate with the presence of sensory dysfunction, and a 
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decreasing likelihood of sweating or oedema abnormalities. However the presence 
of motor and trophic changes did not correlate with duration of symptoms that 
contradicts the expected findings in Stage 3 of the classical stages theorem. 
The other requirement of a validation process is that of external testing, can the 
criteria distinguish between eRPS and patients diagnosed with other neuropathic 
pain conditions? The preliminary report by Galer and colleagues demonstrated 
that applying the 1993 IASP criteria resulted in a diagnosis of eRPS in up to 36.7% 
of patients suffering instead with a painful diabetic neuropathy (Galer et al. 1998). 
The same research group has confirmed the limitation of the 1993 IASP diagnostic 
criteria on a larger population. Assessing a group of one hundred and seventeen 
patients with eRPS according to the 1993 IASP criteria and forty-three neuropathic 
pain patients, the 1993 IASP criteria could not discriminate significantly between 
the two groups. Instead a four subgroup diagnostic model proposed following 
internal validation and factor analysis that requires the presence of signs and 
symptoms has demonstrated an increase in diagnostic accuracy. Various 
combinations of required numbers of symptoms and signs from each factor 
subgroup were subject to testing, the most specific combination being four of four 
symptom categories and two of four sign categories to be positive. This yielded a 
sensitivity of 0.70 and a specificity of 0.94 (Bruehl et al. 1999) (table 3). These new 
criteria were adopted and recommended to the IASP by a consensus workshop in 
Budapest in 2003 as a research tool. A separate but linked clinical diagnostic 
criteria tool has also been proposed with increased sensitivity. This tool differs 
from the research version by requiring only three positive responses from the four 
symptom categories. Recently these new criteria have themselves been externally 
validated amongst a pain clinic population of one hundred and thirteen patients 
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diagnosed with eRPS according to the 1993 IASP criteria and forty-seven patients 
with other neuropathic pain conditions. The results of improved specificity with 
maintenance of an excepted level of sensitivity mirrored those of the earlier study, 
however the anticipated differences in specificity between the research and clinical 
criteria were not evident, raising the question of whether two separate tools are 
indeed needed (Harden et al. 2010). 
Table 3 Modified (ASP diagnostic criteria for CRPS research 
Continuing pain that is disproportionate to any inciting event. 





Sensory: Reports of hyperaesthesia. 
Vasomotor: Reports of temperature asymmetry and/or skin colour changes 
and/or skin colour asymmetry. 
Sudomotor/Oedema: Reports of oedema and/or sweating changes and/or 
sweating asymmetry. 
Motor/trophic: Reports of decreased range of movement and/ or motor 
dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, 
__ __ nails, skl!l) ~________________________________ _______________________________________ .. ______________________________ _ 
2) Must display at least one sign in two or more of the following categories: 
• Sensory: Evidence of hyperalgesia and/or allodynia. 
• Vasomotor: Evidence of temperature asymmetry and or skin colour changes 
and/or asymmetry. 
• Sudomotor/Oedema: Evidence of oedema and/or sweating changes and/or 
sweating asymmetry. 
• Motor/Trophic: Evidence of decreased range of motion and/or motor 
dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, 
__________ nails, ~kin)~ _________ .. ________________________ ~ _____________________ ~ _____________________________ _ 
A further benefit of the revised IASP criteria has also been demonstrated by virtue 
of improved intra observer agreement between clinicians with the new criteria 
over the original 1993 criteria (de Mos et al. 2007). 
There is little evidence to doubt that the evolution of these new criteria will 
improve patient care and also harmonise future pain focused research into both 
eRPS and other perhaps related non-eRPS pain conditions. Whilst these criteria 
have been shown to be valid within the setting of a pain clinic, their integrity within 
an orthopaedic fracture clinic remains unknown. Pain clinicians have solace in the 
knowledge that these criteria will with a considerably powerful degree of accuracy 
distinguish eRPS from non-eRPS neuropathic pain amongst their clinic population. 
The orthopaedic surgeon however is faced with the diagnostic dilemma of 
distinguishing potential eRPS from a number of other commonly encountered 
conditions in the fracture clinic environment such as infection, stress fractures, 
mechanical factors following recent surgery, neuropathy and in particular the 
normal sequelae of the inflammatory cascade and tissue repair and generation. 
Whilst a number of these differential diagnoses can be eliminated with simple 
investigations such as serum inflammatory markers and radiological investigations, 
a significant proportion will not and therefore the possibility of eRPS as a diagnosis 
will be raised. 
1.8 CLINICAL FEATURES 
1.8.1 Signs and Symptoms 
Rather than the classical model of the typical eRPS patient moving sequentially 
through three stages of the condition, the widely accepted view is that of a biphasic 
condition that begins up to a month after the precipitating event. In the acute stage 
of the condition, the symptoms and signs of regional inflammation affecting an area 
larger than the site of injury are characteristic (Figure 1). Later this inflammatory 
picture is replaced by atrophy and contracture (Figure 2). 
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Figure 1 Early CRPS affecting the right hand, following a distal radial fracture. 
Figure 2 Late CRPS affecting the left hand. (pictures courtesy of Prof. R Atkins) 
The condition may spread peripherally and in extreme cases involve the originally 
unaffected limb (Veldman et al. 1993; Veldman et a1. 1996). The pattern of spread 
maybe contiguous or independent in the ipsilateral limb and mirrored if affecting 
the contralateral limb (Maleki et a1. 2000). Recurrence after a period of remission 
from most if not all symptoms can occur, 53% of which are spontaneous (Veldman 
et a1. 1996). Whether recurrence is more likely following surgery to the same or 
differing limb remains unanswered (Dielissen et a1. 1995; Zyluk 2004) , the 
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literature lacks any prospective studies perhaps implying that most would agree 
that surgery in the presence of severe symptoms is risky. Specific management 
measures taken around the time of surgery such as prophylactic calcitonin, precise 
surgical technique and early postoperative mobilisation may be important (Marx et 
al. 2001). 
1.8.2 Pain and Sensory Disturbance 
Throughout the course of eRPS, the pain experienced is neuropathic. Spontaneous 
pain, hyperalgesia, allodynia and hyperpathia (table 4) are common but not 
universal and may not coexist. Pain in the worst examples is unremitting, 
worsening and may radiate with time. In others it may fluctuate and be affected by 
environmental changes. It is disproportionate to the precipitating insult. 
Table 4 1986 IASP Pain definitions 
'---------- ------
• Pain: An unpleasant sensory and emotional experience that we primarily 
associate with tissue damage or describe in terms of tissue damage or both. 
• Allodynia: Pain due to a stimulus that does not normally provoke pain. 
• Hyperaesthesia: Increased sensitivity to stimulation, excluding special senses. 
• Hyperalgesia: An increased response to a stimulus that is normally painful. 
• Hyperpathia: Pain characterised by an increased reaction to a stimulus, 
especially a repetitive one, as well as an increased threshold. 
The distribution of pain tends to be distal to the site of injury and is more 
commonly dorsal when involving the limb (Schwartzman 1993). It is often diffuse 
and not limited to the territory of a single peripheral nerve, dermatome or neuronal 
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plexus. Movement, temperature changes, dependent posture, auditory and visual 
stimuli and emotional upset can all induce a hyperaesthesia (Birklein et al. 2000). 
Classical teaching describes the pain as burning in nature, this however this may 
not be the primary descriptor in many individuals. Sensory pain descriptors rather 
than affective descriptors predominate such as tearing, stinging, and aching in 
addition to hot or burning. The majority will localize the pain as deep in the affected 
limb rather than superficial and the pain tends to be permanent rather than 
episodic, particularly with increasing disease duration (Birklein et al. 2000; 
Schwartzman et al. 2009). 
Other sensory symptoms such as numbness and paraesthesias are also reported to 
be common and one study a third of patients had hemisensory impairment as the 
disturbances of pain and sensory processing (Rommel et al. 1999). 
In a questionnaire study of limb neglect symptoms amongst two hundred and 
twenty-four CRPS patients 840/0 of responders agreed with at least one cognitive or 
motor neglect statement (Galer et al. 1999). 
1.8.3 Vasomotor Instability, sudomotor activity and oedema 
The salient features of an inflammatory process in the early stage of the condition 
are similar to those due to vasomotor instability (VMI). These include skin colour 
changes (pink or red), swelling, altered skin temperature and changes in 
sudomotor function (Figure 3). These symptoms maybe variable and can be related 
to exercise, painful stimuli and changes in environment. Probably due to 
combinations of differing and perhaps in part antagonistic pathophysiological 
mechanisms vasomotor changes are not static (Wasner et al. 2005). In a 
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prospective study of eight hundred and twenty-nine patients 91% had skin 
discolouration, 920/0 had altered skin temperature and 47% had hyperhidrosis. The 
same study subdivided the acute stage into two distinct groups depending on the 
temperature difference findings. The longer the duration of symptoms the more 
likely the finding of cold limb, therefore the terms "warm" and "cold" CRPS were 
coined (Veldman et al. 1993). 
Figure 3 Increased sudomotor function in a foot affected by CRPS. (Picture courtesy of 
Prof. R Atkins) 
Sudomotor dysfunction has been demonstrated under controlled conditions in 
CRPS subjects to be more likely due to peripheral post ganglion induced sudomotor 
stimulation or possible increased sweat gland responsiveness rather than a 
disturbance in the central thermoregulatory mechanism (Birklein et al. 1997b). 
The neuropeptide calcitonin gene related peptide (CGRP) enhances sweat gland 
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activity in normal subjects and is implicated in pathomechanisms related to other 
CRPS features (Schlereth et al. 2006). 
Early oedema may be diffuse or localised and was present in 86% of patients 
examined within two months of onset of symptoms when studied by Veldman 
prospectively (Veldman et al. 1993). In this study the drop in incidence of oedema 
compared to duration of symptoms was more marked than those other early 
symptoms and signs observed such as pain, colour change and temperature 
difference. 
Measurement can be performed simply by either volumetric hand assessment 
utilising water displacement with the contralateral hand as a surrogate baseline 
measure, or by limb or digit circumference measurement. 
Local oedema is caused in part by tissue fluid extravasation secondary to changes in 
small blood vessel diameter and vessel wall permeability. These vascular changes 
are under the influence of a number of neuropeptides released by abnormally 
activated somatic fibres that in affect can mimic the normal physiological affects of 
the sympathetic nervous system. This neuronal phenomenon has been artificially 
exaggerated in CRPS patients by measured increases to local blood flow and protein 
extravasation following transcutaneous electrical excitation of all classes of C-fibres 
in the affected CRPS limb in comparison to healthy control subjects (Weber et al. 
2001). Other possible mechanisms include alterations to autonomically regulated 
lymphatic flow (Howarth et al. 1999). 
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1.8.4 Motor and trophic changes 
Motor symptoms are present in the majority of cases and can include tremor, 
weakness, exaggerated tendon reflexes, dystonia, paresis, akinesia, bradykinesia 
and myoclonic jerks (Birklein et al. 2000; Schwartzman et al. 2009; Veldman et al. 
1993). Joint positioning motor skills are also profoundly affected (Lewis et al. 
2010). Originally not included in the 1993 IASP criteria, recent studies have 
demonstrated their importance to improving the specificity of diagnostic criteria 
(Bruehl et al. 1999; Harden et al. 1999; Harden et al. 2010). 
Limited active range of movement contributes significantly to the disability 
associated with the disorder both in the acute stages and chronically in the cold 
atrophic phase. If contractures manifest then these will be difficult to treat. 
Cosmesis may be of concern to some individuals (Zyluk 2001). 
The aetiology of joint stiffness is multifactorial. Early in the disease pain, joint 
tenderness, oedema, ill-fitting splints joint capsule contracture, collateral ligament 
shortening and early flexor tendon sheath adhesions may all contribute to the 
process. (Figure 4). 
Articular cartilage of the finger joints has not been implicated in loss of finger 
movements (Doury et al. 1981). Later in the disease evolution muscle fibrosis and 
skin contractures will perpetuate the problem. 
With a significant number of patients also experiencing disturbances to the motor 
system that can occur early in the condition, these factors will almost certainly 
contribute to this feature of the disease. 
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Figure 4 Late onset finger contractures in CRPS (Picture courtesy of Prof. R Atkins) 
The skin is thin with joint creases and subcutaneous fat disappearing. Brown-grey 
scaly pigmentation develops in a high proportion of patients. Hairs become fragile, 
uneven and curled. Changes in hair growth were observed in 55% of patients in 
Veldman's prospective series Veldman 1993. Calcitonin gene related peptide, a 
neuropeptide, implicated in the pathogenesis of CRPS has numerous receptors on in 
human hairy skin and may be the explanation to this finding (Hagner et al. 2002). 
Normal finger and toe growth may also be impaired with pitting, ridging, fragility 
and discolouration. Palmar and plantar fascias can thicken and contract causing 
Dupuytren's disease (Livingstone et al. 1999). 
1.B.5 Regions affected 
The upper limb is more commonly affected than the lower (Veldman et al. 1993; de 
Mos et al. 2007) . Distal involvement tends to predominate probably due to the 
relatively higher occurrence of injuries at the wrist in the general population. 
When the entire arm is affected the elbow tends to be spared. Patients with distal 
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upper limb eRPS have a significant incidence of associated shoulder complaints 
(the so called shoulder-hand syndrome). In most this may be due to a biceps 
tendonitis. (Veldman et a1. 1995). It is probable that a significant proportion of 
frozen shoulders can be considered a form of eRPS (Steinbrocker 1968). The 
clinical similarities between the two are supported by changes observed on bone 
scans and plain radiographs (Muller et a1. 2000). eRPS can occur following surgical 
procedures in the upper limb such as carpel tunnel decompression (whether 
performed endoscopically or as open procedure), and Dupuytrens release. eRPS 
affecting the lower limb is recognised following both trauma and surgery. These 
include tibial fractures, amputations and crush injuries to the foot. As well as the 
periphery of the lower limb, eRPS and insults to the knee have also been 
extensively reported on (Katz et a1. 1986; Katz et a1. 1987; Stanos et a1. 2001). 
Rarely it can complicate pregnancy (Perka et a1. 1998; Poncelet et a1. 1999). eRPS 
affecting the face (Melis et a1. 2002) and thoracic wall (Rasmussen et a1. 2009) have 
been described. 
1.9 PATHOGENESIS 
The development of eRPS probably almost certainly involves at least two linked 
pathophysiological processes, one occurring at the site of the injury, involving local 
soft tissues and the peripheral nervous system. The second occurring in the central 
nervous system leading to altered reflexes and neuronal pathways. A number of 
theories have been investigated and discussed (Figure 5): 
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o Central sensitisation 
• Sympathetic nervous system 
-Sympathetic mediated pain 
• Genetic predisposition 
o 1m mobilisation 
• Exaggerated inflammatory 
response 
-Free radical damage 
o Psychological factors 
- Neurogenic inflammation 
- Peripheral sensitisation 
Figure 5 Proposed mechanisms involved in the development of eRPS. 
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1.9.1 Genetic predisposition 
Evidence for an inherited component to the development of neuropathic pain has 
been described in both animal and human studies. Support for inherited forms of 
CRPS arises both from studies of familial prevalence and searches for linked genetic 
factors by human genomic analysis. 
Familial CRPS occurrence has been described in thirty-one families with between 
two and five affected members. Although a clear pattern of inheritance was not 
identified, familial cases of CRPS tended to be more severe and occur at a younger 
age in comparison to individuals with sporadic CRPS (de Rooij et al 2009). The 
condition has been linked to certain variations (polymorphisms) of genes encoding 
angiotensin-converting enzyme (ACE) and human leukocyte antigen (HLA) class I 
and II molecules (Mailis et al. 1994; de Rooij et al. 2009). These genes have a high 
amount of variation and, as they are inherited in a Mendelian fashion, can be useful 
as genetic markers of disease but may also be linked to disease severity, 
progression or phenotype. Of note is that ACE helps to degrade neuropeptides 
linked with neurogenic inflammation such as bradykinin and a small study of CRPS 
patients found a greater prevalence of genetic anomalies in the ACE gene compared 
to controls (de Mos et al. 2009). This observation has however been challenged by 
other investigators (Hiihne et al. 2004). 
In the first prospective examination for genetic factors in patients at risk of 
developing CRPS following a distal radial fracture an increase in the prevalence of a 
known polymorphism for the gene encoding the ula-adrenoceptor I was identified 
in those patients who developed CRPS according to the Bruehl criteria. Other 
known polymorphisms for genes encoding ACE, interleukins, TNFu, transforming 
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growth factor 13, tachykinin and its receptor, calcitonin gene-related peptide, and 
neuropeptide Y were found not to be more prevalent in the CRPS group (Herlyn et 
al. 2010). 
1.9.2 Sympathetic nervous system abnormalities 
The diagnosis of CRPS is dependent on the presence of the symptoms and signs of 
vasomotor instability and trophic changes suggesting sympathetic nervous system 
(SNS) dysfunction. Although the SNS is not normally active in the processing and 
transmission of noxious stimuli in some cases of CRPS the phenomenon of 
sympathetically maintained pain (SMP) exists (Stanton-Hicks et al. 1995). SMP 
maybe relieved by stellate ganglion block to the affected limb (Price et al. 1998) and 
then restored by norepinephrine injection (Torebjork et al. 1995). In CRPS patients 
diagnosed with SMP it has been demonstrated that administering intradermal 
norepinephrine at physiological concentrations evokes greater pain in the affected 
limb than in the contralateral limb or in control subjects (Ali et al. 2000). Further 
evidence arises from the observations that increasing sympathetic activity worsens 
spontaneous pain, mechanical allodynia (Janig 2001) and thermal hyperalgesia 
(Drummond et al. 2001) in CRPS patients. 
The development of norepinephrine-evoked pain may however be time dependent 
and did not affect patients with early acute CRPS in one study (Birklein et al. 
1997a). This finding may well explain why intra venous regional sympathetic 
blockade with guanethidine, traditionally a mainstay of treatment in resistant 
cases, does not improve the symptoms or alter the natural history of CRPS 
following a distal radial fracture (Livingstone et al. 2002). 
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The mechanism by which the SNS may be involved in CRPS pain is not clear. 
Adrenergic supersensitivity in the affected limb may explain this in a number of 
ways. The density of al adrenoceptors is increased in the non-vascular epidermal 
tissue of symptomatic limbs, following partial nerve injury, when both injured and 
uninjured somatic axons start to express al adrenoceptors (Davis et al. 1991; 
Drummond et al. 1996). Cutaneous vasculature shows increased responsiveness to 
noradrenalin in limbs of CRPS patients (Arnold et al. 1993). Thus adrenergic 
supersensitivity could lead to sympathetic over activity causing the sensitisation of 
the somatic sensory nervous system to circulating catecholamines and 
noradrenalin released from post-ganglionic sympathetic terminals. Adrenergic 
supersensitivity may cause vasoconstriction, aggravating tissue inflammation, 
causing a build up of nociceptive mediators produced during the inflammatory 
process. Alternatively adrenergic supersensitivity might interfere with the normal 
production of mediators such as nerve growth factor (NGF). al adrenergic activity 
increases the secretion of NGF, an inflammatory mediator known to stimulate the 
growth of nociceptive afferents and to cause the release of nociceptive mediators 
from mast cells, sympathetic neurones and macrophages (Tuttle et al. 1993). 
Increased az adrenergic activity in the SNS stimulates the synthesis of 
prostaglandins E and I both potent in increasing the excitability of nociceptive 
afferent nerve fibres (Gonzales et al. 1991). 
1.9.3 Peripheral Sensitisation 
Changes in normal neuronal functioning, leading to pain hypersensitivity, including 
allodynia has been attributed to neuronal plasticity. This physiological process is 
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an ongoing phenomenon that reflects changes in neuronal environment and activity 
(Woolf et al. 2000). The experience of pain occurs when small fibre nociceptors (C 
and AS fibres in the skin) are stimulated. These fibres normally require significant 
energy and hence a stimulus that is tissue threatening or damaging for a pain to be 
felt. These fibres are however activity dependent and if stimulated at low intensity 
the perception is crude touch. 
If the stimulus is repetitive and potentially threatening these nOciceptors can 
become sensitised, decreasing their threshold to fire. This is a normal adaptive 
physiological response to injury. Unfortunately this response can become harmful 
when the threatening environment recedes but the nociceptors remain sensitised. 
This pathophysiological state is further compounded by the fact that these small 
fibres proliferate in response to the pro-inflammatory soup of cytokines, 
neurotransmitters and growth factors that are released locally during the initial 
injury phase. 
Histological studies of peripheral nerves from patients with CRPS (type 1) have 
shown normal efferent nerve fibres but abnormal C-nociceptive fibres (van der 
Laan et al. 1998b). 
A combination of activity dependent firing, an adaptive response to a repeated 
stimulus and proliferation in response to an injury environment leads to a vicious 
circle of continuing pain without a noxious stimulus present. 
1.9.4 Central processing changes 
The unexplained pain of CRPS has been linked to central sensitisation. Following 
nerve injury, both injured and non-injured sensory afferents can fire 
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spontaneously. Prolonged input to the dorsal horn as a result of spontaneous firing 
in C fibre nociceptors sensitises dorsal horn neurons so that they abnormally 
respond to innocuous inputs, this may lead to an exaggerated dorsal horn response 
to A-fibre input and thus allodynia. Peripheral nerve injury may also reduce the 
affect of central descending inhibitory pathways. The spread of pain beyond the 
territory of an affected nerve can be reversed by certain receptor antagonists 
implicated in central sensitisation (Woolf et al. 1999). 
1.9.5 Fracture management 
The incidence of eRPS following tibial shaft fracture is not affected by the method 
of fracture management employed (Sarangi et al. 1993). The initial degree of 
fracture displacement, a surrogate marker of injury severity, is linked statistically 
to the development of CRPS (Livingstone 2000) along with increasing Frykman 
grade and ulnar styloid involvement (Bickerstaff et al. 1994). The method of 
anaesthetic employed for initial fracture reduction, the quality of reduction and the 
need for further manipulations following distal radial fracture does not appear to 
be influential (Atkins et al. 1990; (Livingstone 2000). Excessive plaster of Paris cast 
tightness has been linked to the development of CRPS following distal radial 
fracture (Field et al. 1994). Immobilisation has been proposed to cause a "neglect-
like" phenomenon in which the patients find difficulty in initiating movement or 
accurately directing it (Galer et al. 2001). Learned pain avoidance behaviour in 
response to allodynia may exacerbate changes of disuse since normal tactile and 
proprioceptive input are necessary for correct central nerve signal processing. 
Indeed, it has been suggested that abnormal mobility is the entire cause, due to loss 
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of integration between sensory input and motor output (Harris 1999; McCabe et al. 
2003). 
1.9.6 Psychological factors 
Some physicians may feel that the complex array of symptoms, the seemly 
innocuous "minor trauma" preceding the onset (or in deed lack of trauma) and the 
lack of conclusive diagnostic test or imaging points to CRPS being primarily of 
psychological origin. This concept, however, is unsupported (Bruehl 2001). 
Although several studies have linked certain psychological factors with CRPS 
including emotional lability, low pain threshold, hysteria, depression and 
antecedent psychological stress, most CRPS patients are normal (Vincent et al. 
1982). One proposed theory is that of a complex interaction between the, now 
apparent, pathophysiological models for the disease and certain psychological 
processes to explain the progression and longevity seen in certain patients. (Bruehl 
et al. 1996). 
1.9.7 Exaggerated inflammatory response and free radicals 
In the acute stages of CRPS the condition demonstrates all the classical symptoms 
and signs of inflammation: rubor, calor, dolor, tumor and functio laesa (Veldman et 
al. 1993). Sudeck first postulated that an exaggerated inflammatory response could 
contribute to the aetiology of the condition he described in 1900. Over the last 
three decades this theory has been revived and investigated. 
A number of clinical studies indicate that CRPS patients display significant 
increases in the pro-inflammatory cytokines TNF-a and interleukins -1~, -2, and -6 
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in local blister fluid, circulating plasma, and cerebrospinal fluid (Huygen et al. 2002; 
Alexander et al. 200S; Wesseldijk et al. 2008; Kramer et al. 2011) and decreases in 
the plasma levels of the anti-inflammatory cytokines interleukins -4 and -10 
(U~eyler et al. 2007). One source of these locally derived inflammatory mediators 
in the skin are activated keratinocytes (Li et al. 2010). 
Using Indium-lll labelled human non-specific polyclonal immunoglobulin G (In-
lll-IgG) as a macromolecule and scintigraphy, a significant increase in blood flow 
and accumulation of In-lll-IgG in the affected hand was identified in patients with 
upper limb eRPS. This observation was reduced in the subgroup of patients 
included with a diagnosis of eRPS for greater than five months implying that a 
transient increase in vascular permeability occurs early in the disease, indicating an 
inflammatory process (Oyen et al. 1993). 
In a small study of six eRPS patients compared to control subjects with a distal 
radial fracture a significant difference in the accumulation of radiolabeled 
autologous leukocytes in the affected hands of the eRPS group at a mean of seventy-
one days post injury or surgery was observed suggesting an ongoing inflammatory 
response (Tan et al. 200S). 
It has been known for some time that leukocytes are a source of reactive oxygen 
species or free radicals (Babior et al. 1973) and tissue damage following acute 
inflammatory processes is caused in part by free radical deposition (Ward et al. 
1983; Fantone et al. 1982). Evidence for the involvement of free radicals in the 
development of the eRPS has been reported by a number of researchers. 
An animal model has demonstrated a eRPS-like limb following infusion of the free 
radical donor tert-butylhydroperoxide directly into the hind limb of a rat. 
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Significant differences in comparison to a control group of animals injected with 
saline were observed with respect to skin temperature, limb volume, the presence 
of erythema, impaired limb function and pain assessment by observation. 
Histological analysis of the hind limb musculature 24 hours after infusion showed 
cellular degeneration, oedema and leukocyte infiltration (van der Laan et al. 
1998a). Amputated human specimens affected by CRPS show basement membrane 
thickening consistent with overexposure to free radicals (van der Laan et al. 1998b) 
and mitochondrial dysfunction in end stage CRPS (Tan et al. 2011). Maternally 
inherited disorders of mitochondrial dysfunction have also been linked to the 
development of CRPS in children (Higashimoto et al. 2008). 
Salivary markers of oxidative stress are increased in CRPS patients when compared 
to controls, a finding that may be a useful non-invasive way to monitor future 
treatments (Eisenberg et al. 2008). 
In another recently reported animal study, a chronic post-ischaemia pain (CPIP) 
model in a rat has created CRPS-like limb following prolonged ischaemia with a 
tourniquet (Coderre et al. 2004). Whilst the larger neurological structures close to 
the tourniquet do not show signs of injury under detailed microscopic assessment, 
smaller cutaneous nerve ending density in the injured limb is decreased. Also 
observed is the presence of microvascular pathology in the digital nerves and limb 
musculature. This model, in support of an inflammatory process, has demonstrated 
an early rise in the measured local levels of the pro-inflammatory cytokines; 
tumour necrosis factor alpha, interleukin-1 and interleukin-6, and the related 
transcription factor, nuclear factor kappa B in the rat limb soon after the 
development of CRPS-like symptoms. 
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In addition Malondialdehyde, a product of free radical-induced lipid peroxidation, is 
significantly elevated. With the introduction of free radical scavengers, hind limb 
allodynia can be ameliorated, suggesting a key role of free radicals (Laferriere et al. 
2008). This model has led the researchers theorise that the observed early 
inflammatory response to an ischaemia-reperfusion injury produces a form of self 
perpetuating sub acute compartment syndrome that impairs capillary blood flow to 
muscle, nerve, and bone by a "slow-flow /no-reflow" phenomenon (Coderre et al. 
2010). 
In an animal model nitric oxide significantly increases the excitatory neuropeptide 
Substance P release from the peripheral endings of small diameter primary afferent 
neurones (Yonehara et al. 1999). Substance P has been implicated in CRPS via the 
process of neurogenic inflammation. Increased nitric oxide release from the 
leukocytes derived from CRPS patients has been shown following in vitro 
stimulation by the cytokines interleukin-lb and interferon-g (Hartrick 2002). 
1.9.8 Free Radicals and Smoking 
Tobacco smoke is made up of a complex mixture of chemicals including a large 
number known to be free radicals. These compounds exist both in the solid tar 
phase and the gas smoke phase and most have a long half life (Valavanidis et al. 
2009). As well as containing free radicals, tobacco smoke increases the oxidative 
metabolism of leukocytes, a process that in itself releases further free radicals such 
as superoxide, hydrogen peroxide and hydroxyl radicals (Ludwig et al. 1982). 
Depletion of antioxidant levels such as ascorbic acid is known to occur in smokers 
and those exposed to passive smoking (Tribble et al. 1993; Lykkesfeldt et al. 1997). 
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This is due in part to an increased utilization of ascorbic acid to buffer the increased 
levels of free radicals but also may be due to decreased dietary in take when 
compared to non-smokers (Tribble et al. 1993). 
The role of smoking in the pathogenesis of CRPS has not extensively investigated 
and the few reports available are conflicting. An et al from Ohio observed in a 
retrospective study on fifty-three consecutive CRPS patients an increase in the 
prevalence of current active smoking at the time of diagnosis when compared to a 
cohort of control patients made up from hospitalized patients without CRPS (68% 
vs. 370/0) (An et al 1988). More recently retrospectively reviewed data from a 
larger cohort of six hundred and fifty-six patients from Philadelphia diagnosed with 
CRPS recorded a prevalence of smoking at the time of diagnosis of approximately 
50% (Schwartzman et al. 2009). These figures would suggest smoking is a factor 
given the national prevalence of smoking in North America at the time of these 
reports was around 30% and 20% respectively (www.cdc.gov). In contrast a 
prospective study of one hundred and fourteen patients with a distal radial fracture 
found no link between the development of CRPS and a smoking history (Goris et al. 
2007). 
1.9.9 Neurogenic Inflammation 
Stimulation by increased cytokine activity maintains a nociceptors reaction to an 
injury by a process called neurogenic inflammation. During this process 
neuropeptides including substance P, calcitonin gene-related peptide (CGRP) and 
somatostatin are released from neurones. Peripherally neuropeptides contribute 
to changes in vascular permeability whilst centrally they have an excitatory affect. 
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In 1931 von Euler and Gaddum described a tissue extract, preparation P, that they 
noted caused intestinal contraction and vasodilatation. This was a novel substance 
compared to known vasodilators such as histamine, choline, adenosine and 
kallikrein by virtue of its differing chemical and physical properties (V Euler et al. 
1931). 
Substance P is a member of the Tachykinin family of neuropeptides along with 
neurokinins A and Band neuropeptides K and y. It is synthesised predominately in 
type B cells of the dorsal root ganglion in response to stimulation of primary 
afferent nociceptive C fibres. Of the three associated receptor subtypes so far 
identified, Substance P has the greatest affinity for the neurokinin-1 (NK-1) subtype 
(Cascieri et al. 1992). 
Substance P is widely distributed within primary sensory neurones throughout the 
body, but predominately within the central and peripheral nervous systems. The 
mapping of the distribution of NK-1 receptor subtypes has also revealed its 
abundance in bone (Goto et al. 1998). With this knowledge and a myriad of in vitro 
an in vivo studies Substance P has been linked with a variety of physiological and 
pathological actions including pain transmission, neurogenic inflammation, smooth 
muscle contraction, vasodilatation and modulation of bone cell function. 
Due to its involvement with these processes, Substance P has been investigated 
with respect to the underlying pathophysiology of CRPS. Blair et al observed that 
serum levels of a number of different neuropeptides including CGRP, bradykinin, 
and vasoactive intestinal peptide (VIP), but not Substance P were raised in CRPS 
patients (Blair et al. 1998). Leis et al demonstrated an increase in plasma protein 
extravasation following a subdermal injection of Substance P into the skin of CRPS 
patients when compared to control subjects in both their affected and unaffected 
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limbs (Leis et al. 2003). Demonstrating this process occurring in the unaffected 
limb supports the theory of an underlying predisposition, either an increased 
natural density of NK-1 receptors or an impairment of deactivation of Substance P. 
Facilitated neurogenic inflammation by artificial exaggeration in CRPS increases 
local blood flow and protein extravasation following transcutaneous electrical 
excitation of all classes of C-fibres in the affected CRPS limb in comparison to 
healthy control subjects (Weber et al. 2001). This process however appears not be 
present in the unaffected limbs of CRPS patients implying an initiating event is 
required to up regulate neuropeptide synthesis and transmission (Leis et al. 2004). 
Infusion of exogenous substance P into an extremity mimics the signs and 
symptoms of CRPS in a rat model (Gradl et al. 2007) and intrathecal injection in 
another rat model causes thermal hyperalgesia along with release of excitatory 
amino acids and prostaglandin Ez (Hua et al. 1999). Other groups have postulated 
that a defect in neuropeptide enzymatic breakdown may play a role, a theory 
supported by the observation of the measured effects of an induced neurogenic 
inflammation in healthy subjects following percutaneous infusion of 
phosphoramidon, a neuroendopeptidase inhibitor (Kramer et al. 2005). 
In some CRPS patients it appears glucocorticoids can be beneficial (Braus et al. 
1994) (Christensen et al. 1982). This evidence has found support from an animal 
model of CRPS (type 2) whereby neurogenic extravasation and mechanical and 
thermal hyperalgesia were reversed following a continuous infusion of 
methylprednisolone (Kingery et al. 2001a; Kingery et al. 2001b). Under similar 
conditions a substance P receptor antagonist reverses the extravasation, warmth 
and oedema seen (Kingery et al. 2003). A major breakthrough was made by the 
same group when they demonstrated similar results with a substance P antagonist 
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and glucocorticoids in a closed tibial fracture rat model, the closest model yet to 
CRPS (type 1) in humans (Guo et al. 2004). Of interest in the same study was the 
fact that in some control rats who were immobilised but not injured a temporary 
CRPS-like syndrome developed, in keeping with findings observed in healthy 
human volunteers (Butler 2001). 
An understanding of the effects of Substance P on osteoblasts, osteoclasts and their 
derivative cell precursors may explain the associated bony changes seen on both 
simple radiographs and bone scintigraphy. Periarticular patchy osteoporosis and 
the generalised uptake on the delayed phases of scintigraphy have been noted by 
several authors and subject to a variety of theories. 
Normal bone turnover is a complicated and not fully understood process, 
controlled by a number of factors. N europeptide signalling is one such factor and 
has been subject to extensive research. Conflicting reports exist on both the 
presence of Substance P NK-1 receptors in bone and bone cells and the effect of 
Substance P on cellular activity and function within bone. There appears to be an 
important role for Substance P in both bone formation and resorption. 
Some authors report an increase in mature osteoblast numbers as well as protein 
production and mineralisation whilst others report an inhibitory effect on alkaline 
phosphatase activity, mineralisation and osteoblastic gene expression in the 
presence of Substance P (Liu et al. 2007). These differences may be due to the time 
dependent expression of the NK-1 receptor as suggested by more recent studies 
supporting the stimulatory theory (Goto et al. 2007; Wang et al. 2009). 
Substance P is involved in bone resorption, it has a stimulatory affect on osteoclast 
numbers and activity probably via activation of Nuclear factor kappa B (NF-KB), a 
52 
protein that controls the transcription of DNA (Sohn 2005). It may also have 
indirect effects on resorption by increasing inflammatory cytokine levels such as IL-
l, IL-6 and TNF-a, all of which stimulate osteoclastic activity (Liu et a1. 2007). 
Substance P therefore has the ability to stimulate bone formation and resorption, a 
difference almost certainly dependent on dose and an observation that might 
contribute to the mechanisms causing the bone density changes found not only in 
eRPS but other chronic disease states such as rheumatoid arthritis and 
osteoporosis. 
1.10ANTIOXIDANTS AND COMPLEX REGIONAL PAIN SYNDROME 
TREATMENT 
In 1985 Goris began the revival of a theme first muted by Siideck on the role of 
exaggerated inflammation in the pathogenesis of eRPS. The addition of a 
hypothesis of continued toxic free radical production leading to widespread tissue 
damage was suggested (Goris 1985). Earlier separate studies by Fantone and Ward 
had demonstrated the production of toxic oxygen free radicals by activated 
phagocytes during the inflammatory response and their potential to damage 
normal healthy tissue in the process. 
The first pilot study by Goris et al of the effect of the antioxidant free radical 
scavengers dimethyl sulfoxide (DMSO) and mannitol on nine eRPS patients was 
followed by a cross over study on twenty patients comparing topically applied 50% 
DMSO with placebo over a total trial period of fourteen days. The duration of 
symptoms was two months or less in twelve patients diagnosed with eRPS using a 
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predecessor of the Veldman criteria (Veldman 1993) (Table 6). The results were 
encouraging with overall subjective improvements being assessed in fifteen 
patients by the patients themselves and researchers alike. Objective measurements 
were not utilised. The researchers concluded that the earlier the diagnosis of eRPS 
the more likely the success of this treatment (Goris et al. 1987). Similar results 
have been reported by other studies, all carried out in the Netherlands (Zuurmond 
et al. 1996; Perez et al. 2003; Geertzen et al. 1994; Langendijk et al. 1993). The 
treatment however has not gained significant popularity outside the Netherlands 
and indeed these results have yet to be repeated in any other country. 
Other basic science studies and animal model work have supported the free radical 
theory as mentioned previously. 
Table 5 Veldman criteria for the diagnosis of CRPS. 
1. Four out of five signs or symptoms present from:-
• Unexplained diffuse pain 
• Difference in skin colour relative to other limb 
• Diffuse oedema 
• Difference in skin temperature relative to other limb 
• Limited active range o/motion 
2. Occu~~;;;ce~ri~~;-;~-;;~f above signs or symptoms after use 
-3~-Above--signs---and--symptoms p-re--sent---in--an--area--iarger--tlian the -area of 
primary injury or operation and including an area distal to the primary injury 
-----------------------------
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1.11 ANTIOXIDANTS AND THE PREVENTION OF COMPLEX 
REGIONAL PAIN SYNDROME 
Zollinger first reported the use of an antioxidant for the prevention of CRPS 
following distal radial fracture in 1999. A prospective randomised double-blinded 
trial compared the efficacy of SOOmg of ascorbic acid to placebo. CRPS was 
diagnosed according to the Veldman criteria. A per protocol analysis of the one 
hundred and fifteen patients after patient exclusions demonstrated an prevalence 
of 220/0 in the placebo group and 7% in the ascorbic acid group (Relative risk 2.91) 
(Zollinger et al. 1999). 
The same group followed this report with a prospective randomised double-
blinded dose response study, reporting again a statistically significant difference in 
the overall prevalence of CRPS between the ascorbic acid groups and the placebo 
group (2.40/0 vs. 10.1% p=0.002). Significance was observed between the two 
groups at a dosage of SOOmg or 1000mg. At a dosing of 200mg the difference in 
prevalence was not statistically significant. The diagnosis of CRPS was again based 
on the Veldman criteria (Zollinger et al. 2007). 
Other retrospective studies using a mixture of diagnostic criteria and investigations 
have also supported the use of ascorbic acid in the prevention of CRPS in operative 
stabilisation of distal radial fractures (Cazeneuve et al. 2002), foot and ankle 
surgery (Besse et al. 2009) and 1st carpometacarpal joint replacement surgery 
(Zollinger et al. 2010). 
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1.12 ASCORBIC ACID AND ANTIOXIDANT THERAPY 
An antioxidant is any substance that delays, prevents or removes oxidative damage 
to a target molecule. Antioxidants can be complex molecules such as the 
superoxide dismutases, catalases and peroxiredoxins, or simpler ones such as uric 
acid, glutathione and ascorbic acid (Gutteridge et al. 2010) 
Two groups in North America and Hungary discovered the water-soluble 
antioxidant ascorbic acid in 1932 (King et al. 1932; Svirbely et al. 1932). The 
following year its structure was identified and in the same period its first successful 
synthesis (Haworth et al. 1933). 
These events were the accumulation of centuries of experience with the disastrous 
consequences of scurvy in a wide variety of settings including long distance sea and 
land exploration, new world colonisation, famine and war. The first probable 
reports of a condition resembling scurvy can be traced to 1500 s.c. As early as 1227 
Gilbertus de Aquila recognized a condition seen previously on a voyage to Palestine 
and accordingly advised future voyagers to carry ample supplies of fruit and 
vegetables. The first appearance of the term scurvy in an English publication was 
not until 1589 by Richard Hakluyt following a nautical expedition (Sauberlich 
1997). 
Despite early accounts of effective means to avoid scurvy it was not until the 18th 
century that the benefits of antiscorbutics such as lemon juice, nettle juice and 
scurvy grass were widespread amongst explorers. One individual to help promote 
the benefits of citrus fruits against the outbreak of scurvy was James Lind who 
published the findings of what is commonly regarded as the world's first controlled 
trial in clinical science in 1753, "A Treatise of the Scurvy" (KrehI1953). 
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Ascorbic acid is vital for a number of biological pathways, including its role as an 
electron donor to a number of enzymes that are required for functions such as 
amino acid hydroxylation to ensure collagen structural normality and the 
production of norepinephrine from dopamine. It has both antioxidant and in the 
correct environment pro oxidant capabilities, although the relevance of this finding 
in vivo remains controversial (Carr et al. 1999). It is thought to be important in the 
prevention of diseases associated with the phenomenon of oxidative stress 
whereby reactive oxygen species or free radicals build up as a by-product of many 
physiological or pathophysiological processes. These highly reactive chemicals 
inflict damage on cellular structures via damage to DNA and oxidation of enzymes, 
amino acids and fatty acids (lipid peroxidation). Whilst most animals and plants 
are capable of ascorbic acid synthesis from either glucose or galactose, humans are 
not due to a presumed evolutionary loss of the enzyme L-gulonolactone oxidase, a 
trait they share with monkeys, guinea pigs and fruit bats. Diet is therefore the only 
source of ascorbic acid in these species (Burri et al. 1997). 
The precise role of ascorbic acid in the immune system is not fully understood. As a 
requirement of normal cellular function, a large concentration exists within 
leukocytes, which rapidly declines during infection and stress and can be lowered 
in chronic diseases (Lunec et al. 1985), ageing (Milne et al. 1971; Garry et al. 1987) 
and as a result of smoking (Brook et al. 1968). Ascorbic acid deficiency in vivo 
effects normal leukocyte biology by a number of proposed mechanisms including 
cellular apoptosis (Vissers et al. 2007). Supplementation of ascorbic acid has 
demonstrated both in vitro and in vivo to improve leukocyte function (Goetzl et al. 
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1974) and reduce leukocyte free radical production (Herbaczynska-Cedro et a1. 
1994). 
Since its discovery ascorbic acid has been the subject of much interest, debate and 
optimism amongst the health and scientific community as to its potential benefits 
to human society. Thousands of trials have been carried out and whilst some 
benefits have been stated, numerous trials and meta analyses have not reached the 
same conclusions (8jelakovic et a1. 2008). 
Debate still surrounds what is considered to be the recommended daily allowance 
(RDA) for optimising health. As little as 10 mg per day will prevent the onset of 
scurvy, yet the RDA is 7Smg per day for females and 90mg per day for males. 
Others have reported that in order to reach a plasma saturation concentration of 
70mmolfl; an RDA of 200mg is required (Lykkesfeldt et a1. 2010). 
Considering the volumes of studies carried out to ascertain the benefits of ascorbic 
acid in the treatment and prevention of diseases such as cancer, cardiovascular 
diseases and respiratory diseases, the literature on the use of antioxidants for the 
treatment or prevention of conditions associated with the disciplines of pain 
medicine and trauma and orthopaedics are relatively sparse. 
Neuropathic pain models in animals have shown some potential in the efficacy of 
antioxidants. Kim reported on the significant improvement of mechanical allodynia 
following Vitamin E administration at three days after LS spinal nerve root ligation 
in a rat model (Kim et a1. 2006). In another neuropathic rat model the role of 
animal age and early and late intervention with the antioxidant tirilazad on thermal 
hyperalgesia was investigated. The study revealed a significant delay in recovery of 
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thermal hyperalgesia in older animals compared to young. Biochemical markers of 
oxidative stress were also raised in both age groups however the elderly rats had 
significantly higher levels of markers than their younger counterparts. Another 
arm of this study demonstrated that the administration of the long acting 
antioxidant tirilazad to the study group as a whole alleviated thermal hyperalgesia 
when given seven days after nerve ligation. Earlier intervention before seven days 
with this treatment showed no benefit (Khalil et al. 2001). An animal model 
investigating the role of ascorbic acid in free radical associated neuropathic pain 
has not been reported thus far. 
A beneficial effect on muscle function and reduction of inflammatory mediated 
tissue changes and damage has been observed in animal models of ischaemia-
reperfusion and compartment syndrome with pre-treatment of ascorbic acid 
(Kearns et al. 2001; Kearns et al. 2004). Work on fracture healing in animals has 
demonstrated the beneficial effects of ascorbic acid on accelerating fracture healing 
(Sarisozen et al. 2002) and improving the mechanical properties of fracture callus 
(Alcantara-Martos et al. 2007). The protective effects of ascorbic acid on fracture 
healing in rats treated with a free radical donor have also been demonstrated 
(Duygulu et al. 2007). 
The prospective studies reported by Zollinger on CRPS prevention with ascorbic 
acid were partly devised as a result of the benefits of ascorbic acid in burns by 
reducing microvascular leakage of fluid and protein and therefore reducing the 
volume of fluid resuscitation required (Matsuda et al. 1992; Tanaka et al. 2000). 
Since Zollinger's studies no other prospective randomised control trials on the 
benefits of ascorbic acid in CRPS prevention have been published and in fact more 
has been published on the concerns of his trial methodology (Amadio 2000; Fr6lke 
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2007; Rogers et al. 2008; Rohekar 2008), with particular reference to the diagnostic 
criteria, an issue raised by the research group in their conclusion (Zollinger et al. 
2007). 
With such a compelling array of evidence from a variety of human, animal and in 
vitro studies exploring the role of free radicals in the pathogenesis of CRPS, the 
potential benefits of antioxidant treatment to reduce or indeed prevent CRPS 
requires further clinical assessment. 
Confirmation of its usefulness would provide an inexpensive, safe and well-
tolerated means of preventing a condition that can cause extreme disability, 
anguish and pain for sufferers and a financial burden to society as a whole. 
The study is divided into two pillars. The first pillar aim is to validate a set of 
previously utilised diagnostic criteria for confirmation of prospectively studied 
CRPS following distal radial fracture with the most up to date research diagnostic 
criteria as described by Bruehl. 
The second pillar of the study is the investigation prospectively of the efficacy of 
ascorbic acid in the prevention of CRPS following distal radial fracture in adults by 
means of a double blinded randomised control trial, utilising the validated criteria 
from pillar one for diagnosis of the condition. 
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CHAPTER TWO 
HYPOTHESES AND STUDY QUESTIONS 
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2 HYPOTHESES AND STUDY QUESTIONS 
2.1 HYPOTHESES 
2.1.1 PILLAR ONE 
The Atkins criteria for the diagnosis of complex regional pain syndrome (type 1) 
will identify a similar group of patients with the condition following a distal radial 
fracture when compared to the modified IASP criteria according to Breuhl. 
Therefore confirming the validity of this method for the diagnosis of CRPS for 
future research purposes in an orthopaedic setting. 
2.1.2 PILLAR TWO 
Complex regional pain syndrome (type 1) following distal radial fracture is due in 
part to the presence of an increased concentration of free radicals at the site of 
injury in the affected limb during the fracture healing process. Administration of 
the antioxidant, ascorbic acid as an oral preparation for the duration of fracture 
healing will act as a preventative measure against the build up of free radicals and 
therefore prevent the occurrence of complex regional pain syndrome (type 1) when 
compared to a placebo. 
A statistically significant decrease in the incidence of complex regional pain 
syndrome (type 1) following fracture by administration of an antioxidant compared 
to placebo supports strongly the role of toxic free radicals in the pathophysiology of 
the disease. 
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The use of ascorbic acid administered in the early stages of fracture healing can 
provide a simple, cost effective and safe preventative measure against the 
occurrence of complex regional pain syndrome (type 1) following injury. 
2.2 PRIMARY STUDY QUESTIONS 
2.2.1 PILLAR ONE 
1. Does the diagnostic criteria for complex regional pain syndrome as 
described by Atkins agree with the up to date IASP diagnostic criteria 
described by Bruehl when used to assess a series of patients following a 
distal radial fracture? 
2.2.2 PILLAR TWO 
2. Does the administration of ascorbic acid SOOmg once daily for fifty days 
following injury reduce the incidence or prevent the development of 
complex regional pain syndrome (type 1) following a closed distal radial 
fracture? 
3. If the incidence of complex regional pain syndrome (type 1) is not 
significantly altered following administration of ascorbic acid, does the 
treatment: 
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a. Improve any of the individually measured features of the condition 
occurring in the affected hand (pain, tenderness, finger stiffness, grip 
strength, finger swelling)? 
b. Reduce the occurrence of other features of the condition occurring in 
the affected hand (vasomotor instability, motor dysfunction and 
trophic changes)? 
2.3 SECONDARY STUDY QUESTIONS 
2.3.1 PILLAR ONE 
The data collected allowed the following additional questions to be discussed: 
1. Does history of current or recent smoking increase the risk of developing 
complex regional pain syndrome following a distal radial fracture? 
2. Is there an association between the time immobilised in a cast and the 






3 METHODOLOGY PILLAR ONE: 
THE VALIDA TION OF THE A TKINS' CRITERIA IN THE DIAGNOSIS OF COMPLEX 
REGIONAL PAIN SYNDROME (TYPE 1) 
3.1 INTRODUCTION 
A lack of simple diagnostic test has led to an assorted array of diagnostic standards 
employed in studies thus far (van de Beek et a1. 2002). The International 
Association for the Study of Pain (IASP) introduced the term complex regional pain 
syndrome and a set of initial diagnostic criteria (Stanton-Hicks et a1. 1995). Since 
then refinement has been sought in order to provide an accurate and usable 
diagnostic tool both in clinical and research practice. 
The lack of uniformity of diagnostic criteria amongst researchers has led to doubt 
as to the validity and interpretation of several prospective studies that have 
reproducibly shown that CRPS is a common condition, affecting patients with limb 
trauma (Harden et a1. 2003). 
Prospective studies employing a reproducible set of diagnostic criteria, employing 
in part objective assessment tools, have demonstrated that the incidence of CRPS is 
between 190/0 and 37% following both distal radial fractures (Atkins et a1. 1989a; 
Atkins et a1. 1990; Bickerstaff et a1. 1994; Livingstone et a1. 2002) and tibial 
fractures (Sarangi et a1. 1993). These studies have also demonstrated the link 
between plaster tightness (Field et a1. 1994) and the onset of the condition and the 
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ineffectiveness of regional guanethidine blocks in the treatment of the condition in 
the acute phase (Livingstone et al. 2002). Other researchers, using different 
diagnostic criteria have also shown similar incidences following distal radial 
fractures (Zollinger et al. 1999) and total knee replacement surgery (Stanos et al. 
2001). A criticism of these studies has been the lack of validation of the diagnostics 
methods employed. 
In order to test the validity of the diagnostic criteria according to Atkins, a series of 
patients presenting with a distal radial fracture were analysed. The data collected 
was used to diagnose CRPS both with the Atkins' criteria and those of the modified 
IASP criteria (Bruehl's criteria). This diagnostic method provides a sensitive and 
specific clinical test for CRPS and has been internally and externally validated using 
patients with non-CRPS neuropathic pain (Bruehl et al. 1999) (Harden et al. 1999) 
3.2 STUDY METHODOLOGY 
A series of two hundred and sixty-two adult patients that had attended the Bristol 
Royal Infirmary with a closed unilateral distal radial (Co lies') fracture was 
reinvestigated. These patients had been part of a group recruited for a previous 
study on the effect of guanethidine blockade in the early management of CRPS 
(Livingstone et al. 2002). The raw prospective data collected by the original author 
(Mr James Livingstone) was reanalysed. No new data was created other than that of 
the comparative analysis of the original study data. 
All patients were aged eighteen years or older. The fractures were managed by 
manipulation under appropriate sedation or regional anaesthesia into a satisfactory 
position and immobilisation in a forearm plaster. Inclusion in the study did not 
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influence fracture management. Injuries that had required stabilisation with 
external fixators or open reduction and internal fixation were excluded. Also 
excluded were patients with any other ipsilateral or collateral upper limb injury, 
significant pre-existing upper limb pathology and those who were unable to 
cooperate fully with the assessments. 
Local ethics committee approval was obtained prior to the start of the original 
study and all patients gave informed consent to study participation. 
3.3 DIAGNOSTIC METHODOLOGY 
A full clinical assessment to determine the presence of the salient features of eRPS 
(type 1) was performed at an average of 66.3 days following injury by a single 
clinician (Mr James Livingstone). The following responses and measurements were 
recorded: 
• Pain was assessed by direct questioning and finger tenderness by 
dolorimetry. 
• Vasomotor instability was assessed using a standardised questionnaire 
(Atkins et al. 1989a) and clinical examination. 
• Direct questioning and clinical examination assessed motor, trophiC, 
oedema and sudomotor changes. 
• Finger stiffness was assessed using goniometry. 
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From this assessment, the presence or absence of eRPS (type 1) was determined 
using both the Bruehl and the Atkins criteria. 
The Atkins' criteria uses finger dolorimetry, finger goniometry in addition to a 
vasomotor instability questionnaire. To fulfil the Atkins' criteria for eRPS patients 
must have a vasomotor score of three or more, abnormal finger tenderness and 
abnormal finger stiffness. The association of these three features in the diagnosis of 
eRPS has been previously assessed with log linear analysis (Livingstone 2000). 
Bruehl's modified IASP criteria divide the array of abnormal clinical signs and 
symptoms of eRPS into four groups: sensory, oedema and sudomotor, vasomotor 
and motor/trophic, In order to fulfil Bruehl's criteria patients must report 
abnormal pain, symptoms in all four groups and have signs present in at least two 
of the groups (table 3). 
Table 3 modified (ASP diagnostic criteria for CRPS 
Continuing pain that is disproportionate to any inciting event. 
1.Must report at least one symptom in each of the following categories: 
• Sensory: Reports of hyperaesthesia. 
• Vasomotor: Reports of temperature asymmetry and/or skin colour changes 
and/or skin colour asymmetry. 
• Sudomotor/Oedema: Reports of oedema and/or sweating changes and/or 
sweating asymmetry. 
• Motor/trophic: Reports of decreased range of movement and/or motor 
dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, 
nails, skin). 
2.Must display at least one sign in two or more of the following categories: 
• Sensory: Evidence of hyperalgesia and/or allodynia. 
• Vasomotor: Evidence of temperature asymmetry and or skin colour changes 
and/ or asymmetry, 
• Sudomotor/Oedema: Evidence of oedema and/or sweating changes and/or 
sweating asymmetry. 
• Motor/Trophic: Evidence of decreased range of motion. and/ or motor. 
dysfunction (weakness, tremor, dystonia) and/or trophIc changes (haIr, 
___________________ !l_a_il~, skin), ____________________ . __ . ____________ ._. _____ .. _ .--- ---.- --
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3.4 NORMAL RANGES AND REPRODUCIBILITY STUDIES 
The reference ranges for of finger dolorimetry and finger goniometry values were 
calculated using control subjects of similar age with no known fractures or upper 
limb pathology. The reference ranges were calculated as the mean ± 2 standard 
deviations. Reproducibility of these measurements was assessed by re-examining 
twelve of the control group on a separate occasion. Coefficients of variation were 
then calculated to express the degree of reproducibility. 
3.4.1 Sensory abnormality 
The presence of abnormal pain and allodynia (mechanical and thermal) in the hand 
and forearm was recorded after direct questioning. Finger tenderness in both 
hands was assessed using finger dolorimetry to provide a ratio of affected to 
unaffected hand. This method has been shown previously to be reproducible 
(Atkins et al. 1989b). The reference range for the expected dolorimetry ratio in 
normal subjects in this study was 1.15 to 0.85. The coefficient of variation was 
6.3%. 
3.4.2 Oedema and sudomotor abnormalities 
Patients were questioned on changes in the appearance of their hand since their 
injury had occurred. Excessive sweating in the affected hand was also recorded. 
Assessment of hand swelling was made by clinical examination and by water 
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displacement using a graduated Perspex cylinder. Abnormal sweating noted on 
clinical examination was recorded. 
3.4.3 Vasomotor abnormalities 
Vasomotor changes since the injuries were assessed using a standardised 
questionnaire (Atkins et al. 1989a). A positive response to a question was scored as 
1. For the Atkins criteria a score of three or more was deemed to be abnormal. 
Both hands were assessed clinically and any asymmetry of skin colour, temperature 
or sweating documented. 
3.4.4 Motor and trophic changes 
Patients were asked directly whether they had noticed any changes in fingernail 
growth or thickness or the presence of new or thicker hair growth affecting the 
hands. Recording the presence of grip strength changes, fine motor control 
problems or new onset tremor, assessed subjective motor dysfunction. 
Both hands were examined and any asymmetry of skin, fingernails or hair recorded. 
Grip strength was measured using a Jamar dynamometer. Finger stiffness was 
assessed using a finger goniometer. The range of finger movements for each hand 
was assessed by measuring maximum flexion at all of the joints of all four fingers. 
The readings obtained were summed for each hand. The total of the affected hand 
was then subtracted from the total of the unaffected hand to give a finger stiffness 
value. The reference range for the expected finger stiffness value in normal 
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subjects in this study was + 61 degrees to - 61 degrees. The coefficient of variation 
was 16.8%. 
3.5 STATISTICAL ANALYSIS AND DATA PROCESSING. 
Data from this part of the study was stored on a personal computer (MacBook Pro, 
Apple inc.). The original data had been stored and processed on the following 
personal computer (K&K Pentium processor, K&K computers). Data analysis was 
performed using the following software. 
Windows 95 (Microsoft Corporation, USA) 
Microsoft Excel 6.0 (Microsoft Corporation, USA) 
Microsoft Excel 2008 for Mac (Microsoft Corporation, USA) 






4 METHODOLOGY PILLAR TWO: 
THE EFFICACY OF ASCORBIC ACID (VITAMIN C) IN THE PREVENTION OF 
COMPLEX REGIONAL PAIN SYNDROME (TYPE 1) FOLLOWING DISTAL RADIAL 
FRACTURE 
4.1 STUDY DESIGN 
4.1.1 Inclusion criteria for study 
Patient recruitment was approved by and occurred in two centres, Bristol Royal 
Infirmary and Weston General Hospital. 
All patients with closed, unilateral fractures of the distal radius over the age of fifty 
years who met the inclusion and exclusion criteria attending one of the hospitals 
involved in the trial were asked to take part in the study. Patients were recruited as 
soon after their injury as possible. A combination of direct referrals from the 
emergency department and by examination of case notes and plain radiographs of 
patients waiting for fracture clinic review were employed. All patients were asked 
to commence their allotted trial medications on the day of recruitment. Patients 
were seen at a minimum of four weeks following their plaster removal and 
assessed for the presence or absence of complex regional pain syndrome. 
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4.1.2 Consent and ethical committee approval 
All patients who agreed to take part in the study were given a full verbal and 
written explanation of the study design and the nature of complex regional pain 
syndrome and its incidence following distal radial fracture (Appendix 1). Written 
consent was obtained from each patient prior to them joining the trial (Appendix 
2). Their general practitioners were informed of their study inclusion (Appendix 
3). Full local ethical committee and research department approval was obtained 
from each of the hospitals taking part prior to the study commencing. 
United Bristol Healthcare Trust Ethics Committee Log No. E5611 
United Bristol Healthcare Trust Research Department Log No. SU/2003/1359 
Weston Area Health NHS Trust Research Department Log No. E375 
4.1.3 Exclusion criteria: 
1. Patients with other ipsilateral or contralateral upper limb injury 
2. Patients with dementia who are unable to co-operate fully with the 
assessment. 
3. Patients with pre-existing hand pathology that would effect the 
measurements when comparing the contra lateral limb (e.g. severe 
rheumatoid arthritis or Dupuytren's contracture). 
4. Patients less than 50 years old. 
5. Patients treated with orthopaedic implants or external fixators. 




4.1.4 Initial assessment 
At the time of recruitment a trial proforma was completed (Appendix 4). 
Information recorded included personal details, date and time of the injury, type of 
initial treatment, history of smoking and current vitamin or multivitamin usage. 
4.2 FRACTURE MANAGEMENT 
The management of individual patients and their fractures was not influenced by 
the study. The primary injury assessment was performed by a member of the 
emergency department of either of the recruiting centres. 
Initial fracture reduction, if required, was carried out in the emergency department 
as per the departmental guidelines. Patients were referred to the next available 
fracture clinic and remained under the care of the consultant in charge. Routine 
follow-up included review at one and two weeks with an anteroposterior and 
lateral radiograph in plaster to determine the position of the fracture. 
Patients subsequently requiring remanipulation and stabilisation with 
percutaneous kirschner wires were not excluded. Remanipulation was not usually 
attempted after the second week. The attending orthopaedic surgeon determined 
the period of immobilisation. Physiotherapy was commenced following plaster 
removal at the discretion of the attending orthopaedic surgeon. 
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4.3 RANDOMISATION 
The Bristol Royal Infirmary pharmacy department using a block randomisation 
method performed trial medication randomisation. Patients were allotted a trial 
number that was recorded on all documentation and capsule bottles. 
4.4 TRIAL MEDICATIONS 
Patients were randomised to one of two treatment arms, ascorbic acid or placebo. 
The course of treatment was for 50 days. Both groups received their medications 
enclosed in a gelatin capsule (DHP Ltd, Crickhowell, UK) produced by the Bristol 
Royal Infirmary Pharmacy Department. One group received five hundred 
milligrams of ascorbic acid (Alpharma Ltd, Barnstaple, UK) divided into two 
capsules to be taken once daily. The other a lactose tablet placebo (Penn Pharma 
Ltd, Tredegar, UK) divided into two capsules to be taken once daily. Patients were 
asked to commence their trial medications on the day of recruitment. 
Patients were asked to return their pill bottles at the end of trial assessment; 
compliance was recorded by counting any remaining capsules. 
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4.5 OUTCOME FOLLOWING FRACTURE IMMOBILISATION AND 
TRIAL MEDICATIONS 
The study end point was the presence or absence of complex regional pain 
syndrome (type 1) at a minimum of four weeks following plaster removal. 
Assessment was made using diagnostic criteria described by Atkins (Atkins et al. 
1989a). The use of finger dolorimetry, finger movements and a questionnaire for 
vasomotor instability has proved sensitive, quantitative and reproducible tests for 
the presence and severity of individual features of complex regional pain syndrome 
(type 1) following distal radial fracture. The Atkins criteria was employed for this 
section of the study rather than that of Bruehl, primarily due to the fact that this 
had been chosen during the initial study design and planning. The decision to 
compare the two criteria in Pillar 1 was made after ethical approval for Pillar 2 had 
been granted, and a change to this part of the study was felt not be warranted given 
the previous work performed using the Atkins methodology. 
Before starting the final assessment further questions were asked regarding any 
problems encountered during plaster immobilisation. The extent and duration of 
any physiotherapy was recorded. 
The returned medication bottles were inspected and any remaining capsules 
counted and recorded. 
Predefined questions were then asked to each patient regarding symptoms and 
signs the patient had experienced only in the hand or fingers and specifically not in 
the wrist. 
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A 100mm visual analogue score supplemented pain assessment and the short form 
of the McGill Pain Questionnaire read to the patient and recorded by the author. 
The patients' hand was examined for dystrophic and vasomotor changes. 
Measurements in the following order were then taken from both hands; finger 
movements, index finger swelling, grip strength and dolorimetry. 
4.6 PROCESSING OF DATA 
Data recorded during the study was stored on a personal computer (MacBook Pro, 
Apple inc, USA). Personal information recorded on each patient was not stored 
electronically in accordance with the Data Protection Act 1998. Only the unique 
randomised trial number identified the patient's computerised data entry. Paper 
records recording personal information were kept in a secure filing cabinet at all 
times. 
The analysis and processing of data was performed on the pre-mentioned computer 
using the following software programmes: 
Word processing; Microsoft Word 2008 (Microsoft®, USA) 
Spreadsheet; Microsoft Excel (Office 2008) (Microsoft®, USA) 
Statistics; SPSS for Mac (version 19.0) (IBM, USA) 
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4. 7 STATISTICAL ANALYSIS 
Data analysis was performed on a personal computer along with reference to the 
following texts: 
Discovering Statistics Using SPSS (3 rd Edition) A Field. Sage Books 2009. 
Statistics at Square One. T 0 V Swinscow and M J Campbell. BMJ Books 2002. 
Statistics at Square Two. M J Campbell. BMJ Books 2001. 
Statistical advice was also provided by Ms Alison Smith B.Sc M.Sc, Statistician, 
Musculoskeletal Research Unit, Avon Orthopaedic Centre and by Professor Roger 
Atkins MA OM FRCS. 
Data was analysed using standard methods for both nominal and continuous 
variables. For nominal variables Pearson's Chi squared test and Fisher' exact test 
was used. For continuous variables, data set means were analysed for normality 
using the Kolmogrov-Smirnov test and then analysed using a Students t-test or 
Mann-Whitney test as appropriate. 
Statistical significance was defined as a p value of < 0.05. 
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4.8 STUDY SIZE CALCULATION 
The number of patients required to complete the study in order to achieve 
adequate statistical significance was calculated using a comparison of proportions 
formula. 
An estimate of the proportions expected to be affected in the two treatment arms of 
the study was based on previous work on the incidence of CRPS occurring following 
distal radius fracture by Atkins and others (Atkins et al. 1989a; Atkins et al. 1990; 
Field et al. 1997; Zollinger et al. 1999; Livingstone et al. 2002) and the incidence 
reported on by Zollinger following prophylactic treatment with ascorbic acid 
(Zollinger et al. 1999). 
The expected incidence of CRPS in the placebo group was set at 25% and the 
predicted incidence in the ascorbic acid group was set at 10%. 
The value for U and 13 for this calculation was set at 0.05 and 0.1 respectively to 
reduce the risk of type I and II errors. The study would therefore be powered at 
900/0 with 950/0 significance. 
The number of patients (n) needed in each treatment was calculated from the 
following equation (Campbell et al. 1995) without a continuity correction. 
n> ((zzuv'(2p(1-p)) + (zzl3v'(pA(l-pA) + (p8(1-p8)))Z 
(pA-p8)Z 
Where:-
ZZU = 1.96 (2 sided u = 0.05) 
zzf3 = 1.28 (1-13 = 0.9) 
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pA = expected proportion in the placebo group 
pB = predicted proportion in the ascorbic acid group 
P =pA+ pB 
2 
4.9 STUDY SIZE RESULTS 
The sample size (n) required to detect a difference in the expected proportion 
(25%) versus the predicted proportion (10%) at a power of 90% and 95% 
significance equals one hundred and thirty-one patients in each group. 
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4.10 PAIN ASSESSMENT INCLUDING DOLORIMETRY 
4.10.1 INTRODUCTION 
An accurate, quantifiable and reproducible objective assessment of pain for 
research purposes has thus far eluded researchers and clinicians. Historically 
differences between neuropathic pain and inflammatory mediated pain were 
apparently clearly defined by symptoms alone. As our understanding of the 
pathophysiology of pain mechanisms has improved these distinctions have become 
less clear. 
Pain assessment tools vary in their level of objectivity and applicability. Laser 
Evoked Potentials uses laser stimulators to produce radiant heat pulses to 
selectively excite the free nerve endings of A& and C nociceptive fibres producing a 
quantitative objective response. Quantitative Sensory Testing analyses perception 
in response to an external stimulus, this may be mechanical or thermal in nature, 
can be objectively measured and quantified but requires a subjective evaluation by 
the patient. 
Pain questionnaires rely entirely on patient subjectivity. The commonly used one-
dimensional subjective tools to measure pain intensity are the Visual Analogue 
Scale (VAS), the Numeric Rating Scale (NRS), the Verbal Descriptor Scale (VDS) and 
the Faces scale. Descriptive pain assessment is performed with questionnaires 
such as the McGill Pain questionnaire. These different methods all have advantages 
and disadvantages. 
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No specific validated pain questionnaire exists for complex regional pain syndrome. 
As well as simple spontaneous pain at rest the condition may patient may also 
experience mechanical and thermal allodynia, hyperalgesia, hyperpathia and 
exercise induced pain. These pain phenomena require evaluation by direct 
questioning. 
In this study a combination of simple questions requiring a yes/no answer to 
establish the occurrence of these phenomena was used with the short form of the 
McGill Pain Questionnaire (Melzack 1987) including a Visual Analogue Scale. 
Quantitative Sensory Testing was performed to distinguish abnormal finger 
tenderness. 
4.10.2 FINGER DOLORIMETRY 
The instrument to assess finger tenderness is a dolorimeter. First used to quantify 
articular finger tenderness in patients with rheumatoid arthritis (McCarthy et al. 
1965), Kozin et al then applied it to the diagnosis and investigation of reflex 
sympathetic dystrophy (Kozin et al. 1976a). The technique has subsequently being 
used to investigate algodystrophy complicating distal radial fractures and tibial 
fractures (Atkins et al. 1989b; Sarangi et al. 1993; Bickerstaff et al. 1994; Field et al. 
1994; Livingstone et al. 2002). 
The dolorimeter is a modified commercial engineering compression extension 
gauge used in the compression mode that enables the investigator to apply a 
steadily increasing pressure to an anatomical site until a pain threshold is reached. 
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It consists of a hollow tube containing a spring that is fixed at a closed end. The free 
end of the spring sits in a metal cup that attaches to a metal rod that protrudes from 
the cylinder. A slit in the side of the cylinder allows a pointer attached to the metal 
cup to move up and down a graduated linear scale. To the end of the metal rod is 
attached a small plastic button (0.5cm 2) covered with orthopaedic felt. The 
dolorimeter used had a full-scale deflection of 5kg force. One kg force is equivalent 
to 20 Newtons per cm2 pressure (Figure 6) . 
At each site on the hand to be examined the felt covered plastic button was steadied 
on the subjects skin to prevent slipping and compression was applied at a rate of 
approximately 1.5 kgF per second. The subject was instructed to say, "stop" as soon 
as the force being applied became uncomfortable. This command was standardised 
in all patients being assessed. 
Figure 6 A dolorimeter 
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The assessment of hand tenderness was performed in a controlled fashion, to 
maximise reproducibility of the measurements taken. The subject's hands and 
forearms were placed flat on a table at a comfortable height. Sequential readings 
were taken from each finger in turn. Measurements were taken in turn from the 
dorsal surface overlying the metacarpophalangeal joint, the proximal phalanx, the 
proximal phalangeal joint, the middle phalanx and the distal interphalangeal joint. 
The thumb was not assessed. 
The unaffected limb was assessed first followed by the affected limb. The 
measurements taken were summed and the total dolorimetry scores for each hand 
are expressed as a dolorimetry ratio by dividing the affected hand score by the 
unaffected hand score. 
4.10.3 NORMAL RANGE 
The investigators reference range was calculated by performing dolorimetry on the 
hands of nineteen healthy control subjects, selected at random from members of 
staff working in the Bristol Royal Infirmary Trauma and Orthopaedic clinic and 
patients without active or pre-existing pathology affecting their upper limbs. 
The reference range was defined and calculated as the mean ± 2 standard 
deviations. 
The standard error of the limit of the reference range was calculated as: v(3s2 In) 
where s=standard deviation and n=sample size. 
86 
The 95 0/0 confidence limits on these intervals were calculated accordingly: mean ± 
Zs ± 1.96 x Y(3s 2 In). 
4.10.4 TEST RELIABILITY 
The reliability of the dolorimetry testing was performed on twelve control subjects 
and ten patients recruited into the trial who developed CRPS. The initial 
dolorimetry values were recorded and each subject re assessed within one hour. 
The reliability data sets were taken without cross-reference to the primary data 
sets. 
In accordance with the recommendations of the Consensus-based Standards for the 
selection of health Measurement Instruments (COSMIN) group (Mokkink et al. 
Z010), the Intra-class correlation coefficients along with a standard error of 
measurement were calculated for the dolorimetry readings of individual sites on 
each finger, the whole finger, individual sites on all fingers, the whole hand and the 
dolorimetry ratios calculated. 
The standard error of measurement was calculated accordingly: 




The mean age of the group was 65 years (range 53 to 81 years). There were 
thirteen females and six males. 
Individual dolorimetry values at were analysed between the two hands. A 
statistically significant difference was observed only at the ring finger proximal 
phalanx site (p=0.037) (Full results in Appendix Sa). 
The mean dolorimetry ratio was 1.00 (standard deviation 0.092). A reference 
range of was thus calculated for this study of 1.18 to 0.82. (95% confidence 
intervals for this range were calculated as 1.13 to 1.23 and 0.77 to 0.87) (Full 
results in Appendix 5b). 
Control group reliability 
The intra-class correlation coefficient and standard error of the measurement for 
dolorimetry measurements of the whole right hand was 0.852 (95% CI 0.664-
0.939) and 1234.99; for the left hand 0.572 (95% CI 0.184-0.805) and 1591.09 and 
for the dolorimetry ratio was 0.895 (950/0 CI 0.772-0.953) and 0.086 (Full results in 
Appendix 5c). 
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Complex Regional Pain Syndrome group reliability 
The intra-class correlation coefficient and standard error of the measurement for 
dolorimetry measurements for the whole control hand was 0.996 (95% CI 0.984-
0.999) and 1213.81, for the affected hand 0.997 (95% CI 0.988-0.999) and 833.20 
and for the dolorimetry ratio was 0.992 (95% CI 0.970-0.998) and 0.073 (Full 




A number of methods have been described to quantifying finger stiffness. The 
simplest is a linear measurement from the fingertip to the distal palmar crease 
(Boyes 1955). The total active motion and total passive motion ranges (TAM, TPM) 
have been used to assess digital performance, especially after flexor tendon repair 
(Strickland 1985). The percentage loss of motion in a finger can be calculated 
through a complex combination of the measured finger joint motion using finger 
motion impairment tables described by Swanson et al. (1987). More recently 
computer aided motion analysis has been utilised to assess dynamic angular 
changes of each finger joint and the fingertip motion area for injured fingers. This 
method however requires specialist equipment and is time consuming to perform 
(Chiu et al. 2000). Active range of motion (AROM) assessment for finger stiffness 
using a goniometer remains a viable, quick and practical method both for clinical 
and research uses. 
Subjective finger stiffness was documented prior to the objective assessment. Each 
patient was asked about the presence or absence of finger stiffness, whether this 
was a daily occurrence and whether it was throughout the day or only confined to 
the morning or evening. 
An objective evaluation of finger stiffness was then made using a Perspex finger 
gonoimeter to measure the degree of maximal flexion at the joints of each finger in 
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both hands. A sum of these measurements gave a total reading for each hand. A 
finger stiffness value was calculated by subtracting the sum total for the affected 
hand from the sum total of the unaffected hand. 
The goniometer readings were taken in a standardised fashion. The patients' hand 
was placed on a flat surface with the elbow flexed and the forearm and wrist in the 
neutral position. 
The patient was asked first to make a fist to allow recording of maximum flexion at 
the metacarpal phalangeal joint and proximal interphalangeal joint of each finger. 
To allow measurement of maximum flexion at the distal interphalangeal joint, the 
patient was asked to extend the metacarpal joints and maintain full flexion at the 
proximal and distal interphalangeal joints. 
4.11.2 NORMAL RANGE 
The investigators reference range for the finger stiffness value was recorded using 
this method to evaluate the hands of nineteen healthy control subjects, selected at 
random from members of staff working in the Bristol Royal Infirmary Trauma and 
Orthopaedic clinic and patients without active or pre-existing pathology affecting 
their upper limbs. 
The reference range was defined and calculated as the mean ± 2 standard 
deviations. 
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The standard error of the limit of the reference range was calculated as: v(3s2 In) 
where s=standard deviation and n=sample size. 
The 950/0 confidence limits on these intervals were calculated accordingly: mean ± 
2s ± 1.96 x v(3s 2 In). 
4.11.3 TEST RELIABILITY 
The reliability of this method of testing was performed on twelve control subjects 
and ten patients recruited into the trial who developed CRPS. The initial finger 
stiffness values were recorded and each subject re assessed within one hour. The 
reproducibility data sets were taken without cross-reference to the primary data 
sets. 
In accordance with the recommendations of the Consensus-based Standards for the 
selection of health Measurement Instruments (COSMIN) group (Mokkink et al. 
2010), the Intra-class correlation coefficients along with a standard error of 
measurement were calculated for the finger stiffness readings of individual sites on 
each finger, the whole finger, individual sites on all fingers and the whole hand. 
The standard error of measurement was calculated accordingly: 




The mean age of the group was 65 years (range 53 to 81 years). There were 
thirteen females and six males. 
The mean cumulative finger flexion difference was 0 degrees (standard deviation = 
31.13°). This gave a reference range for this study of -62.26° to 62.26°. (95% CI for 
this range = -79.40° to -45.12° and 45.12° to 79.40°). A statistically significant 
difference was observed only at the little finger metacarpal phalangeal joint site 
(p=0.002) (Full results in Appendix 6a & b). 
Control group reliability 
The intra-class correlation coefficient and standard error of the measurement for 
cumulative finger flexion of the right hand was 0.993 (95% CI 0.974-0.998) and 
12.90, for the left hand 0.996 (95% CI 0.986-0.999) and 8.98 and for the cumulative 
finger flexion difference was 0.891 (95% CI 0.666-0.967) and 15.49 (Full results in 
Appendix 6c). 
Complex Regional Pain Syndrome group reliability 
The intra-class correlation coefficient and standard error of the measurement for 
cumulative finger flexion of the control hand was 0.999 (95% CI 0.996-1.000) and 
3.92, for the affected hand 0.999 (95% CI 0.996-1.000) and 5.18 and for the 
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cumulative finger flexion difference was 0.996 (95% CI 0.983-0.999) and 6.81 (Full 




Vasomotor instability as an indicator of sympathetic nervous system dysfunction or 
an exaggerated inflammatory process is a key feature in the diagnosis of eRPS. The 
objective assessment of each component is time consuming, requires specialist 
equipment and testing must be performed in a carefully controlled environment. 
Previous clinical studies have utilized an eleven point screening questionnaire to 
determine recent features suggestive of vasomotor instability (Atkins et al. 1990). 
This tool focuses on the subjective presence or absence of temperature, colour, 
sweating and swelling changes noticed by the patient. 
The same questionnaire was employed in this study, the questions were asked at 
the beginning of the assessment prior to any clinical examination of the subjects' 
hands to minimize bias. 
The questionnaire has been previously validated and was also put to nineteen 
control subjects in this study. There were no positive answers recorded amongst 
this group. 
The questions were: 
1. Have you noticed any changes in the appearance of your hand compared to 
the other recently, and if so, what changes exactly? 
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2. Have you noticed any changes in the colour of your hand recently, and if so 
what? 
3. Has your hand felt any different from the other hand recently, since the 
accident, and if so, in what way? 
4. Has the temperature of your hand felt in any way different from the other 
hand recently, and if so in what way? 
5. Has your hand been bluer than the other hand recently, or bluer than it was 
before the accident and if so under what circumstances? 
6. Has your hand been redder than the other hand recently, or redder than it 
was before the accident and if so under what circumstances? 
7. Has your hand felt warmer than the other hand recently, or warmer than it 
did before the accident and if so under what circumstances? 
8. Has your hand felt cooler than the other hand recently, or cooler than it did 
before the accident and if so under what circumstances? 
9. Has your hand responded differently to changes in environmental 
temperature recently, and if so in what way? 
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10. Have you noticed you hand going red and warm in a hot environment or 
blue and cold in a cool environment? 
11. Does your hand sweat or perspire more than it used to or more than the 
other side recently? 
4.12.2 CLINICAL EXAMINATION 
Following this questioning, both hands were compared and assessed for any signs 
of vasomotor instability by the investigator. Specific features assessed and 
recorded were the presence or absence of colour changes, temperature difference, 
finger or hand swelling and sweating. 
During this assessment specific trophic changes were also recorded; the presence 
or absence of fingernail changes (length, thickness and ridging), ectopic hair 
growth, skin changes and Dupuytrens nodules. 
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4.13 INDEX FINGER SWELLING 
4.13.1 INTRODUCTION 
Following clinical assessment of the subjects' affected hand and fingers for swelling, 
a quantitative evaluation was performed using an arthrocircometer to measure the 
circumference of the index finger. The device allows three simultaneous 
measurements to be taken by virtue of its structure. Three flexible metal strips, 
approximately 5 mm apart are attached to a plastic housing with a graduated scale 
along a recess for each metal strip. Each metal strip has a plastic marker to allow 
the reading of the measured circumference from the graduated scale. One end of 
the device is curved to allow the finger to sit comfortably against it during its use. 
The metal strips are tensioned against the skin of the finger and the circumference 
is recorded. To standardise the process the measurements are taken with the 
central metal strip centred over the proximal interphalangeal joint of the index 
finger. 
Three readings are taken from the index fingers of both hands. The nine values are 
summed and an index finger ratio calculated by dividing the affected finger total by 
the unaffected finger total. 
4.13.2 NORMAL RANGE 
The investigators reference range for index finger swelling was calculated by 
assessing the index fingers of nineteen healthy control subjects, selected at random 
from members of staff working in the Bristol Royal Infirmary Trauma and 
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Orthopaedic clinic and patients without active or pre-existing pathology affecting 
their upper limbs. 
The reference range was defined and calculated as the mean ± 2 standard 
deviations. 
The standard error of the limit of the reference range was calculated as: v(3s2 In) 
where s=standard deviation and n=sample size. 
The 950/0 confidence limits on these intervals were calculated accordingly: mean ± 
2s ± 1.96 x {(3s2 In). 
4.13.3 TEST RELIABILITY 
The reliability of the index finger swelling testing was performed on twelve control 
subjects and ten patients recruited into the trial who developed CRPS. The initial 
index finger values were recorded and each subject re assessed within one hour. 
The reliability data sets were taken without cross-reference to the primary data 
sets. 
In accordance with the recommendations of the Consensus-based Standards for the 
selection of health Measurement Instruments (COSMIN) group (Mokkink et al. 
2010), the Intra-class correlation coefficients along with a standard error of 
measurement were calculated for the index finger swelling readings from each 
hand. 
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The standard error of measurement was calculated accordingly: 
Standard deviation of the mean differences 
vi2 
4.13.4 RESULTS 
The mean age of the reference range group was 65 years (range 53 to 81 years). 
There were thirteen females and six males. 
The mean index finger swelling ratio was 1.01 (standard deviation = 0.17). This 
gave a reference range for this study of 0.67 to 1.35. (95% CI for this range = 0.58 to 
0.76 and 1.26 to 1.44) (Full results in Appendix 7a). 
Control group reliability 
The intra-class correlation coefficient and standard error of the measurement for 
right index finger was 0.991 (95% CI 0.977-0.996) and 0.49, for the left hand 0.996 
(950/0 CI 0.989-0.998) and 0.34 and for the index finger swelling ratio was 0.803 
(95% CI 0.507-0.919) and 0.06 (Full results in Appendix 7b). 
Complex Regional Pain Syndrome group reliability 
The intra-class correlation coefficient and standard error of the measurement for 
the control index finger was 0.980 (95% CI 0.921-0.995) and 0.38, for the affected 
index finger 0.982 (95% CI 0.929-0.995) and 0.41 and for the index finger swelling 
ratio was 0.964 (95 0/0 CI 0.864-0.991) and 0.05 (Full results in Appendix 7c). 
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4.14HAND GRIP STRENGTH 
4.14.1 INTRODUCTION 
Handgrip strength was assessed using a Jamar dynamometer. The assessment was 
performed with the subject sitting, shoulder adducted to the side, elbow flexed to 
90 degrees with the forearm and wrist in the neutral position. 
Three consecutive readings were recorded from each hand and the mean reading 
calculated. 
The grip strength ratio was calculated by dividing the affected hand mean reading 
by the unaffected hand mean reading. 
4.14.2 NORMAL RANGE 
The investigators reference range for grip strength was recorded using this method 
to evaluate the hands of nineteen healthy control subjects, selected at random from 
members of staff working in the Bristol Royal Infirmary Trauma and Orthopaedic 
clinic and patients without active or pre-existing pathology affecting their upper 
limbs. 
The reference range was defined and calculated as the mean ± 2 standard 
deviations. 
The standard error of the limit of the reference range was calculated as: v'(3s2 In) 
where s=standard deviation and n=sample size. 
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The 95% confidence limits on these intervals were calculated accordingly: mean ± 
2s ± 1.96 x v'(3s2 In). 
4.14.3 TEST RELIABILITY 
The reliability of this method of testing was performed on nineteen control subjects 
and twelve patients recruited into the trial. The grip strength values were recorded 
and each subject re assessed within one hour. The reliability data sets were taken 
without cross-reference to the primary data sets. 
In accordance with the recommendations of the Consensus-based Standards for the 
selection of health Measurement Instruments (COSMIN) group (Mokkink et al. 
2010), the Intra-class correlation coefficients along with a standard error of 
measurement were calculated for the grip strength readings of each hand. 
The standard error of measurement was calculated accordingly: 
Standard deviation of the mean differences 
~2 
4.14.4 RESULTS 
The mean age of the group was 65 years (range 53 to 81 years). There were 
thirteen females and six males. 
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The mean grip strength ratio was 1.01 (standard deviation = 0.13). This gave a 
reference range for this study of 0.74 to 1.26. (95% CI for this range = 0.67 to 0.81 
and 1.19 to 1.33) (Full results in Appendix 8a). 
Control group reliability 
The intra-class correlation coefficient and standard error of the measurement for 
grip strength measurements of the whole right hand was 0.988 (95% CI 0.969-
0.995) and 1.14, for the left hand 0.995 (95% CI 0.988-0.998) and 0.71 and for the 
grip strength ratio was 0.792 (95% CI 0.537-0.914) and 0.09 (Full results in 
Appendix 8b). 
Complex Regional Pain Syndrome group reliability 
The intra-class correlation coefficient and standard error of the measurement for 
grip strength measurements for the whole control hand was 0.998 (95% CI 0.991-
0.999) and 0.55, for the affected hand 0.996 (95% CI 0.991-0.999) and 0.91 and for 







5 RESULTS PILLAR ONE: 
THE VALIDATION OF THE ATKINS' CRITERIA FOR THE DIAGNOSIS OF COMPLEX 
REGIONAL PAIN SYNDROME (TYPE 1) 
5.1 INCIDENCE OF CRPS AND DIAGNOSTIC AGREEMENT 
The incidence of eRPS (type 1) at nine weeks following injury was similar using 
either criteria (table 7). Fifty-four patients (20.61%) were diagnosed with eRPS 
(type 1) according to the Bruehl criteria and fifty-nine patients (22.52%) were 
diagnosed with eRPS (type 1) using the Atkins criteria. Using the Bruehl criteria as 
a gold standard, there was strong diagnostic agreement (kappa = 0.79, sensitivity = 
0.87, specificity = 0.94). 
Table 7 Incidence of Complex Regional Pain Syndrome according to 
criteria method 
CRPS No CRPS Total 
Bruehl Criteria 54 (20.61%) 208 (79.39%) 262 
Atkins Criteria 59 (22.520/0) 203 (77.48%) 262 
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5.2 DIAGNOSTIC DIFFERENCES 
Disagreement between the Breuhl and Atkins methods was found in nineteen out of 
two hundred and sixty-two patients (Table 8). The main difference between the 
two methods was found to be in pain assessment. Sixteen patients had abnormal 
pain, vasomotor instability, swelling, motor changes, an abnormal joint stiffness 
value and a vasomotor questionnaire score of three or more. Twelve of these 
patients did not complain of any sensory abnormalities (i.e. mechanical or thermal 
hypersensitivity). Their finger dolorimetry ratio however was lowered. Therefore 
these cases have eRPS (type 1) by the Atkins' criteria but not by Bruehl's method. 
In contrast the remaining four patients in this sub-group had a normal finger 
dolorimetry ratio but abnormal forearm hypersensitivity and therefore had eRPS 
by Bruehl's criteria but not using the Atkins' method. 
A further three patients differed due to their finger stiffness assessment. These all 
had eRPS using Bruehl's criteria but did not meet Atkins' criteria because despite 
having an abnormal vasomotor score and an abnormal finger dolorimetry ratio, 
their finger stiffness values were normal. 
No other diagnostic differences were found in the remaining two hundred and 
forty-three patients. 
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Table 8 Diagnostic criteria differences 
Bruehl YES Bruehl NO Totals 
Atkins YES 47 12 59 
Atkins NO 7 196 203 
Totals 54 208 262 
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5.3 DISCUSSION 
Complex regional pain syndrome is commonly seen by two different sets of 
clinicians, orthopaedic surgeons and pain physicians. These two groups will see a 
somewhat different spectrum of disease and their clinical emphasis will be 
different. Thus the orthopaedic surgeon is likely to see patients at an earlier stage 
of disease evolution, the condition may be milder and there may be a greater 
propensity for self-resolution. The mainstay of treatment for these cases is likely to 
be physical therapy and analgesic medication and the orthopaedic surgeon's major 
concern will be restoration of normal joint movement. Such cases have previously 
been labelled "community CRPS" (Wilson et al. 2005). In contrast the pain 
physician will tend to see more severe refractory cases, which require more 
complex pain management and there will be a greater emphasis on pain relief. 
These differences in clinical emphasis have led to researchers from the two 
specialities producing different criteria for the diagnosis of the condition, which has 
contributed to a lack of transparency of research between the disciplines. 
The incidence of CRPS following distal radial fractures historically in retrospective 
studies is low «20/0) (Bacorn et al. 1953; Green et al. 1956; Frykman 1967; Plewes 
1956; Cooney et al. 1980), however prospective studies of patients with injuries to 
the distal radius, tibia and following knee replacement in the acute, early stage of 
recovery from these conditions have repeatedly demonstrated a much higher 
incidence (11-370/0) (Atkins et al. 1990; Schurmann et al. 2007). Some of these 
patients may be considered as having a sub clinical form of CRPS as they could be 
easily missed by the nature of the relative mildness of their symptoms and signs, 
however with detailed clinical assessment and the use of these diagnostic tools they 
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will be recognised in this form of prospective study. Fortunately most of these 
milder forms of eRPS will settle within twelve months of their onset, with 
reassurance, physical therapy and specific specialist pain management only when 
clinically indicated. 
This study demonstrates that the Atkins and the modified IASP (Bruehl's) criteria 
for the diagnosis of eRPS are basically concordant, at least when applied to a group 
of patients with a homogeneous upper limb injury. The differences observed are 
caused by the emphasis on quantification of pain with a consequent concentration 
on the fingers to the exclusion of the remainder of the forearm. 
By using finger dolorimetry to assess hypersensitivity, an area out of the zone of 
direct injury is objectively assessed, a distinction that is not a requirement of 
Bruehl's criteria. 
Quantifying hypersensitivity using finger dolorimetry recognises that mechanical 
allodynia maybe sub clinically apparent to the patient and therefore exclude the 
diagnosis in some patients with eRPS using hypersensitivity as a subjective 
diagnostic requirement. 
Another possible explanation for these sensory differences is that these patients are 
beginning to demonstrate impairment of sensory processing causing 
hypoaesthesia, a phenomenon that has been described in chronic cases of eRPS 
(Veldman et al. 1993). 
There are some limitations to this study that warrant discussion. Firstly 
quantitative equipment to measure temperature or colour changes in the hands of 
our study population was not employed, these techniques have been well described 
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in other studies and would have increased the diagnostic accuracy and strength of 
these conclusions. However previous work by Perez suggests that clinician's 
assessment does correlate well with most measured values in eRPS patients (Perez 
et al. 2005). 
The modified ISAP method of diagnosis has evolved from the original IASP criteria· 
using patients with chronic symptoms and signs of eRPS referred to specialist pain 
units. These patients were assessed at an average of just over nine weeks following 
their injury in a relatively acute situation. It could therefore be argued that patients 
diagnosed with eRPS at this early stage are a completely different entity to the 
typical refractory patient seen in the pain clinic. This again raises the possibility 
that two different types of eRPS exist, one that resolves spontaneously and a more 
refractory type seen in the pain clinic. What is still unclear is whether these two 
extremes of the disease share the same pathophysiological mechanisms. 
One may also question the clinical usefulness of these diagnostic tests. This study 
further highlights that these methods are really only best utilised as research tools. 
They are time consuming to perform in the busy clinic situation and furthermore 
with regards to the Atkins criteria, require baseline comparative data for each 
assessor or clinician for the calculation of abnormal dolorimetry and finger stiffness 
values. A simple, quick, sensitive and specific clinical test for eRPS remains a 
problem. 
This study attempts to further validate those previous prospective studies that 
demonstrate a seemingly high incidence of eRPS following a range of common 
injuries and surgical interventions. This study therefore adds further evidence to 
support this finding. Awareness of a higher than commonly reported incidence of 
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CRPS will perhaps encourage clinicians to assess further those patients in whom 
persisting pain or restriction of limb function goes undiagnosed. 
Whilst it is widely accepted that the majority of these patients labelled with CRPS 
using these diagnostic methods will settle within 12 months, those small numbers 







6 RESULTS PILLAR TWO: 
THE EFFICACY OF ASCORBIC ACID (VITAMIN C) IN THE PREVENTION OF 
COMPLEX REGIONAL PAIN SYNDROME (TYPE 1) FOLLOWING DISTAL RADIAL 
FRACTURE 
6.1 INTERIM ANALYSIS OF RESULTS 
The aim of recruiting a total of two hundred and sixty-two p.atients in order to 
achieve the predetermined level of power and significance was unfortunately not 
possible. 
Due to an irresolvable problem with acquisition of placebo medication towards the 
end of the recruitment period the trial had to be halted early. Statistical advice was 
sort and a decision to perform an independent interim analysis of the results was 
made. 
The results of the interim analysis revealed that attempts at further recruitment 
would be futile given both time restraints and the revised power study results. 
6.2 STUDY EXCLUSIONS 
A total of twenty-nine patients were assessed and excluded from participation in 
the study for various reasons (Figure 7) (Full details in Appendix 9). 
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Figure 7 Trial profile flow chart 
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Completed trial 
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6.3 STUDY WITHDRAWALS 
Following study inclusion, randomisation and receipt of trial medication, a total of 
fifteen patients withdrew from the trial and were not assessed for the study end 
points. 
Eight patients withdrew themselves from the trial and did not wish to take part in 
the study end point analysis. Five patients, despite multiple attempts, were unable 
to be contacted and therefore lost to follow up. One patient was withdrawn after 
developing significant dementia following a fall and subsequent proximal femoral 
fracture. A further patient developed significant symptoms from a cervical nerve 
root radiculopathy secondary to a previous cervical spine injury after inclusion that 
would have prevented a satisfactory clinical assessment (See Appendix 10 for full 
details). 
6.4 PATIENT WITHDRAWALS PRIOR TO PER PROTOCOL 
ANALYSIS 
Eighteen patients were assessed fully for the study end points but were withdrawn 
prior to the per protocol analysis, due to protocol breaches. 
Sixteen patients returned bottles with trial medications remaining and therefore 
had not completed their study medications, one patient despite completing the 
study medications, volunteered she had taken a significant break during the study 
period due to ill health and one patient was excluded due to the requirement of 
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internal fixation of his wrist fracture following late displacement of the initial 
fracture reduction (See Appendix 11 for full details). 
6.5 EFFECT OF ASCORBIC ACID ON THE INCIDENCE OF COMPLEX 
REGIONAL PAIN SYNDROME FOLLOWING A UNILATERAL 
CLOSED DISTAL RADIAL FRACTURE 
6.5.1 METHOD OF ANALYSIS 
The study results were analysed using both an intention to treat analysis and a per 
protocol analysis due to a number of withdrawals following study inclusion and 
randomization. 
6.5.2 GROUP RANDOMIZATION AND COMPLIANCE 
One hundred and two patients were randomised to receive ascorbic acid 500 
milligrams, for fifty days and one hundred and nine patients were randomised to 
receive a lactose placebo. 
The mean time following injury to study inclusion in the ascorbic acid group was 
2.9 days (950/0 confidence interval 2.5-3.4 days, range 0-7 days). The mean time 
following injury to recruitment in the placebo group was 3.6 days (95% confidence 
interval 3.0-4.0 days, range 0-7 days). This difference was not significant (Mann 
Whitney U =3768.000, Z=-1.866, p=0.062). 
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Patients were asked to return their study medication bottles for assessment of 
compliance. In the ascorbic acid group seventy-one patients (73.2%) returned their 
study bottles empty, a further twenty-one (21.6%) stated the study capsules had 
been finished, but had disposed of their bottles prior to the eRPS assessment. Five 
patients (50/0) returned bottles with capsules remaining. In the placebo group sixty-
six (66.7%) returned empty bottles, twenty-five (25.3%) stated the study capsules 
had been finished but did not return their medication bottles and eight patients 
(80/0) returned bottles with capsules remaining. 
6.5.3 POST RANDOMISATION WITHDRAWALS AND INTENTION TO TREAT 
ANALYSIS 
Thirteen patients (120/0) from the ascorbic acid randomisation group were 
withdrawn following study inclusion, leaving eighty-nine patients in the per 
protocol analysis. 
Twenty patients (180/0) from the placebo randomisation group were withdrawn 
following study inclusion, leaving eighty-nine patients in the per protocol analysis. 
End of study outcome assessments were performed on all patients, including those 
withdrawn due to the study protocol wherever possible. Ninety-seven patients 
were assessed for the presence or absence of complex regional pain syndrome in 
the ascorbic acid group. Ninety-nine patients were similarly assessed in the placebo 
group. 
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6.5.4 PATIENT REPORTED ADVERSE AFFECTS OR COMPLICATIONS 
There were no patient reported adverse affects or complications that were 
attributable to the study medications 
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6.6 INCIDENCE OF COMPLEX REGIONAL PAIN SYNDROME 
6.6.1 INTENTION TO TREAT ANALYSIS 
There was no significant difference between the two groups in the incidence of 
complex regional pain syndrome diagnosed using the Atkins diagnostic criteria 
(chi-squared=1.196, p=0.305). 
Sixteen patients (16.50/0) in the ascorbic acid group and eleven patients (11.1 %) in 
the placebo group were diagnosed with complex regional pain syndrome (Relative 
Risk=0.67, 950/0 confidence interval = 0.33-1.38) (table 9). 
6.6.2 PROTOCOL TO TREAT ANALYSIS 
There was no significant difference between the two groups in the incidence of 
complex regional pain syndrome after withdrawn subjects data had been excluded. 
(chi-squared=0.419, p=0.667). 
Fourteen patients (15.70/0) in the ascorbic acid group and eleven patients (12.4%) 
in the placebo group were diagnosed with complex regional pain syndrome 
(Relative Risk=O.79, 950/0 confidence interval=O.38-1.64) (table 9). 
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Table 9 
Effect of Ascorbic acid on the incidence of complex regional pain syndrome 
Intention to treat analysis 
Ascorbic acid Placebo Total 
CRPS 16 11 27 
No CRPS 81 88 169 
Unknown 5 10 15 
Total 102 109 211 )(,2=1.196 
p=0.305 
Per protocol analysis 
Ascorbic acid Placebo Total 
CRPS 14 11 25 
No CRPS 75 78 153 







6.7 EFFECT OF ASCORBIC ACID ON THE INCIDENCE AND SEVERITY 
OF THE FEATURES OF COMPLEX REGIONAL PAIN SYNDROME 
FOLLOWING A UNILATERAL CLOSED DISTAL RADIAL 
FRACTURE - INTENTION TO TREAT ANALYSIS 
6.7.1 FINGER TENDERNESS ASSESSED BY DOLORIMETRY 
Thirty-three patients (340/0) in the ascorbic acid group and twenty-eight patients 
(28.90/0) in the placebo group had abnormal finger tenderness, defined as a 
dolorimetry ratio of less than 0.82. There was no significant difference between the 
groups (chi-squared=0.598, p=0.536). 
The mean dolorimetry ratio in the ascorbic acid group was 0.88 (95% confidence 
interval=0.84-0.92, range=0.38-1.30, median =0.91). The mean dolorimetry ratio in 
the placebo group was 0.88 (95% confidence interval=0.84-0.91, range=0.20-1.35, 
median=0.91). The dolorimetry ratios of the two groups were not significantly 
different (Mann-Whitney U =4739.500, Z=-0.34, p=0.973) (table 10). 
There were significant associations across both groups between an abnormal 
dolorimetry ratio and any pain experienced in the hand or fingers (chi-
squared=15.16, p=<O.OOOl), spontaneous hand or finger pain (chi-squared=4.969, 
p=0.037), exercise induced hand or finger pain (chi-squared=17.44, p=<O.OOOl) 
and allodynia of the hand or fingers (chi-squared=9.071, p=0.004) (table 11). 
There was a significant correlation between the visual analogue score and the 
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dolorimetry ratio (Pearson correlation coefficient=-0.387 (95% confidence interval 
-0.245 to -0.517), p=<O.OOOl) (Table 12). 
6.7.2 PAIN ASSESSMENT 
There was no significant difference between the ascorbic acid and placebo groups 
in the number of patients reporting any hand or finger pain (chi-squared=1.641, 
p=0.253); spontaneous hand or finger pain (chi-squared=0.324, p=0.631); exercise 
induced pain (chi-squared=2.463, p=0.148) and allodynia of the hand or fingers 
(chi-squared=0.370, p=0.594) (table 13). 
The mean Visual Analogue Score (max score=100) in the ascorbic acid group was 
23.0 (950/0 confidence interval 18.0-28.3, range 0-98, median=ll). The mean score 
in the placebo group was 18.3 (950/0 confidence interval 14.0-23.1, range 0-88, 
median=O). There was no significant difference observed between the two groups 
(Mann Whitney U =4327.500, Z=-1.285, p=0.199). 
The Short form McGill pain questionnaire (max score=39) total mean for the 
ascorbic acid group was 4.4 (950/0 confidence interval 3.3-5.7, range 0-27, 
median=1.5). The total mean score for the placebo group was 3.6 (95% confidence 
interval, range 0-27, median=O). The two groups total scores were not significantly 
different (Mann-Whitney U =4616.500, Z=-1.187, p=0.236) (table 10). 
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6.7.3 VASOMOTOR INSTABILITY 
An abnormal vasomotor questionnaire score (max=ll) of three or more was 
recorded in thirty-five patients (36.1%) in the ascorbic acid group and in thirty-
eight patients (38.4%) in the placebo. There was no significant difference between 
the two groups (chi-squared=O.lll, p=0.769). The mean vasomotor instability 
score in the ascorbic acid group was 2.4 (95% confidence interval 1.9-2.9, range 0-
10, median=2). The mean vasomotor instability score in the placebo group was 2.2 
(95% confidence interval 1.7-2.7, range 0-10, median=l). There was no significant 
difference between the two groups (Mann Whitney U = 4616.500, Z=-0.477, 
p=0.634). 
Analysis of the occurrence of the features of vasomotor instability assessed by the 
vasomotor instability questionnaire demonstrated no significant difference 
between the two groups with respect to hand or finger swelling (chi-
squared=0.013, p=1.000), colour changes in the hand or fingers (chi-
squared=1.116, p=0.333), temperature difference between the hands (chi-
squared=0.493, p=0.565) and excessive sweating (chi-squared=1.917, p=0.189) 
(table 13). 
6.7.4 INDEX FINGER SWELLING 
There was no significant difference observed following the analysis of finger 
swelling (p=<O.OOOl). Sixteen patients (16.50/0) in each group had abnormal index 
finger swelling by virtue of an arthrocircometry ratio of 1.33 or greater. 
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The mean index finger arthrocircometry ratio observed in the ascorbic acid group 
was 1.09 (950/0 confidence interval 1.05-1.15, range 0.65-1.88, median=1.0S). The 
mean index finger arthrocircometry ratio observed in the placebo group was 1.11 
(950/0 confidence interval 1.06-1.15, range 0.71-1.69, median=1.09). No significant 
difference was observed between the two groups (Mann-Whitney U =4431.000, Z=-
0.700, p=0.485) (table 10). 
There was a significant association between the presence of reported hand or 
finger swelling in the vasomotor questionnaire and an abnormal index finger 
arthrocircometry ratio across the two groups (chi-squared=12.26S, p=0.001) (table 
15). 
6.7.5 FINGER JOINT STIFFNESS 
An abnormal range of flexion in the finger joints of the affected hand was defined as 
cumulative difference between the hands of -62 degrees or less. This was observed 
in thirty-five patients (36.10/0) in the ascorbic acid group and thirty-five patients 
(35.7%) in the placebo group. No significant difference was detected (chi-
squared=0.003, p=1.000). 
The mean difference in cumulative finger joint range of motion in the ascorbic acid 
group was -59.5 degrees (950/0 confidence interval -78.3 to -43.4 degrees, range= -
372 to +88 degrees). The mean difference in cumulative finger joint range of 
motion in the placebo group was -60.9 degrees (95% confidence interval -78.S to -
44.7 degrees, range= -400 to +S6 degrees). There was no significant difference 
detected between the groups (Mann-Whitney U =4692.000, Z=-0.1SS, p=0.878) 
(table 10). 
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A significant association was observed between the presence of reported subjective 
finger stiffness and abnormal measured finger stiffness across the two groups (chi-
squared=26.106, p=<O.OOOl) (table 16). 
A significant association was also observed across both groups between the 
presence of abnormal measured finger stiffness and an abnormal index finger 
arthrocircometry ratio (chi-squared=26.002, p=<O.OOOl) (table 17). 
6.7.6 GRIP STRENGTH 
Seventy-five patients (78.90/0) in the ascorbic acid group and seventy-nine patients 
(82.3%) in the placebo group had abnormal grip strength by virtue of a grip 
strength ratio of less than 0.73. No significant difference between the two groups 
was observed (chi-squared=0.342, p=0.587). 
The mean grip strength ratio in the ascorbic acid group was 0.55 (95% confidence 
interval 0.51-0.60, range 0.10-1.17). In the placebo group the mean grip strength 
ratio was 0.54 (950/0 confidence interval 0.49-0.58, range 0.13-1.07). No significant 
difference was observed between the two groups (t-test, t=0.617, p=0.538) (table 
10). 
A significant association was demonstrated between patients reporting either a 
severe or slight grip weakness and an abnormal grip strength ratio across both 
groups (chi-squared=87.401, p=<O.OOOl, fishers exact test: p=<O.OOOl) (table 18). 
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6.7.7 TROPHIC CHANGES 
Twenty-five patients (26.0%) in the ascorbic acid group and thirty-nine patients 
(39.4%) in the placebo group reported changes in fingernail growth in the affected 
hand. The difference noted was significant (chi-squared=3.941, p=0.049). 
Eighteen patients (18.80/0) in the ascorbic acid group and sixteen patients (16.2%) 
in the placebo group reported changes in hair growth in the affected hand or 
forearm. The difference was not significant (chi-squared=0.227, p=0.707) (table 
10). 
Significant associations across the two groups were observed between reported 
fingernail changes and observed fingernail changes (chi-squared=19.139, 
p=O.OOOl, fishers exact test: p=<O.OOOl) and reported hair growth changes and 
observed hair growth changes (chi-squared=59.691, p=<O.OOOl) (table 19). 
6.7.8 MOTOR DYSFUNCTION 
Patient reported fine motor control disturbances in the affected hand were 
recorded in thirty-six patients (37.5%) in the ascorbic acid group and forty-one 
patients (41.40/0) in the placebo group. No significant difference was observed (chi-
squared=O.312, p=O.661). 
Eighteen patients (18.80/0) in the ascorbic acid group and thirteen patients (13.1 %) 
in the placebo group reported the presence of a tremor in the affected hand. No 
significant was observed (chi-squared=1.151, p=O.33) (table 10). 
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Table 10 
Effect of ascorbic acid on the features of complex regional pain syndrome 
Intention to treat analysis 
Ascorbic acid Placebo Significance 
n=102 n=109 
Visual Analogue Scale n=97 n=99 U=4327.500 Mean (950/0 CI) 23.0 (18.0-28.3) 18.3 (14.0-23.1) Z=-1.285 
Range 0-98 0-88 p=O.199 
(max score = 100) 
Short form McGill pain score n=96 n=99 U=4321.500 Mean (950/0 CI) 4.4 (3.2-5.7) 3.6 (2.5-4.8) Z=-1.187 
Range 0-27 0-27 p=O.236 
(max score = 39) 
Vasomotor Instability Score n=97 n=99 U=4616.500 
Mean (950/0 CI) 2.4 (1.9-2.9) 2.2 (1.7-2.7) Z=-O.477 
Range 0-10 0-10 p=O.634 
(max score = 11) 
Dolorimetry ratio n=97 n=98 U=4739.500 
Mean (950/0 CI) 0.88 (0.84-0.92) 0.88(0.84-0.91) Z=-O.340 
Range 0.38-1.30 0.20-1.35 p=O.973 
Abnormal dolorimetry ratio n=97 n=98 X2=O.673 
Yes 33(34.0%) 28(28.6%) p=O.443 
No 64(66.0%) (71.4%) 
Index finger circumference n=97 n=97 U=4431.000 
ratio Z=-O.700 
Mean (950/0 CI) 1.09 (1.05-1.15) 1.11 (1.06-1.15) p=O.485 
Range 0.65-1.88 0.71-1.69 
Abnormal index finger n=97 n=97 
circumference ratio x2=<O.OOOl 
Yes 16 16 p=1.000 
No 81 81 
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Finger stiffness (degrees) n=97 n=98 (Cumulative ROM difference) 
U=4692.000 Mean (95% CI) Z=-O.155 
Range 
-60 (-78 to -43) 
-61 (-78 to -45) p=O.878 
-372 to 88 
-400 to 56 
Abnormal finger stiffness n=97 n=98 




No 62(63.9%) 63(64.3%) 
Grip strength ratio n=97 n=96 t=O.617 Mean (950/0 CI) 0.55 (0.51-0.60) 0.54 (0.49-0.58) p=O.538 
Range 0.10-1.17 0.13-1.07 
Abnormal grip strength ratio n=95 n=96 
Yes X2=O.342 
No 75(78.9%) 79(82.3%) p=O.587 
20(21.1%) 17(17.7%) 
Abnormal hair growth n=96 n=99 
reported 
Yes 18(18.8%) 16(16.2%) x2=O.227 
No 78(81.2%) 83(83.8%) p=O.707 
Abnormal finger nail growth n=96 n=99 
reported 
Yes 25(26.0%) 39(39.4%) )(;2=3.941 
No 71(74.0%) 60(60.6%) p=O.049 
Fine motor control n=96 n=99 
dysfunction reported 
x 2=O.312 Yes 36(37.5%) 41(41.4%) 
No 60(62.5%) 58(58.6%) p=O.661 
Tremor reported n=96 n=99 
Yes 18(18.8%) 13(13.1%) X2=1.151 
No 78(81.2%) 86(86.9%) p=O.330 
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Table 11 
The relationship of reported pain and abnormal finger tenderness 
(dolorimetry ratio <0.83) 
Intention to treat analysis 
Abnormal Normal Significance 
dolorimetry Dolorimetry 
n=61 n=134 
Any pain symptoms 
Yes 42(68.9%) 52(38.8%) 1(2=15.157 
No 19(31.1 %) 82(61.2%) p=<O.OOOl 
Spontaneous pain 
Yes 23(37.7%) 30(22.4%) 1(2=4.969 
No 38(62.3%) 104(77.6%) p=0.037 
Pain on exercise only 
Yes 
No 39(63.9%) 43(32.1 %) 1(2=17.444 




Yes 20(32.8%) 19(14.2%) 1(2=9.071 
No 41(67.20/0) 115(85.8%) p=O.OO4 
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Table 12 
The relationship of reported pain (Visual analogue score) and finger 
tenderness (dolorimetry ratio). 
Intention to treat analysis 
Pearson's correlation coefficient 
Visual analogue score and 0.387 (95 0/0 CI 0.245-0.517) 
Dolorimetry ratio p=<0.0001 
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Table 13 
Reported hand and finger symptoms following distal radial fracture 
Intention to treat analysis 
Ascorbic acid Placebo Significance 
n=97 n=99 
Any reported pain 
Yes 51 (52.6%) 43 (43.4%) X2=1.641 
No 46 (47.4%) 56 (56.6%) p=O.253 
Spontaneous pain 
Yes 28 (28.9%) 25 (25.3%) X2=O.324 
No 69 (71.1%) 74 (74.7%) p=O.631 
Exercise induced pain 
Yes 46 (47.4%) 36 (36.4%) X2=2.463 
No 51 (52.6%) 63 (63.6%) p=O.148 
Allodynia 
Yes 21 (21.6%) 18 (18.2%) X2=O.370 
No 76 (78.4%) 81 (81.8%) p=O.594 
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Table 14 
Reported features of vasomotor instability 
Intention to treat analysis 
Ascorbic acid 
n=97 






























The relationship of reported swelling and index finger circumference. 
Intention to treat analysis 
Abnormal index Normal index 






Yes 21(65.60/0) 53(32.7%) x,2=12.265 
No 11(34.4%) 109(67.3%) p=0.001 
Table 16 
The relationship of patient reported finger stiffness and measured finger 
stiffness. 
Intention to treat analysis 
Abnormal finger Normal finger 




Yes 49(71.00/0) 41(32.8%) x,2=26.002 
No 20(29.00/0) 84(68.2%) p=<0.0001 
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Table 17 
The relationship of measured index finger circumference and measured 
finger stiffness 
Intention to treat analysis 
Abnormal finger Normal finger 






Yes 24(34.8%) 8(6.4%) X2=26.002 
No 45(65.20/0) 117(93.6%) p=<0.0001 
Table 18 
The relationship between reported severe weakness and an abnormal grip 
strength ratio. 
Intention to treat analysis 
Abnormal grip Normal grip Significance 
strength ratio strength ratio 
n=153 n=37 
Patient reported 
Severe weakness X2=87.401 
p=<O.OOOl 
Yes 127(83.00/0) 1(2.7%) Fisher's test 
No 26(17.0%) 36(97.2%) p=<O.OOOl 
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Table 19 
The relationship between reported and observed trophic changes in the 
affected hand. 
Intention to treat analysis 
Abnormal growth· Normal growth Significance 
observed observed 
Patient reported n=14 n=181 
abnormal finger 
nail growth )(2=19.139 
p=<O.OOOl 
Yes 12(85.70/0) 52(28.7%) Fisher's test 
No 2(14.30/0) 129(71.3%) p=<O.OOOl 
Patient reported n=30 n=165 
abnormal hair 
growth 
Yes 20(66.70/0) 14(8.5%) )(2=59.691 
No 10(33.3%) 151(91.5%) p=<O.OOOl 
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6.8 COMPLEX REGIONAL PAIN SYNDROME RELATIONSHIPS. 
The data of one hundred and ninety-six patients who were assessed for the 
presence or absence of eRPS were available for review as part of the intention to 
treat analysis to explore associations with the development of eRPS. Twenty-seven 
patients (incidence 13.80/0) were diagnosed with eRPS and one hundred and sixty-
nine patients were considered not be suffering with eRPS (table 20). 
INTENTION TO TREAT ANALYSIS 
6.8.1 CRPS AND GENDER 
Of the twenty-seven patients with eRPS, twenty-five were female (92.6%). In the 
non-eRPS patient group one hundred and forty-seven patients were female 
(87.0%), this difference was not significant (Fishers exact test, p=0.540). 
6.8.2 CRPS AND AGE 
The mean age of the eRPS patient group was 67.4 years (95% confidence interval 
64.0-70.7 years, range 51.0-83.1 years). The mean age of the non-eRPS patient 
group was 69.8 years (95% confidence interval 68.2-71.2 years, range 50.0-92.0 
years). This difference was not significant (t=-1.174, p=0.242). 
136 
6.8.3 CRPS AND SMOKING 
Six of the twenty-seven patients (22.2%) with eRPS regularly smoked tobacco. 
There were twenty-eight patients (16.6%) in the non-eRPS group who regularly 
smoked. This difference was not significant (chi-squared=O.519, p=O.583). 
6.8.4 CRPS AND WORKING STATUS 
Seventeen of the patients with eRPS were employed and ten were retired. There 
was no significant association observed between working status and the 
development of eRPS (chi-squared=1.100, p=O.359) 
6.8.5 CRPS AND HAND DOMINANCE 
There were no associations observed either with the side injured and the 
development of eRPS (chi-squared=2.422, p=O.143) or whether the side injured 
was dominant and the onset of eRPS (chi-squared=1.159, p=0.301). 
6.8.6 CRPS AND REGULAR MULTIVITAMIN USAGE 
Five patients (18.50/0) within the eRPS patient group and sixteen patients (9.5%) in 
the non-eRPS group regularly took a multivitamin tablet prior to study inclusion. 
No significant association was observed between the regular intake of a 
multivitamin tablet prior to study inclusion and the development of eRPS. (Fishers 
exact test, p=O.178). 
137 
6.8.7 CRPS AND FRACTURE MANAGEMENT 
One hundred and four patients (53.3%) required a manipulation as part of their 
fracture care. Twenty-one patients out of a total of twenty-seven who developed 
eRPS underwent a manipulation of their fracture, this association was significant 
(chi-squared=7.524, p=0.007). 
Twenty patients required a remanipulation of their fracture. There was no 
significant association with the need for a remanipulation and the subsequent 
development of eRPS (chi-squared=<O.OOOl, p=1.000). 
The mean time spent in cast in the eRPS patient group was 42.2 days (95% 
confidence interval 39.8-44.7, range 29-61 days). The mean time spent in cast in 
the non-eRPS patient group was 39.5 days (95 0/0 confidence interval 38.3-40.6, 
range 24-65). 
A significant difference was observed in the time spent in cast in the eRPS group 
(median = 43 days) compared to the time spent in cast in the non eRPS group 
(median = 38 days) (Mann Whitney U= 1582.000, Z-score = -2.152, P =0.031). 
Plaster problems were not significantly associated with the development of eRPS 
(chi-squared=4.057, p=0.053). 
The need for physiotherapy prior to clinical study assessment and the development 




The relationship between the development of complex regional pain 
syndrome and patient demographic variables. 
Intention to treat analysis 
CRPS No CRPS Significance 
(n=27) (n=169) 
Gender 
Male 2(7.4%) 22(13.0%) Fisher's test 
Female 25(92.6%) 147(87.0%) p=0.540 
Age (Years) 
Mean (95% CI) 67.4 (64.0-70.7) 69.8 (68.2-71.2) t=-1.174 
Range 51.0-83.0 50.0-92.0 p=0.242 
Smoking 
Yes 6(22.2%) 28(16.60/0) X2=0.519 
No 21(77.8%) 141(83.4%) p=0.583 
Working status 
Working 10(37.0%) 46(27.2%) X2=1.100 
Not working 17(63.0%) 123(72.8%) p=0.389 
Side injured 
Left 12(44.40/0) 102(60.4%) X2=2.422 
Right 15(55.60/0) 67(39.6%) p=0.143 
Dominant arm 
Affected? 
Yes 14(51.9%) 69( 40.8%) X2=1.159 
No 13(48.1%) 100(59.2%) p=0.301 
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CRPS No CRPS Significance 
(n=27) (n=169) 
Multivitamins 
Yes 5(18.50/0) 16(9.5%) Fisher's test 
No 22(81.5%) 153(90.5%) p=0.178 
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Table 21 
The relationship between the development of complex regional pain 
syndrome and fracture management variables. 
Intention to treat analysis 




Yes 21(77.8%) 84(49.7%) x,2=7.524 
No 6(22.20/0) 85(50.3%) p=O.OO7 
Fracture 
remanipulated 
Yes 3(11.1%) 19(11.2%) Fisher's test 
No 24(88.9%) 150(88.8%) p=1.000 
No. of days 
immobilized 
U=1582.000 
Mean (950/0 CI) 42.2 (39.8-44.7) 39.5 (38.3-40.6) Z=-2.152 
Range 29-61 24-65 p=O.031 
Plaster problems 
reported 
Yes 8(29.60/0) 24(14.2%) X2=4.057 




Yes 17(63.00/0) 50(29.6%) x,2=11.528 
No 10(27.00/0) 119(70.4%) p=O.OO1 
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6.9 STUDY GROUP DEMOGRAPHICS 
The demographic data of the two treatment groups were analysed in order to 
demonstrate any significant differences within the variables collated. The data was 
subjected to both an intention to treat analysis and a per protocol analysis. 
INTENTION TO TREAT ANALYSIS 
6.9.1 AGE 
The mean age of the ascorbic acid group was 69.7 (95% confidence interval 67.6-
71.7, range 50.0-91.1). The mean age of the placebo group was 69.1 (95% 
confidence interval 67.1-70.9, range 51.0-92.0). No significant difference was 
observed (t-test, t=0.458, p=0.647) (table 22). 
6.9.2 SEX 
There were eleven males (10.80/0) and ninety-one females (89.2%) in the ascorbic 
acid group. In the placebo group there were fourteen males (12.8%) and ninety-five 
females (87.20/0). No significant difference was observed (chi-squared=0.214, 
p=0.696) (table 22). 
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6.9.3 SMOKING 
Thirteen patients (12.7%) in the ascorbic acid group and twenty-five patients 
(22.90/0) in the placebo group were regular tobacco smokers. This difference was 
not significant (chi-squared=3.706, p=0.072) (table 22). 
6.9.4 EMPLOYMENT STATUS 
Thirty patients (29.40/0) in the ascorbic acid group and 31 patients (28.4%) in the 
placebo group were in regular employment. The remainder in each group were 
either retired or housewives. There was no significant difference in working status 
between the two groups. (chi-squared=0.024, p=0.881) (table 22). 
6.9.5 INJURY SIDE AND DOMINANCE 
Fifty-seven patients (55.9%) were left-handed and forty-five (44.1 %) right handed 
in the ascorbic acid group. Sixty-five patients (59.6%) were left-handed and forty-
four (40.4%) were right handed in the placebo group. There was no significant 
difference observed (chi-squared=0.304, p=0.676). 
Forty-one patients (40.2%) in the ascorbic acid group and forty-nine (45%) 
patients in the placebo group had injured their dominant wrist. There was no 
significant difference observed (chi-squared=0.488, p=0.490) (table 22). 
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6.9.6 TREATMENT GROUPS STUDY PROTOCOL ANALYSIS 
The mean time from day of injury to day of recruitment and commencement of 
study medications was 3.0 days (95% confidence interval 2.5-3.4, range 0-7) in the 
ascorbic acid group and 3.6 days (95% confidence interval 3.0-4.0, range 0-7) in the 
placebo group. There was no significant difference between the two groups (Mann-
Whitney U=3768.000, Z=-1.866, p=0.062). 
Patients were asked to return their study medication bottles as a marker of 
medication compliance and were also asked if they had managed to complete the 
fifty day treatment course. Ninety (92.8%) of the ascorbic acid group and ninety 
(90.90/0) of the placebo group stated that they had taken their study medications as 
prescribed. No significant difference was observed (chi-squared=0.236, p=0.79S). 
Of the ascorbic acid group who had completed the study medications seventy-one 
(78.90/0) returned their study medication bottles empty. Of the placebo group who 
had completed their study medications, sixty-six (73.3%) returned their study 
medication bottles empty. No significant difference was observed (chi-
squared=0.764, p=0.485) (table 23). 
6.9.7 FRACTURE MANAGEMENT 
Fifty patients (49.50/0) in the ascorbic acid group and sixty-three patients (57.8%) 
in the placebo group required a manipulation of their fracture as part of their initial 
fracture management. There was no significant difference observed (chi-
squared=1.451, p=0.268). 
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Remanipulation of the fracture was required in twelve patients (11.8%) in the 
ascorbic acid group and in eleven patients (10.1 %) in the placebo group. There was 
no significant difference observed (chi-squared=0.152, p=0.826). 
The mean length of time spent in cast was 39.7 days (95% confidence interval 38.3-
41.3, range 27-65) in the ascorbic acid group and 40.0 days (95% confidence 
interval 38.6-41.5, range 24-64) in the placebo group. No significant difference was 
observed (Mann-Whitney U =4035.000, Z=-0.669, p=0.505). 
Physiotherapy was initiated in the fracture management following cast removal in 
thirty-six patients (35.3%) in the ascorbic acid group and thirty-one patients 
(28.40/0) in the placebo group. No significant difference was observed (chi-
squared=0.733, p=0.452) (table 24). 
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Table 22 
Treatment groups demographic data 
Intention to treat analysis 
Ascorbic Acid 
n=102 
Age (years) n=102 
Mean (950/0 CI) 69.7 (67.6-71.7) 
(Range) 50.0-91.1 
Sex n=102 
Male 11 (10.80/0) 
Female 91 (89.2%) 
Smoker n=102 
Yes 13 (12.70/0) 
No 89 (87.3%) 
Employment n=102 
Retired 69 (67.6%) 
Employed 30 (29.4%) 
Unemployed 1 (1%) 
Housewife 2 (2 0/0 
Fractured wrist n=102 
Dominant side? 




























Trial medicine data 
Intention to treat analysis 
Ascorbic Acid 
n=102 
Days recruited post n=92 
injury 
Mean (950/0 CI) 2.9 (2.5-3.4) 
Range 0-7 
Trial medicines n=97 
completed? 
Yes 90 (92.8%) 
No 7 (7.20/0) 
Trial medicine n=92 
compliance 
Bottles empty 71 (77.2%) 
Bottles not returned 21 (22.8%) 
Clinical assessment n=97 
(Days post injury) 












90 (90.9%) p=0.795 
9 (9.1 %) 
n=91 
X2=0.764 








Treatment groups fracture management 





Yes 50 (49.5%) 
No 51 (50.5%) 
Type of anaesthesia n=50 
used 
Biers block 26 (52%) 
Haematoma block 9 (18%) 
Sedation 14 (28%) 
General anaesthetic 1 (2%) 
Fracture n=102 
remanipulated 
No 90 (88.2%) 
Yes 12 (11.8%) 
Time in plaster cast n=92 
(Days) 
Mean (95 O/oCI) 39.7 (38.3-41.3) 
Range 27-65 
Physiotherapy after n=97 
cast removal 







63 (57.8%) p=0.268 
46 (42.2%) 
n=63 
Fishers test = 
21 (33.3%) 13.402 
16 (25.4% 













31 (28.4%) p=0.452 
68 (62.4%) 
6.10 PER PROTOCOL ANALYSIS 
Other than no statistical significance detected in the incidence of reported 
fingernail changes between the two groups (p=O.054), there were no differences 
observed in the results for features of eRPS study group demographics or study 
protocol analysis when a per protocol analysis was applied to the study data. 
These results are summarised in tabular form in Appendix 12. 
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6.11DISCUSSION 
The efficacy of ascorbic acid on the prevention or reduction in incidence of eRPS at 
a minimum of nine weeks following a distal radial fracture was investigated. 
The evidence for a significant role for free radical induced tissue-damage, as an 
initiator in the pathogenesis of the condition is compelling. A small number of 
prospective and retrospective studies have demonstrated that administration of 
ascorbic acid may well prevent the development of CRPS in some individuals 
following a traumatic insult such as a fracture or elective surgery. 
The results of this study demonstrate that the administration of ascorbic acid for a 
period of fifty days during fracture healing following a distal radial fracture did not 
influence the incidence of eRPS when diagnosed using a criteria that has been 
successfully validated against a widely accepted and reported on gold standard. In 
addition the individual features of eRPS in the hand such as pain, tenderness, finger 
stiffness, vasomotor instability and motor symptoms and signs which lead to much 
of the disability and suffering endured by individuals with the condition were not 
improved by administration of ascorbic acid. There was a statistically significant 
difference observed in the placebo group for reported incidence of fingernail 
growth using an intention to treat analysis (p=0.049). 
The incidence of CRPS in the ascorbic acid group was in fact higher than in the 
placebo group, although with the numbers recruited, this was not statistically 
significant. 
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Based on an intention to treat analysis, to detect a difference of 5.4% (15.5% versus 
10.1 %) with a significance of 0.05 and a power of 0.80, a sample size of 601 per 
group (1,202 in total) would be required. For a power of 0.90, this would be 80S 
per group (1,610 in total), assuming no loss to follow up. Whether the observation 
of a potential deleterious affect of ascorbic acid on the occurrence of CRPS in this 
study is in deed true remains to be proven. This study is underpowered with 
respect to this observation; therefore these results and trends may simply reflect a 
type II error. 
The incidence of eRPS in either group in this study is lower than those previous 
studies using the Atkins criteria (Atkins 1990; Bickerstaff 1994; Sarangi 1995; 
Livingstone 2002). The lower limit of the reference range for normal dolorimetry 
in this study was calculated as 0.82, which is lower than previous studies. Even 
allowing for this as a factor and reanalysing the results with the higher limit of 0.92 
described by Bickerstaff et al, would only increase the yield of CRPS diagnoses to 
20.590/0 in the ascorbic acid group and 16.51 % in the placebo group. 
Whilst this study cannot directly explain this finding, there may be a number of 
possible explanations. The care of distal radial fractures may have improved with 
regard to minimising the period of immobilisation and providing patients with 
lightweight, appropriately fitting upper limb casts that do not restrict finger and 
thumb movement, and do not increase the risk of cast induced swelling. There may 
be better patient education with regards to early and appropriate analgesia and 
anti-inflammatory medication, self-mobilisation and the importance of upper limb 
elevation to minimise swelling. The health of the population maybe changing for 
the better and the observed fall in incidence maybe an indirect marker of this. 
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Further studies are required to confirm this observation that may also allow the 
investigation of whether there are specific environmental or genetic factors 
involved. 
The diagnostic criteria utilised differed from those of Zollinger's study. The 
elements of the Veldman criteria do not differ significantly from those of Atkins or 
Bruehl and it would therefore seem unlikely that the differences observed in this 
study could be attributable purely to the criteria used. 
The length of prophylactic intervention, dosage and administrative route were all 
intentionally designed to mirror Zollinger's study to allow comparison. 
This study was designed to allow recruitment of a continuous group of patients 
presenting with an acute injury. The ideal was to recruit patients on the day of 
injury but due to the nature of the fracture referral system to the orthopaedic 
fracture clinic and the large number of emergency department clinicians dealing 
with potential study participants this was not always possible. Although there was 
no statistical difference between the two treatment groups there was on average 
three days between injury and recruitment. It remains to be proven whether this 
factor had any bearing on the results observed in this study. 
Although this study endured a not insignificant drop out rate, a problem not 
encountered in a previous similar study (Zollinger et al. 2007), there was no 
difference seen between the per protocol analysis and the intention to treat 
analysis with respect to the primary and secondary study questions. 
Evidence from a variety of clinical and animal studies supports the benefits of 
antioxidant treatment in preventing symptoms and reducing the markers of free 
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radical damage or oxidative stress following acute }'nJ'ury ho h d' 
, wever ot er stu les 
report conflicting results. 
It is known that in vitro ascorbic acid acts as a pro-oxidant reacting with free iron 
to produce the ascorbate free radical, this is believed in healthy subjects not be of 
physiological significance, however in healthy subjects loaded with ascorbic acid 
and iron salts DNA damage in leukocytes has been observed (Rehman et al. 1998). 
Free iron release from tissue does however occur in the presence of inflammation 
(Biemond et al. 1984) and sepsis. Increasing levels of ascorbate free radical have 
been observed in septic patients supplemented with ascorbic acid compared to 
controls (Galley et al. 1996). 
In a clinical study on healthy volunteers supplementation with either ascorbic acid 
and the water-soluble antioxidant N-acetyl cysteine or placebo following an 
exercise-induced acute muscle injury to the upper limb caused an increase in 
detectable antioxidant levels, free iron cellular damage markers and markers of 
oxidative stress in the treatment group. Subjective pain and arm range of 
movement were not significantly different at the study end pOint between the two 
groups (Childs et a1. 2001). 
Recently the benefits observed in an animal model of acute pancreatitis following 
antioxidant treatment have not been reproduced in a prospective blinded 
randomised human clinical trial. Supplementation with intravenous N-acetyl 
cysteine, selenium and ascorbic acid was compared to placebo, with a primary end 
point of organ dysfunction at seven days measured. Early interim analysis revealed 
no statistically significant difference between the two groups, for either the primary 
end point or other secondary end points. A trend towards increased mortality and 






7.1 ANSWERS TO PRIMARY STUDY QUESTIONS 
7.1.1 PILLAR ONE 
1. Does the diagnostic criteria for complex regional pain syndrome as 
described by Atkins agree with the up to date IASP diagnostic criteria 
described by Bruehl when used to assess a series of patients following a 
distal radial fracture? 
The results of the first pillar of this study comparing the Atkins criteria with those 
of the modified IASP criteria described by Bruehl when assessing a series of two 
hundred and sixty-two patients following a distal radial fracture for CRPS show a 
strong agreement between the two methods. 
The incidence of CRPS at nine weeks following injury was 20.61 % according to the 
Bruehl criteria and 22.520/0 using the Atkins criteria. Using the Bruehl criteria as a 
gold standard, there was strong diagnostic agreement (kappa = 0.79, sensitivity = 
0.87, specificity = 0.94). 
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7.1.2 PILLAR TWO 
2. Does the administration of ascorbic acid SOOmg once daily for fifty days 
following injury reduce the incidence or prevent the development of 
complex regional pain syndrome (type 1) following a closed distal radial 
fracture? 
In this study the incidence of CRPS following a distal radial fracture was not 
reduced or prevented when assessed for at a minimum of nine weeks following 
injury. There were a greater number of individuals diagnosed with CRPS in the 
ascorbic acid group (16.5 0/0) than in the placebo group (11.1%), this was not 
statistically significant. 
3. If the incidence of complex regional pain syndrome (type 1) is not 
significantly altered following the administration of ascorbic acid, does the 
treatment: 
• Improve any of the individually measured features of the 
• 
condition occurring in the affected hand (pain, tenderness, 
finger stiffness, grip strength, finger swelling)? 
Reduce the occurrence of other features of the condition 
occurring in the affected hand (vasomotor instability, motor 
dysfunction and trophic changes)? 
In this study administration of ascorbic acid following a distal radial fracture did 
not significantly improve any of the individual disease features associated with 
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eRPS other than fingernail changes. The incidence of t d f" . . repor e mgernall changes m 
the ascorbic acid group was 26.0% and in the placebo group 39.4% (p=0.049). 
7.2 SECONDARY STUDY QUESTIONS 
7.2.1 PILLAR ONE 
1. Does history of current or recent smoking increase the risk of developing 
complex regional pain syndrome following a distal radial fracture? 
In this study the incidence of a history of smoking was 22.2% in patients diagnosed 
with eRPS and 16.60/0 in patients diagnosed as non-eRPS. This difference was not 
statistically significant (p=0.583). This result would therefore support the view 
that the risk of developing eRPS is not increased by a history of smoking. 
2. Is there an association between the time immobilised in cast and the 
occurrence of complex regional pain syndrome? 
This study demonstrated that those individuals who developed eRPS were 
statistically more likely to have been immobilised in a forearm cast for longer than 
those assessed not to have developed eRPS. There was also a significant 
relationship between the need for fracture reduction and the development of eRPS, 
suggesting that those with a more significantly displaced fracture, requiring 
reduction and therefore perhaps a longer period of immobilisation may be at risk of 
developing eRPS. Length of time in cast maybe dictated by the clinical assessment 
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of fracture union, this includes assessment of tendernes h f . 
s over t e racture sIte. 
This feature maybe difficult to accurately assess in the patient who has developed 
eRPS and therefore additional cast time may be advised in these patients. 
7.3 FUTURE RESEARCH 
Many questions remain unanswered concerning eRPS, in particular what are the 
exact events that trigger the condition and does more than one condition exist 
under the umbrella of eRPS. 
The role of the inflammatory system remains at the forefront of research into the 
pathophysiology of the condition and with the recent development of two 
interesting animal models to compliment ongoing human trials further knowledge 
and developments are anticipated. 
This study is one of a small number that have investigated the potential of a simple, 
apparently safe and inexpensive intervention to prevent the development of eRPS 
following a traumatic insult. It is however the first to demonstrate that ascorbic 
acid may not prevent the onset of eRPS and in fact may increase the risk of 
developing it. 
With compelling evidence in the literature suggesting a role for free radicals in the 
development of eRPS further studies are needed to investigate this theory. Further 
trials using validated diagnostic criteria are needed to confirm the results of this 
study that when given acutely after an injury ascorbic acid confers no benefit on the 
patient. As well as trials on patients following trauma, studies involving elective 
surgical interventions such as total knee replacements could be utilised. Such a 
population groups offers the advantage of a more controlled study group, which 
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allow some of the confounding factors encountered in a traumatic group, such as 
timing of administration of pharmaceutical interventions to be minimised. 
Human trials may benefit from animal study confirmation of the role of 
antioxidants in the prevention or treatment of eRPS, such work would allow the 
investigation of different types and combinations of antioxidants and also whether 
timing of the intervention in relation to the insult has any bearing on the outcome. 
The condition as a whole requires further assessment into its effect on functional 
outcome in a prospective setting. Whilst we know from historical studies that the 
majority of cases of post traumatic eRPS improve given time, the impact of the 
individual components of the condition, particularly pain, stiffness, motor 
dysfunction and sensory disturbance over time have not been fully assessed with 
contemporary functional outcome measures and quality of life scores. In addition 
to those patients who meet the criteria for a full-blown case of eRPS following 
trauma are those who have some features of the condition but not enough to meet 
the diagnostic criteria. It is plausible that these patients function are as affected as 
those labelled with eRPS, suggesting that the spectrum of eRPS needs to widened to 
include these patients to ensure that appropriate rehabilitation and pain 
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9.1 APPENDIX 1 
Patient information sheet 
g~ University of 
UJf:j BIUSTOL 
United Bristol Healthcare '~/:kj 
NHS Trust 
Department of Orthopaedic & Trauma Surgery 
PATIENT INFORMATION SHEET 
A trial of the effectiveness of Vitamin C to prevent CRPS following wrist fracture 
A double blind randomised controlled trial to compare Vitamin C 500mg daily and 
placebo in the prevention of Complex Regional Pain Syndrome (CRPS) in patients 
following wrist fracture 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with your friends, family or your GP if you wish. Ask us if there is anything that is 
not clear or if you would like more information. Take time to decide whether or not 
you wish to take part. 
What is the purpose of the study? 
About one quarter of patients who fracture their wrist will develop a condition 
called Complex Regional Pain Syndrome (CRPS). CRPS causes pain, swelling and 
changes in the colour of the skin of the hand after a wrist fracture. The condition is 
usually temporary and most people's symptoms have settled after 1 year. 
We would like you to help us test the effects of whether Vitamin C, taken as a tablet 
whilst your fracture is healing in a plaster, can stop CRPS occurring. 
Why have I been chosen? 
You have been invited to take part because you have fractured your wrist and have 
only required minimal treatment in a plaster cast so far. We cannot effectively test 
for CRPS in patients with certain hand or arm problems or who have had an 
operation on their fracture. You are therefore suitable to take part in this trial. 
183 
Do I have to take part? 
No, taking ~art is voluntary. It is ~p to you to decide whether or not to take part. If 
you do decIde to take part we WIll ask you to sign a consent form and give you a 
copy of this in~ormation s?eet and the consent form to keep. If you decide to take 
part you are ~tIll free to WIthdraw at any time. If you decide not to take part you do 
not have to gIVe a reason, nobody will be upset and the standard of care you receive 
will not be affected. 
What willI be asked to do if I take part? 
You will either be given the test drug (Vitamin C) or a placebo. A placebo is a 
dummy tablet that looks like the real thing but contains no active ingredients. You 
will be allocated to either Vitamin C or the placebo by chance, that is randomly, like 
flipping a coin. You have an equal chance of being allocated either Vitamin C or the 
placebo. The tablets are made to look identical so that neither you nor the research 
doctor will know which tablet you are taking. At the end of the trial we break the 
code to find out which tablet you a have been taking. We will ask you to take the 
tablet once a day for 50 days. 
If you agree to join the study today we will ask you some questions about your 
general health and the how you fractured your wrist. 
We will ask you to start the tablets from today. 
Over the next few weeks you will be under the care of one of the orthopaedic 
consultants and will receive the normal standard care for wrist fractures that 
usually involves being in a plaster cast for up to six weeks. 
When you return for your follow up appointment in the fracture clinic in nine 
weeks as well as the routine questions and examination that normally takes place 
at this appointment, you will be asked some specific questions about your hand and 
some simple measurements will be taken to assess the size of your hand and the 
movements in your fingers. 
One of these measurements involves testing for any discomfort in your hand. The 
device we use for this is made from a piece of blunt plastiC. It may cause you some 
discomfort for a few seconds. It does not involve a needle or any other sharp parts. 
These tests and measurements will enable us to tell you whether you have CRPS or 
not. If you do develop CRPS we will refer you for treatment. 
Will I need to attend any extra clinic appointments? 
No. Instead of seeing one of the normal clinic doctors after you come out of plaster 
at nine weeks you will see the research doctor who will assess your hand for the 
presence of CRPS as well as ensuring your fracture as healed satisfactorily. This 
appointment will take about 30 minutes to complete. 
What are my responsibilities? 
During the study you will need to take the study tablets every day. It does not 
matter what time of day you take them. You may take all your usual tablets and any 
painkillers that you may need to take whilst your fracture is healin~. When you 
come to the clinic in nine weeks please bring your study tablet bottle WIth you. 
Can I buy and take my own Vitamin C tablets? 
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It is very important in this study that you do not buy and take Vitamin C tablets on 
top of the study tablets you have been given. If you do this will adversely affect the 
results of the study. 
What other treatments are available? 
At the moment there are no other known treatments to prevent CRPS occurring. 
What are the possible side effects of taking part? 
As far as we know taking Vitamin C SOOmg once a day is entirely safe. It has been 
used in a wide range of trials for other medical conditions without any clinically 
significant side effects. 
What are the possible benefits in taking part? 
We hope that Vitamin C will help you more than the placebo, but this cannot be 
guaranteed. The information we get from this study may help us prevent or reduce 
the number of CRPS cases we see occurring after wrist fractures. 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the treatment being studied. If this happens your research doctor 
will discuss it with you and you can then decide whether you wish to continue in 
the study. 
What happens when the research study is finished? 
If you develop CRPS you will be referred for treatment. If you require treatment for 
any other condition related to you wrist fracture this will continue under the care 
of your orthopaedic consultant. 
Will my taking part in this study be kept confidential? 
Your medical records will only be examined by the research doctor. No outside 
body or drug company is involved with this trial. 
Will my GP be informed of my involvement in this study? 
Yes we will inform your GP so he/she understands the reason why you have been 
asked to take a tablet whilst your fractured wrist is healing. If you do not want your 
GP to know about your involvement in this trial this would prevent you from taking 
part. Again this will not affect your treatment and you do not have to tell us why 
you do not want your GP informed. 
What will happen to the results at the end of the research study? .. 
The results of this study will not be known until sometime after the last patIent ~n 
the study has been examined (in about 18 months time). The research doctor. WIll 
let you know the results and which treatment you were taking. The re.sults .':111 be 
reported in professional publications or meetings but you will not be IdentIfIed by 
name. 
Who has reviewed the study? 
The United Bristol Healthcare Trust Research Ethics Committee and Weston Local 
Research Ethics Committee has approved the study. 
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Thank you for considering taking part in this research. 
Mr Andrew McBride MRCS(Ed) 
Clinical Research Fellow 
Department of Orthopaedic & Trauma Surgery 
Bristol Royal Infirmary 
Tel: 0117 928 2878 
Version No.2 April 2003 
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9.2 APPENDIX 2 
Consent form 
CONSENT FORM 
~~ University of ~f:J BIUSTOL 
United Bristol Healthcare '~/:bj 
NHS Trust 
Department of Orthopaedic & Trauma Surgery 
A trial of the effectiveness of Vitamin C to prevent CRPS following wrist fracture 
Patient ID 
trial: 
Please initial box 
Patient ID No. for 
I confirm that I have read and understand the information sheet dated '--
(version ) for the above study and have had the opportunity to ask o 
questions. 
I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being 
affected. 
I agree to take part in the above study. 
Name of Patient 
Researcher 
Mr Andrew McBride 




Department of Orthopaedic & Trauma Surgery 
Bristol Royal Infirmary 
Marlborough Street 





March 2004 (Version 2) 
o 
9.3 APPENDIX 3 
General practitioner information sheet 
tt~ Universitvof m~BIUSTbL 
United Bristol Healthcare '~l:kj 
NHS Trust 
Department of Orthopaedic & Trauma Surgery 
GENERAL PRACTITIONER INFORMATION SHEET FOR CLINICAL TRIAL 
Prevention of Complex Regional Pain Syndrome after Wrist fractures 
Your patient: 
HAS AGREED TO TAKE PART IN THE FOLLOWING RCT: 
Complex Regional Pain Syndrome (CRPS) is a little understood condition 
comprising of excessive tenderness, swelling, joint stiffness and colour, 
temperature and sweating abnormalities of the arm or leg that may occur following 
an injury. 
For every four people who fracture their wrist one person will develop a form of 
CRPS. This is usually a mild form and symptoms settle over four to six months. The 
more severe form is less common but causes considerable disability and is often 
difficult to treat successfully. 
CRPS maybe caused by free radical induced damage 
Vitamin C may help to reduce the chances of developing CRPS following wrist 
fracture. 
We would like to assess scientifically the effectiveness of Vitamin C in reducing or 
preventing patients getting CRPS after a wrist fracture and this can only be done 
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th.rolugh a PROSPECTIVE, RANDOMISED, DOUBLE BLIND, CONTROLLED clinical 
trIa. 
We are asking all pati~nts ove.r SO years old with a wrist fracture to take part in a 
study where some patIents WIll be given Vitamin C tablets and some patients will be 
given a sham or placebo tablet which has no effect. 
Involvement in this trial will involve: 
Recruitment into the trial will take place within 24 hours of presentation to 
Frenchay Hospital. 
If your patient agrees to enrol they will be given a course of tablets to take over the 
next SO days. They may be given Vitamin C 500mg or the inactive placebo tablet, 
which will mean taking TWO CAPSULES PER DAY. The BRI pharmaCist will hold the 
trial code and decide which tablet your patient is given. 
The dose of Vitamin C is safe and will not affect other medications they are taking. 
If your patient normally takes other Vitamins or multivitamins they should 
continue taking them. 
They will continue to be treated by the orthopaedic team responsible for their wrist 
fracture. Involvement in the trial will not affect the type of treatment they receive. 
At nine weeks from the time of the fracture your patient will be seen in the fracture 
clinic by the research doctor who will ask some questions and then perform some 
tests on their hands and fingers to look for symptoms and sign of CRPS. 
Patients are not obliged to enter this study and are free to withdraw from the trial 
at any time without giving a reason. This will not affect any other treatment they 
may need. 
Please feel free to contact us for any other information. 
INCLUSION CRITERIA: 
1. Over SO years of age 
2. Isolated unilateral closed fracture of the distal radius that is managed by cast 
immobilisation (+ I-MUA) (+ I-percutaneous wire fixation) 
EXCLUSION CRITERIA: 
1. Patients with any other ipsilateral upper limb injury. . 
2. Patients with any contra lateral upper limb injury. The contra later~l.arm IS 
used as an internal control in the study and any injury would affect the valIdIty of 
this method. 
3. Patients with dementia or who are unable to fully co-operate with the 
assessment are excluded as the assessments of pain and dolorimetry rely on 
patient's subjective response to a stimulus. 
4. Patients with pre existing hand pathology that woul~ affect the 
measurements (Le. rheumatoid arthritis, severe Dupuytren. s contract~re e:c) are 
excluded as this would compromise the validity of comparIng the patIents Injured 
and uninjured hand. Conditions that would alter the patients pain threshold or 
finger movement would affect the validity of the assessment method. 
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5. Patients currently taking a therapeutic dose of Vitamin C on medical 
grounds. 
6. Patients with fractures treated with operative fixation. Internal fixation 
requires significant tissue dissection and risks injury to small cutaneous nerves that 
may prejudice pain responses. External fixators may similarly cause cutaneous 
nerve injury and restrict tendon movement thus potentially affecting finger 
stiffness. (percutaneous wire fixation is permitted) 
In the event of any difficulty or problems you can contact 
Mr Andrew McBride MRCS(Ed) 
Clinical Research Fellow 
Department of Orthopaedic & Trauma Surgery 
Bristol Royal Infirmary 
Bristol 
BS2 8HW Tel: 0117928 2878 Version 4 January 2004 
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9.4 APPENDIX 4 
Trial proforma 
Vitamin C/CRPS Trial Proforma 









Sex: Male D Female D 
Occupation 
Smoker Yes D No D 
Injury 
Date Time 
Injured Wrist Left D Right D Frykman 
Dominant Hand Yes D No D 
Treatment Date Time 
Initial Reduction None D MUA D 
Anaesthetic Biers block GA Sedation Haematoma block None 
No of Remanipulations 0 1 2 3 4 K-Wires D 
Pre-existing ipsilateral or contralateral upper limb pathology YES D 
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Currently taking Vitamin supplements YES D 
Patient Trial No. 
Second Visit 
Days post 1st reduction 
Removal of POP date ____ _ 
No. of days immobilised 
Plaster problems? Yes D No D 
Physiotherapy Yes D No D 
Physio started on: 
Trial medications completed? Yes D No D 
Pill bottle returned? Empty D Capsules remaining D 
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Visual Analogue Score 
NO PAIN 
Present Pain Intensity 







Nail Growth Yes 
Hair Colour/Growth Yes 
Yes D No D 
Yes D No D 
Yes D No D 
Mild Moderate Severe 
SEVERE PAIN 
EJ NOEJ No 
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Patient Trial No. 
Function 






Present Yes D No D 
Daily Yes D No D 
am D pm D all day D 
Vasomotor Instability 
Have you noticed any changes in the appearance of your hand compared to the 
other recently, and if so, what changes exactly? 
Have you noticed any changes in the colour of your hand recently, and if so what? 
Has your hand felt any different from the other hand recently, since the accident, 
and if so, in what way? 
Has the temperature of your hand felt in any way different from the other hand 
recently, and if so in what way? 
Has your hand been bluer than the other hand recently, or bluer than it was before 
the accident and if so under what circumstances? 
Has your hand been redder than the other hand recently, or redder than it was 
before the accident and if so under what circumstances? 
Has your hand felt warmer than the other hand recently, or warmer than it did 
before the accident and if so under what circumstances? 
Has your hand felt cooler than the other hand recently, or cooler than it did before 
the accident and if so under what circumstances? 
Has your hand responded differently to changes in environmental temperature 
recently, and if so in what way? 
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Have you noticed you hand going red and warm in a hot environment or blue and 
cold in a cool environment? 
Does your hand sweat or perspire more than it used to or more than the other side 
recently? 
Clinical Findings 
Swelling Yes D No D 
Colour Red D Blue D White D Normal 0 
Sweating Yes D No D 
Skin Changes Yes D No D 
N ail Changes Yes D No D 
Hair Growth Yes D No D 
Others 
Dolorimetry 
Fracture side Control 







Patient Trial No. 













Fracture side Control 







INDEX FINGER SWELLING 
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9.5 APPENDIX Sa 
Dolorimetry measurement results from 19 control subjects. 
Statistical significance between the right and left hand was assessed using a paired t 
test. 
Finger Right Standard 
Location Mean Deviation 
.. ......... 
IMCP] 2578.94 892 .92 
IPP 2731.57 1060.42 
IPIP] 3026.31 972 .30 
-- ...................... -... . ......... ........ ........ 
IMP 3047.36 905.15 
..................... , ................................ t····· 
lDIP] 3257.89 1110.21 
............................................................... 
MMCP] 2515 .78 941.19 
.......... 
MPP 2794.73 1011.85 











MPIP] 2836.84 955 .80 2805.26 
. ' ..... . ............. ....... . 
MMP 3352.63 962.84 3421.05 
....... ............... . ....... - ...... . 
MOIP] 3089.47 1009.89 3247.36 
... -. ....................... ' .......................................... -
RMCP] 2642.10 859.14 
................ ............ 
RPP 2742.10 818.74 





























....... - .... 
2468.42 936.92 
............ 
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Sex Right:Left Left: Right 
F 0.93 1.07 
F 0.76 1.32 
F 1.03 0.97 
M 1 1 
F 1.03 0.97 
0.99 1.01 
M 0.96 1.04 
M 1.04 0.96 
F 1.02 0.98 
M 1.05 0.96 
M 0.99 1.01 
F 0.88 1.13 
F 0.9 1.11 
F 0.96 1.05 
F 0.94 1.06 
F 0.99 1.01 
M 0.98 1.02 
F 1.19 0.84 
F 1.05 0.96 
198 















Std. Error of Skewness 
Kurtosis 



























Stu De,' 092 
N • 38 
9.7 APPENDIX 5c 
Control group reliability study - dolorimetry scores for individual finger sites 
right hand 
Finger' Mean Right . Mean Right 
r- .. - ~f,JSI~~f,JI1J ________ -------- ...... _____ Jst ' ____________ _____ .J,(ll:l_~ Standard Error of Intraclass 
__ _ _ ___________M(!a~Il!~ment _ _ _______ _____ __ _ ___c::~(!t'licient 9S%Ci 
2733.33 2925.00 
.- .. , ... ,., ........ "-- .. _------ .............. _---- 711.21 0.500 ________ ~(),()'!~_t() 0.825 
2916.67 i 
.... · .. ·· .. ·····'-----.. 7 .. _____ J~J~·.~Z: _ ________ _ ____ _ __ ______ ______ ______ ______§??~?_~ 0.796 (),1}3to 0.937 
r
iJ.rtp.L---------- _. __________ L _____ . ______ ~_?Jl_~_,~_~ __ ! .. __ . ______ ..... _._ .. 3.J.3.}_,~~,-
1 ! j 
I.JM.P._. _________ . __________ I_}JQ_~,~_~ ____ I _________ · ______ }?1JAZ __ .1. __ . ___ ---
4Q~,?1 __ ____ _ _____ _ ____ _ ___ __ ______Q,_1:I88 _____________ _Q,~EtoO. 96_6_ 
301.95 0.930 0.776 to 0.979 
I I i _.JP.JrI--------- ····--------e--- ___ ______ ~_1:Z~,_Q() __ j__I~??,()() __ L---. -----------______4Z~,.?J.___()At~J___ 0.515 to Q.948 
l ___ M.M~.P.L - L -------- -.?@-~,-~}-J-?~f3.-~-,~~----i----- -------- ----- --- ---}~-?-,~~l _ ----------_Q_,~QL~ ___ _____ (),?()1t()J~,9J~" MMP~~~-I.. 2915,00 i . .2941,67] 413,1B ' 0,B95 +_ DBOB to MB' 
--M!'I.!'L--------------i------- ·----------?-~()-I3.,-~-~---t __________________ EZ~,_Q() ___ +-------- --.4E·?I3.--·t -- ---- _____ ___ ()_,~?1 . .!..-.---.9-,E!!()-Q·9~~ < 
._.M.M_P. _____________ -------J------------}-~!!~,}~--i-- __ ________ I~_?_5,()()_J______ _______ . _____ . ___ -.-- __ 4~~,_?4: ___ i- _______________ ____ (),Z99 ______ Q,4:?J_t()Q,9~_? ____ : 
3358.33 I 3216.67 I 418.43 I 
_ .M!?JRL.-.------- -------------1-- ----------------------------j------------------------------f-- - - - - - -------------
RMCP1 I 2858.33 : 2841.67 I 572.46 i ~;~-~-l··-;~~~·~;r-~;;,;;r .... ··········-···::::~r 
.Jt.P.H>.L_i. ----?'~()Q'()()-I- _____ __ ~()TS._&() __ I ... -- ----------------------.'1'-- -
i RMP __ ___ I~_~_Q,().Q..! _____ }?_~_~_,~_~ _____ l- __ . _ ---?-I:I§,?}-i . -
r~;~-!-;;~-:-~~-::----~------------i ---~Js.().'Q()-t--n?Eq~---j__- -






I L.~P_ _ ________: 2900.00 ___ ?'_§9.!AZ __ :_ _ ______ _ 
i ~_~J:)!P.I ___________________?_ns.,QQ' __?_~?S.,QQ 
200 
292.86 • 







________________________ .Q,_1:I99 ________________ Q,@?~()0,970 _ 
0.785 : 0,411 to 0.973 
~.~s.~ __ r---- _ 0.850 to 0.987 







______ Q,ilH to 0.983 . 
___ ().?4:s._~c:J Q,I)??' ~ 
I 
0.779 to 0.980 • 
0.924 toO.933 . 
Q,~~1.~()O.987 . 
0.79()toQ,981 
Control group reliability study - dolorimetry scores for individual finger sites left 
hand 
1 ................................................ 7 ............... ••••••·•••••••••• .. ········T .. ···· .. · .... ···· .. · .. ·· .. ····· .. ·· .. ··-T .. ···· .. · .............................................................................. . 
, Finger' Mean Left ! Mean Left i Standard Error of ; ···-···········intracias·s··:···· .. ··_···· .. ··· .. ··_-· .. - r 
l ... ·· .. ··········.J~~·~·~·~~~·~····,··················· ..... !.s..Lt······················~·~·«:I···I··········~~~.s..':I.~!.I!!.~.':I.LL ................ ~~.~f!!.9.~!l.! ... ~ ....... _.-...... ~~~ .. ~L 
\~;~PL_.._. -::!!:!!i---!::':: I- - _._- - - - --- :;~;:.--- :!!;~-:!~!.~~; 
······································f··································· .. · .. · .. -··-f·_ .. -·····-·· .. ···· .. ·-···-·-l 
I I 579.28 : 0.709' 0.256 to 0.906 
······································1···· .. ···· .. ················ .. ··· .. ······---.. i···-.. ··· .. -··-··-·--· .... · .. ··l 
475.66 ' 0.831 I 0.515 to 0.948 i 
------- ---------"-------.--...... --......... ------------------.... ]" .. ------.--.--.----.. ----.. ----..... ------.. ,j-------------------."-1 
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Control group reliability study - dolorimetry ratios (right: left) for individual 
finger sites 
202 
Control group reliability study - dolorimetry scores for whole fingers right hand 
















0.91 00,719 tgQ~~?3 
0.9600.86Bto 0.988 
0.968 0.892 to 0.991 
0.985 0.950 to 0.996 
Control group reliability study - dolorimetry scores for whole fingers left hand 
Mean Score Mean Score 
1st i 2nd 
............................ ----------_._-----
Standard Error of 
Measurement Finger 
Index !?n6:~?! ...... . 16141.67 1131.94 
! 
Middle 
[{ing + ............... J5()?~~9QL . 
Little 15050.0Q L 




......................... ......... -........................ --... ~.2~·:Q·?····f···-·· 
1131.86 
.. ..... " .. - .. ------..... __ ........... -............ __ ............. _--. 
755.92 
Intraclass 
Coefficient 95% CI 
0.942 0.812 to 0.983 
0.961 0.872 to 0.989 
0.936 0.793 to 0.981 
0.974 0.912 to 0.992 
_. -... -
Control group reliability study - dolorimetry ratio (right: left) for whole fingers 







Mean RaJi(}2 Ild . Standard ErrorC>.(M~."'~I,l.~~.~~J:l~.. ~Ilt~~(;l'!~~c::()~f!icient 95% CI 
1.07 0.11 0.626 0.111 to 0.876 




0.671 0.188 to 0.893 
0.797r:~.~;7 t~ 0.937 
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Control group reliability study - dolorimetry scores for individual positions right 
hand 
r······ .. · 
I 
I ,oint Mean Score 1st Mean Score 2nd Standard Error of Measurement Intraclass Coefficient 95% CI I· .... ··· ....... " 


















0.977 0.922 to 0.993 
0.970 0.899 to 0.991 
0.970 0.899 to 0.991 
I 
. ·············· .. ······---r-.. _· ....... . 
0.972 0.906 to 0.992 
Control group reliability study - dolorimetry scores for individual positions left 
hand 
'oint Mean Score 1st Mean Score 2nd Standard Error of Measurement Intraclass Coefficient 95% CI 
MCPjs 11925.00 11858.33 662.32 0.959 0.865 to 0.988 
PPs 12683.33 I 12291.67 811.14 0.954 0.848 to 0.986 







Control group reliability study - dolorimetry ratios (right: left) for individual 
positions 
,oint Mean Ratio 1st Mean Ratio 2nd Standard Error of Measurement Intraclass Coefficient 95%CI 
...... ........ ~ 
---- .. ''--".' --.... 
0.94 0.94 0.16 0.579 0.039 to 0.857 ' MCPjs 
PPs 0.93 0.97 0.05 0.823 0.496 to 0.946 I 
. "'-"'1 
PIPJs 1.01 0.97 0.11 0.764 0.366 to 0.926 I 
--_._------- .. ----...... --.----... --_ .... -
0.99 1.01 0.07 0.855 0.573 to 0.956 MPs 
DIPjs 1.01 1.08 0.13 0.402 -0.194 to 0.731 
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Control group reliability study - dolorimetry scores for the whole of right hand 
Mean Score 1st Mean Score 2nd Standard Error of Measurement 
IntraclassCoefficient 95% CI 
36630.00 I 36040.00 1234.99 0.852 0.664 to 0.939 
. ___ ........ 1.. ............ _ .... . 
Control group reliability study - dolorimetry scores for the whole of left hand 
Standard Error of Measurement 
Intraclass Coefficient 95% CI 
1591.09 0.572 0.184 to 0.805 
Control group reliability study - dolorimetry ratios for the whole hand (right: 
left) 
Mean Ratio 1st Mean Ratio 2nd Standard Error of Measurement 
Intraclass CoeftJ<:i~IlL 95% CI 
1.01 ··················.·io.~.I··.·.····· 0.08 0.893 0.672 to 0.968 
205 
9.8 APPENDIX 5d 
Study group reliability study - dolorimetry scores for individual finger sites 
fracture side 
_ .......... ---........ 
Finger Mean Mean Standard Error of Intraclass Position 1st 2nd Measurement Coefficient 95% Ci .. , ... _-------.......... 
0.708 to IrvtCP) 1810 1560 292.76 0.919 0.979 
0.962 to IPP 2160 2070 126.96 0.990 0.998 
0.875 to IPIP) 1770 1730 215.39 0.967 0.992 
0.970 to IMP 
...................... + .. ..... ?330 .! 2190 
... 
110.82 0.994 0.999 
Ji)IPJ 2040 2040 i 184.70 
.................. + ......... 
0.919 to 
0.979 0.995 
i 0.770 to 
MrvtC~J 1690 1630 268.29 0.937 0.984 
0.512 to 
MrvtJ> 2030 1920 418.03 0.851 0.961 
0.840 to 
MPIP) 1650 1650 218.54 0.958 0.989 
0.905 to 
f .. ·tv1MY 2160 1990 206.71 i 0.976 0.994 .......... ........ ·····r··· .... ········ .. ··· 
0.731 to 
MDIP) 2100 2050 
... }1!i.21·t 0.926 0.981 
0.913 to 
>.I,{rvt~~J .... 1830 1740 167.51 0.978 0.994 
0.835 to 
RPP 1980 1960 263.80 0.956 0.989 
0.934 to 
RPIP) 1570 1560 139.75 0.983 0.996 
0.920 to 
RMP 2100 2170 206.71 0.980 0.995 
0.962 to 
1750 1730 99.46 0.990 0.998 L.RP!J:lJ 
._ ............. • .. 0 
0.685 to 
1330 1380 203.38 0.911 0.997 ~tv1q)L I .... · ..···· 0.896 to 
..... 1f32Q .. j ... 1750 149)9 .. 0.973 0.993 LPP 
0.912 to 
I 
0.977 0.994 J.PWJ ............................. + ............ 1550 ! 1570 122.51 .j ............. 
I 0.687 to 
LMP 1530 1480 238.15 0.912 0.977 
0.772 to 
251.22 0.938 0.984 
. ~J)IJ>L 1670 1... ......... 1670 .. 
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Study group reliability study - dolorimetry scores for individual finger sites 
control hand 
~~~~;~lM~~~~~~.~:O'~~~~:::~~~~~~~.~~~+~:::-
: .. !.!'IRl...... . .. H···········I··············?·~·~Q···l·················?·~Q.Q·····f· . ... .................... ·········J~·5.·~·~I:l··-i···· .. _ .... __q.:?I:!.~ .. ~ . ..Q:~3 ~.~o_9.: 996 
: IMP 361.11 i 0.938 • 0.772 to 0.984 
,r·······--_ .... · .. ·---·.... .. ····.·''------· .. ·.-···--------.·-·r ..... ·--· .... ············----·--.. -.--.--.... ---1------... --.. ---___ . 
211.40 i 0.980 i 0.923 to 0.995 . 
····· .. --.. ····---·----1-----···· .. ·--· .. ·-----·····- ...... ---.--.-------..... ---.---.:-.--.---.... ---.----, 
i 1 
..................... ......... ?Q!bI5. ... L.._. .._ ... .Q.~~fg.JJ>..'!~'!_to 0.99 L; 
I 
........... --~.~.~&5. .... L ................... _ ..Q.~}§ .. j._'!:?§~_tp..Q~?.~~ __ : 
1 
..... _ .... ....... .... . ............. ?.3. !~.61 .. ..1 ..._._ ... __ <!:.?§..5_+jgl.§.~t~.Q:~?L; 
171.28 i 0.986 ! 0.994 to 0.996 I 
.............................................. -............... ).. ···H .... H········ .. · .. ·H ....... _ ............... --.-. ..,.-... _ ........ _____ ... __ ........... i 
'e . .MP.!Pl . -- -............ 1. ....... - .. ·?·~·~Q· .. ·t ................. ? 7 40 . i . ·········- .. ··?·Q·Q~·QQ··+·-·······-···-O':~?I:l····I-Q:?.·!?!'?._o.:?.'!.Lj ~~:~!~~~l~---=:~:~r:~==~~;,;;1 
·········-········-·_·-.. ··_·····1-·--·-····· .. ·--_·····-......... -.; 
0.976 I 0.905 to 0.994 : 
.. H-............ H .. H···-· .. ···· .. ·-.. ·t-·--··--· .. ·····-····· ... _ ..-.,. 
0.968 I 0.878 to 0.992 I 
:::.::::::::-.::.~:~~_~.~:~'~~~;.~-~~-.~:~-~-.-: 
i 
I I' 141 87 ............. _...... ..... _ .. Q.~~~I} .. _ O.:~_s.!_tQ.Q.:?·?Jl ~;~E1~~:!I=:===-=;I~ ··::~;:t:!~~::::!: 
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Study group reliability study - dolorimetry ratios (right: left) for individual finger 
sUes 
... --......... _ ........... -._ ........... "(" .. · .. ··,,· .. · ...... · .. ·T·· ............... _-.,...... . .... __ ................. . .. ----..... --....... -................ -................ __ ... _-................ ~._. __ . ___ .. 
I I i 
Finger I Mean Ratio I Mean Ratio ! Standard Error of Intraclass 
Position i 1st I 2nd: Measurement Coefficient 95% CI 
I r' t' ---- ____ ... __ ........... 1... i' · .. ·• .... · .. · .. · .. ··························T······ .. ······-· ............. - ...................................•................ , ....... -.......................... • ............ __ ..... _ ...... _ ... _ ...... _. ___ ._._ .. .. 
IMCPJ : 0.77 I 0.74 i 0.13 1 0.884' 0.602 to 0.970 
IIPP!'" 'O.7sTo.7S t········ .. ················ 0.13 ' 0.893 I 0.631 to 0.972 
t··i;ip,· ........ · .... ····· .. ····'j"······-········ .. ··-0:·6S···r· .. -·· .... ·-............ 0:·66 .. r ..·· .. · ....········ ...... -...... ····0~iz·· .. !·· .. · .. -- .. ·· .. · .. ·· .. O:870--···0:·S63 .. t~0.966'" 
iMp····..jo.731 ".,"',. "'0:711 '" 0.13 : 0.861 1 0.538 to 0.964 1 
· .. · .. ·· .. ·-······························1· .. ········ .. ····················---T····················· .. ············ .. ·····r·· ...................... ·········-···················· .. · ..·· .... ······-···1 ...... --·---·-·-.. ····· .. ··-· .. ······ .. ;-...... --------.. -1 
IDIPJ I 0.83 I 0.81 ! 0.07 i 0.950 I 0.813 to 0.987 ' 
·MMCPJ···j····o:s'2l 0.50 ................. ·0.09t .. · .... ···· .. ·-· .. ········ .. ··· ........ 0·:0·4·7 i -"0:501 to"0.960 ~ 
.. ··· .. ······ .. ··--· .. ··--· .. ····· .. t······· .. · .... ·········· .. --············t········· ...... ····-.. · .. ·········· .. ······ ...................... . ....................................... + .... -... --.. --........... ·· ........ -.... ~.-.... --.-.-... ----i 
MMP i 0.71 0.69 0.18 I 0.703 i 0.175 to 0.917 i 
· .. ··-····-.. ·· .. -· .. ········· .. -·t·······--····· .. ··· .. --· .. · ............................................................................................................. ···· .. ············ .. ······r····· .. · .... · .... ··· .. ······· ...... ···-.... - ... -.. t--.... - -.--! 
.. _~=_IP! ......................... !i____O:S4r __ ~__________~:09_t____ __ O~~~+~~O~~~:~:'"_1 
~:~-,--~------:~:'-----~:t-----~:~~r~::: ::::-
"'RMC'i~J"" ·············1 .. ······· .. ····_·- · .... 0~6'i'·1 .. ····· .. ············ .. · ···0~63 .. -...... ............ ... ···· .. ··········-·····0:"17· .. ····· .. ········· .. ···········-···o·:5i5··l····~o:099 t~ 0.860-
t::PJ-' ---,[--~ ·--~~Jl····· ............ ····-.. ··············· .. ·· ..  .. ····-···· .. ::·::·::I'--==~~~F~I~~::~~ 
II ~~~~=:=~:=~::~~fr~_=:-=~==~~~~~~~r~j 
I·-LMCPJ--·· .. ············ .. ·!··· ...... __ .. ···· .. ····-o:·sz .. ······ .. · ..·················· .. ·0:·S·5 .. ·-[-·· .. ··· 0.10 t 0:~30J_ ... a..:~55 ~~.~.95~ i ~:7-=i=~==-=~l==-====~~ft=~=3~J=i~~~~iJ 
' .. ·'LMP---······· .. ·· .. ·-·T ···· ·· .... __ ·· .. ·O:49-.. t········ .. ····· .... ·····"0:;·9· r" .... ............... 0.11 t 0.748 .~.0.2~~to_.?~~!. .... 1 
I I ILl.................................. .. l·~~!.~J .. ·=~_ .... : .. ·t::.~:: .... :.::.~ ... o:~~:.·L: ... ::··::····.:·=~:~.~6.J.: .... :.......................... . .... ::~:~::::.~.~~~~:]:::::::: .. : .. ::.:. . .... ...... ~:~.=.~ .. l ........ ~:~~?~~.?.: ~B= .... ! 
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Study group reliability study - dolorimetry scores for whole fingers affected hand 
Finger Mean Score 1st Mean Score 2nd Standard Error of Measurement Intraclass Coefficient 95%CI 
Index 10110.00 9590.00 438.63 0.994 0.937 to 0.999 
Middle 9630.00 9240.00 648.35 0.984 0.937 to 0.996 
Ring 9230.00 9160.00 528.98 0.989 0.958 to 0.997 
Little 7900.00 7850.00 449.11 0.985 0.940 to 0.996 
Study group reliability study - dolorimetry scores for whole fingers control hand 
i-.. --·_·· __ ·· __ · __ ···· -
Finger Mean Score 1st 
Index 13300.00 




\ ..... _._._ .. __ ..... 





Standard Error of Measurement Intraclass Coefficient 95%CI 
- ------ .. ---- -_._ ... +----_ ... -_ .... __ .. __ .-... _ .. _ .._.-




0.993 0.971 to 0.998 
0.992 0.969 to 0.998 
0.991 0.966 to 0.998 
Study group reliability study - dolorimetry ratio (affected: control) for whole 
fingers 
Mean Ratio Mean Ratio Standard Error of Intraclass 
1st 2nd Measurement Coefficient 95%CI 
.-
0.863 to 0.991'-'\ 
Index 0.75 0.72 0.06 0.964 
--
Middle 0.61 0.60 0.04 0.970 
0.885 to 0.992 
0.62 0.04 0.974 0.901 to 0.994 Ring 0.60 · ...... ·_· .... 1 
0.55 0.56 0.04 0.967 
0.875 to 0.992 
Little 
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Study group reliability study - dolorimetry scores for individual positions 
affected hand 
Mean Score 1st Mean Score 2nd ,oint Standard Error of Measurement IntracIass Coefficient 95%CI tM~;: 6660.00 6310.00 381.32 0.987 0.949 to 0.997 7990.00 7700.00 390.61 0.992 0.967 to 0.998 
l 
PIPjs 6540.00 6510.00 479.95 0.982 0.930 to 0.996 
-L 
MPs 8120.00 7830.00 323.75 0.995 I 0.979 to 0.999 I 
--
................ " .......... 
.- ... -.----------......... _ .... " .... _-,-_ ... 
DIPjs 7560.00 7490.00 512.60 0.983 0.934 to 0.996 
Study group reliability study - dolorimetry scores for individual positions control 
hand 
Mean Score Mean Score Standard Error of IntracIass 
,oint 1st i 2nd Measurement Coefficient 
.. - .-... -.... _-.. _---_._ .... 
MCPjs 11050.00 10550.00 605.57 0.981 
PPs 11420.00 11250.00 541.72 0.988 
- -- ------.--~ .. 
PIPjs 11410.00 11550.00 672.56 0.982 
..... _--_ .. __ ........ , ....... 
MPs 12770.00 12310.00 402.96 0.994 
DIPjs 10740.00 10430.00 478.88 0.990 
Study group reliability study - dolorimetry ratios (affected: control) for 
individual positions 
-------------------1--------------------
,oint Mean Ratio 1st I Mean Ratio 2nd Standard Error of Measurement . IntracIass Coefficient 
MCPjs 0.58 0.57 0.04 0.952 
______ .. J.... 




0.57 0.56 0.06 0.936 
MPs 0.61 0.60 0.04 0.970 




. ::::::: :::~~ 
0.929 to 0.995 
-- -------------1 
0.976 to 0.999 
0.961 to O:_~~~_J 
95% CI 
0.819 to 0.988 
0.906 to 0.994 
0.765 to 0.984 
0.886 to 0.993 
0.788 to 0.985 
Study group reliability study - dolorimetry scores for the whole of affected hand 
Mean Score 1st Mean Score 2nd 
t:~:::::::::::::.: .... : 57390.00 56090.00 







0.984 to 0.999 
Study group reliability study - dolorimetry scores for the whole of control hand 
Mean Score 1st Mean Score 2nd 
36870.00 35690.00 
............................. 1. .................. . 






Study group reliability study - dolorimetry ratios for the whole hand 
Standard Error of 
Mean Ratio 1st Mean Ratio 2nd Measurement Intraclass 
Coeft:ic;i(!':1t .. 
" _._-------------------.,----
0.62 0.61 0.01 ' 0.992 i 
..... .1. .......... -------............ ,. 
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95%CI 
0.988 to 0.999 
95%CI 
0.967 to 0.998 
9.9 APPENDIX6a 
Joint movement measurements in 19 control subjects 
Statistical significance between the right and left hand was assessed using a 
paired t test. 
················ .. ··T···· .. · 
I Standard Standard 
Joint Right Mean Deviation Left Mean Deviation P-Value 
.......... ~--..... -.--- . 
IMCPJ 72.05 8.64 74.32 7.17 0.283 
I. 
IPIPJ 105.63 6.69 104.37 7.85 0.353 
IDIPI 67.89 11.43 70.26 10.29 0.245 
MMCPI 79.47 6.41 79.47 4.38 1.000 
MPIPJ 103.05 6.49 104.47 5.39 0.363 
"---_.,, ... "r----" 
MDIPI 74.26 13.17 76.00 10.01 0.455 
RMCPJ 81.68 5.68 80.16 6.44 0.260 
I 
-._--------..... -.. -......... 
6.31 0.465-·~ RPIPI 102.95 6.26 101.89 
RDIPI 70.42 10.77 . 70.68 14.33 0.917 
LMCPI 89.16 7.33 83.95 6.30 0.002 
LPIPI 97.00 10.68 95.16 7.68 0.469 
LDIPI 78.58 11.76 78.42 12.70 0.960 
. ---_ ................. 
Standard Standard 
Joint Right Mean Deviation Left Mean Deviation P-Value 
Hand Total 1022.16 . 53.52 1019.16 56.85 0.682 
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9.10APPENDIX 6b 
Cumulative finger movement differences (in degrees) for 19 control subjects. 
Patient No Age Sex Right - Left Left _ Right 
1 70.5 F 15 -15 
2 59.11 F 14 -14 
3 77 F 71 -71 
4 58.11 M 9 -9 
5 53.1 F 17 -17 
6 57.9 F 12 -12 
7 55.1 M 36 -36 
, 8 57.8 M 22 -22 
9 62.1 F 1 -1 
1. _____ ... _____ •••• ____ .· 
M 31 -31 I 10 67.8 
I 
~ ..... - •.............. 
11 75.2 M 53 - -53 I , , 
! 
12 67.1 F 5 -5 
.-.. ---_ .... _-_ ......... 
76.11 F 11 -11 13 
14 78.1 F 50 -50 
1 -1 15 56 F I 
"-1 
16 ; 57.1 F 7 -7 I 
17 57.2 M 46 -46 
.... ······1 
18 81.8 F 19 
-19 
----._->----_ •.. _---- ...... 35 -35 19 76.1 -, F 
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Control group cumulative finger movement difference data and histogram 

































Std. De ••. 092 
N "3& 
9.11APPENDIX 6c 




















···· ...... ·1 .......... ·]6.08 
82.42 
L. RPIPJ 102.33 
I RDIPI ". 72.50 
















... ,j .............. -.... _-_ .. " .. -. ---





Standard Error of Intrac\ass 
. Measurement Coefficient 95% CI 
3.84 0.898 0.686 to 0.970 
4.26 0.785 0.410 to 0.933 
4.43 
"",.----- ....... 
0.919 0.743 to 0.976 
4.63 0.733 0.302 to 0.915 
4.54 0.775 0.389 to 0.930 
2.73 0.980 0.931 to 0.994 
4.09 0.732 0.301 to 0.915 
3.03 0.864 0.595 to 0.959 
2.02 0.984 0.944 to 0.995 
2.36 0,l~1)!J t ...... 0.684 to 0.969 
1.90 0.981 0.935 to 0.994 
~,:t§ 0.975 0.917 to 0.993 
Control group reliability study - finger stiffness values for individual finger sites 
left hand 
Finger Mean Mean Standard Deviation of Error of Intrac\ass 
Position 1st 2nd Measurement Coefficient 95%CI 
Il'1C:.P.L . 76.50 77.08 3.63 0.855 0.574 to 0.956 
IPIPJ 103.33 102.58 2.34 0.949 0.834 to 0.985 
IDIP! i 73.75 72.58 2.56 0.964 0.880 to 0.989 
.. ·t ...... ·· . . ...... 
f 
81.50 3.18 0.837 0.582 to 0.950 MMCPJ i 79.92 
MPIPJ 103.50 102.50 2.11 0.873 0.617 to 0.962 
MDIPJ 76.50 77.17 3.18 L 0.943 0.815 to 0.983 
RMCPJ 79.00 80.58 3.71 0.835 0.524 to 0.950 
... ~PIPJ 102.58 102.75 2.82 0.838 0.532 toO,951 
RI)If>J. 73.50 75.58 2.38 0.981 0.936 to 0.995 
LMCPJ 84.00 83.50 2.06 0.923 0.757 to 0.977 
LPIPJ 
.. ·1· 
94.50 95.00 1.02 0.986 0.952 to 0.996 .. --
i 1.26 0.995 0.984 to 0.999 LI)IPJ i 77.67 78.00 
... ! 
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Control group reliability study - finger stiffness values for whole fingers right 
hand 
Finger Mean Score 1st Mean Score 2nd .~t<tI1d.<trd.E:rr()T.()fl~leasurement Intracla~sCoefficient 95% CI --------------···''-1" 
Index 249.33 246.75 4.96 0.944 0,1319 to 0.984 
Middle 259.42 ?S5.08 6.82 0.872 0.617 to 0.961 
~ Ring 257.25 253.83 6.14 0.913 0,7?8 to 0.974 
I Little 268.58 269.00 3.69 0.968 0.894 to 0.991 
Control group reliability study - finger stiffness values for whole fingers left hand 













..--......... -... -•.... ~--
Intraclass 
Coefficient 95% Cil 
-_. 'l 
9.9.63 0.793 to 0.981 
0.957 0.857 to 0.987 
0.929 0.774 to 0.979 
0.980 0.933 to 0.966 
. ... -
Control group reliability study - finger stiffness values for individual positions 
right hand 
Joint .. M.an Scoee ,,, . M.an Sc<><e~nd .~~d.,d.!COCor".a~c~m.~~+':~:CI""'C.o.fficl.nt 9 5% CI 











0.829 to 0.985 ,,\ 
0.964 to 0.997 






Mean Score ! Mean Score 
!~!...I"'''''''''''''' ......... 2nd 
319.42.1........ 322.67 
, 




Standard Error of 











0.958 to 0.996 
Control group reliability study - finger stiffness values for the whole of right hand 
Mean Score 1st Mean Score 2nd Standard Error of Measurement 
1 ___ ... ____ _ 
1 ___........ _--
-.- .. t·---1034.58 
, ..... -.. -_ .......... -... _ ......... --. 
1024.67 10.25 
Illtraclass Coefficient 95% CI 
0.963 0.877 to 0.989 
Control group reliability study - finger stiffness values for the whole of left hand 
Mean Score 1st 
r---------------- 1024.75 
I 
Mean Score 2nd 1 Standard Error of Measurement 
. .. ,,-._--
1028.83 8.17 
Intraclass Coefficient 95% CI 
................. _- . ....... -- .--.. -~---.--- . 
0.997 0.987 to 0.999 
Control group reliability study - finger stiffness values differences for the whole 
hand (right - left) 
Mean Ratio 1st Mean Ratio 2nd 
1. ___ _ 
4.67 -4.17 




Intra class Coefficient 95% CI 
-- -.-.-------------- ..... -- -0.687- --0.216 t~0.89<) 
9.12APPENDIX 6d 













LPlI'I ............................ . 















Mean 2nd ofMea~urement 













0.938 to 0.996 
0.832 to 0.989 
0.954 to 0.997 
0.956 to 0.997 













2.67 I 0.983 
r·· 
2.68 I 0.974 
·····················t .............. .. 
1.81 0.987 
0.933 to 1.000 
0.935 to 0.996 
0.973 to 0.998 
0.934 to 0.996 
0.898 to 0.993 ~ 
I 
0.948 to 0.997 
Study group reliability study - finger stiffness values for individual finger sites 
control hand 
Standard Error Intraclass 
. Finger Position Mean 1st Mean 2nd of Measurement Coefficient 95%CI 
IM~i>J 72.20 72.30 1.77 0.949 0.809 to 0.987 ........ ---_. 
I 
i 0.960 0.849 to 0.990 IPIP) 99.80 ! 99.30 2.23 
···t··" .. -
! 1.36 0.994 0.976 to 0.999 !DIP) 62.70 61.90 
... _,,--- .. -, .. -- .. 
MMCP) 79.40 79.30 2.39 t· ..... 0.868 0.557 to 0.965 
MPIP] 102.50 100.30 2.47 
I 
0.943 0.788 to 0.986 
MDlP) 71.50 71.00 1.99 0.991 0.962 to 0.998 
.RMCPL 81.50 81.50 0.92 0.993 0.971 to 0.998 
I~J)II'L 98.50 97.90 1.66 0.984 0.936 to 0.996 
RDIP) 61.60 60.60 1.24 0.995 0.979 to 0.999 
LMCP) 80.30 80.40 1.62 0.981 0.926 to 0.995 
LPIP) 90.30 89.20 1.27 0.991: 0.977 to 0.999 
66.20 1.36 0.984 0.937 to 0.996 LDIP) 66.00 
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Study group reliability study - finger stiffness values for whole fingers affected 
hand 
. JI ; Standard Error 





<:()f! ffi ci e n t 
0.971 
95% CI 
0.887 to 0.993 














0.968 to 0.998 
0.963 to 0.998 
0.960 to 0.997 Li!tl(! ... ___ ................... 1?T 19 .. , ...................... !.?8.00 
""" ... ---_ .. _---------
Study group reliability study - finger stiffness values for whole fingers control 
hand 
...... _,_ ..... _ ....... _.-. 
Standard Error Intraclass 
.~.i.~g~! . Mean Score 1st Mean Score 2nd of Measurement Coefficient 95% CI 
---------------_ ...... --. 
Index 231-,'70 233.50 2.61 0.991 0.963 to 0.998 
Middle 253.40 250.60 2.14 0.994 0.976 to 0.999 
lUng .. 241.60 240.00 1.90 0.996 0.983 to 0.999 
Little 236.60 235.80 2.02 0.993 0.972 to 0.998 
Study group reliability study - finger stiffness values for individual positions 
affected hand 
r-········ · ...... · ..-·-.. -r .. · .. · ... .. .. .. -.... ·-1-----.. --· .... 
I Standard Error 
I()illt. Mean Score 1st Mean Score.~~~ ... of Ml,!asurf!lJl.ent 
MCPjs 
. PIf'Js .... 

















0.992 to 1.000 
0.987 to 0.999 
0.991 to 0.999 
Study group reliability study - finger stiffness values for individual positions 
control hand 
Mean Score Mean Score Standard Error of 
Intraclass 
Coefficient 95%CI j()int 1st 2nd Measurement I ...... 
.. T ...... ·-
3.39 0.977 0.909 to 0.994 MCPjs 313.40 313.5.9... ............... .... 
0.987 0.949 to 0.997 4.41 L .... PIPjs 391.10 .. 386:?9. 
I 0.992 to 1.000 2.42 0.998 
DIPjs 261.80 259.70 
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Study group reliability study - finger stiffness values for the whole of affected 
hand 
................ " .......... ,,----_._----_ ..... _----... . 
Standard Error of 
Mean Score 1st Mean Score 2nd Measurement 
771.00 767.20 
................. L ...."" ....... "" .. " .... . 5.17 
Intraclass 
. Coeffi(:i~llt .. 
0.997 
95%CI 
0.989 to 0.999 
Study group reliability study - finger stiffness values for the whole of control 
hand 
,'-""'"-'''''''-''' ! Mean Score 1st 
.................................. , .... ----........ _.--._-
Standard Error of 
Mean Score 2nd . Measurement Intraclass 
Coefficient 95% (I 
......... __ ........... ---..... . 
966.30 959.90 3.92 0.997 . 0.987 to 0.999 
___ .. _l._. ____ ._. 
Study group reliability study - finger stiffness values differences for the whole 
hand (affected - control) 
Mean Ratio 1st Mean Ratio 2nd 
-195.30 -192.70 
Standard Error of : 
Me,Meme.' l ~::~~:~:_ 
6.s1' .. j··"·" .... ·_·"" .. ,,.. 0.996 
..• ___ • _____ 1 __ •• ___ •• __ ••••• ____ .••••••.• _____ ••• _ ... 
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95% (I 
0.983 to 0.999 
9.13APPENDIX 7a 
Control group index finger swelling normality measurements (mm) and ratios in 
19 subjects 
I" PtNo. 
f. ... _ .. _ ..... . 
I 1 






~-..... -.. -.. .... 5 








































M . 24.67 


















M ' 23 19.67 
.. --_. __ .... __ .. -_ .... 














































10.33 10 1.03 
--_ ... -"'--- --
9.33 7.33 1.27 
13.33 12.67 1.05 
............. 1.._ ... __ .. _ .. 
25.67 24 1.07 
·14.3-3·+··--······· __ ··- "15-' .. _ ..... _ ...... _...... 0.96 
15 14 1.07 
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Index finger swelling ratio normality data and histogram 
6 












Std. Error of Skewness 
Kurtosis 
























M ~J l. Ol 
Std . Dev l 6S 
N 3S 
9.14APPENDIX 7b 
Control group reliability study - index finger swelling left hand 
Mean Score 1st Mean Score 2nd 
15.73 15.54 





.---_ ...... -----... ~ .... . 
0.996 
Control group reliability study - index finger swelling right hand 
Mean Score 1st Mean Score 2nd 
17.21 17.26 






Control group reliability study - index finger swelling ratio (Right: Left) 
Mean Score 1st Mean Score 2nd 
1.12 1.14 
.. _--_ .... _-_ .... __ ..... _ ... ------- ....... _-_ .. . 








0.989 to 0.998 
95%CI 
0.977 to 0.996 
95%CI 
0.557toO.919 
.. _. __ .... __ ..l 
9.15APPENDIX 7c 
Study group reliability study - index finger swelling affected hand 
: .. ····· .. ···r··· .. ·· .. 
I Mean Score 1st 
I ................  
I 
l 14.93 
Standard Error of 
Mean Score 2nd Measurement 
...........f.-.............  
15.10 I 0.41 




Study group reliability study - index finger swelling control hand 
Standard Error of . 
Mean Score 1st Mean Score 2nd Measurement Intraclass 
.,..........................Coefficient 
11.87 11.90 0.38 : 0.980 
.1. .. 
95%CI 
0.929 to 0.995 
95%CI 
0.921 to 0.995 
Study group reliability study - index finger swelling ratio (affected: control) 
Standard Error of 
Mean Score 1st Mean Score 2nd Measurement 




..... _----- - ------ .. --.... --~--... 
0.964 
95% CI 
0.864 to 0.991 
9.16APPENDIX 8a 
Control group hand grip strength measurements and ratios in 19 subjects. 
PtNo. Age Sex Right Left Ratio R:L Ratio L:R 
l·l 70.5 F 42 42 1 1 [. 
i 2 59.11 F 30 31 0.97 1.03 I I 1..-........ 
I 3 77 F 21 19 1.11 0.9 I l-- -----.--... ------------,------4 58.11 M 40 38 , 1.05 0.95 
... _0_.' .. _---------------_ ....... ." ....................... ; ................................................... -........... --... ---.1-----... -..... .. "" .. ,. -_ .... _-_ .... , 
5 53.1 F , 20 17 ! 1.18 0.85 
.• , ..••••• _--------_. __ ._-.j •••••• 
6 57.9 F 26 , 20 1.3 0.77 
.. -.- -----_.-._-----. ---_._---_ ...... 
7 55.1 M 39 42 0.93 1.08 
-1 
8 57.8 M 52 58 0.9 1.12 ! 
9 62.1 F ! 32 33 0.97 1.03 
i 
. _, .. __ ................... ._---------- ......... ----.... ---... ,,- .. 
, 
10 67.8 M 25 20 1.25 0.8 
f··_················ 11 75.2 M 44 43 1.02 0.98 
~.-......... -.-. 
12 67.1 F 22 24 0.92 1.09 , 
.+ 
13 76.11 F 18 14 1.29 0.78 
22 I···· 1.1 0.91 14 78.1 , F 20 
15 , 56 F 25 22 1.09 0.88 
..... -.. -------_.---_ ..... 
16 57.1 F 24 20 1.2 : 0.83 I ..+ ........ _-_. __ . L_ .................. __ •. 1.03 0.97 I 17 57.2 M 34 ! 33 i 
--.~--.... -.......... --.. ------ ,------ 0.89 -·······-·1 18 81.8 F 16 18 1.13 
.............. 
... -_ .. 
I 19 76.1 F 18 18 1 1 I 
........... _--_ ....... _1 .............. _ .......... I L. ___ •• __ 
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Control group grip strength no rmali ty data and his togram 
6 











Std. Error of Skewness 
Kurtosis 


























Mc~n 1. (1 1 
Std . Dcv . 166 
N 33 
9.17 APPENDIX 8b 
Control group reliability study - grip strength left hand 
Standard Error of 
Mean Score 1st Mean Score 2nd Measurement 
28.00 28.26 0.81 
Control group reliability study - grip strength right hand 
Mean Score 1st Mean Score 2nd : 
28.95 29.16 
Standard Error of 
Measurement I 
_._ .. _-----_ .. ---------_ ..... _.j ..... _ ..._ .......... . 
1.15 
.............................. --.... _-
Control group reliability study - grip strength ratio 
Standard Error of 
Mean Score 1st Mean Score 2nd Measurement 
.. -........ . 












0.988 to 0.998 
95%CI 
0.969 to 0.995 
95%CI 
0.537 to 0.914 
9.18APPENDIX 8e 
Study group reliability study - grip strength affected hand 
r·············· 
I 
\ ............... Mean Score 1st 
l ... _..... 8.83 
Mean Score 2nd 
9.30 






Study group reliability study - grip strength control hand 
Mean Score 1st , Mean Score 2nd 
I 24.74 25.74 
1.. .. 






Study group reliability study - grip strength ratio (affected: control) 
Mean Score 1st Mean Score 2nd 
0.31 0.32 








0.984 to 0.999 
95%CI 
0.991 to 0.999 
---l 
95% CI 
0.728 to 0.981 
9.19APPENDIX 9 
Study exclusion reasons 
!_ ........ o. 
j 
PTNo AGE SEX REASON FOR EXCLUSION 
1 74 F Takes 5g Vitamin C daily 
2 80 F Lives in Dorset normally and unable to return for follow up 
3 84 F Patient refusal 
4 70 F Presented more than one week post injury 
5 I 83 F Patient suffers with dementia/memory loss 
L,,~ ..... __ ... I 
······1-···· .. · 
~1 ... 76 F Fracture requires internal fixation I ........... ~ ........ " 
7 87 F I Patient suffers with dementia/memory loss 
8 75 F Sustained bilateral wrist fractures 
9 97 M Dementia/ipsilateral humeral fracture 
10 73 F Presented more than one week post injury 
11 74 F Recent bereavement and patient refusal (injury at husbands funeral) 
12 88 F Previous cerebrovascular accident and Parkinsons disease 
13 71 F Bilateral Dupytrens disease affecting hands 
14 74 F Patient suffers with dementia 
15 61 F Takes 500mg ascorbic acid daily 
, 16 i 54 F Ipsilateral humeral fracture 
i ...... ;. .. ,. __ ........ 
r 17 74 F Patient refusal 
1-··_····· .. ·· 18 89 F Patient suffers with dementia 
r········· .. ·· ...... 
56 F Fracture requires internal fixation I 19 
1 t···· 
20 i 86 F Patient suffers with dementia 
I" F Patient registered blind I 21 82 I I .......... -. .... j'"'' Patient suffers with Parkinsons disease I 22 77 F I 
f··· 23 86 F Patient suffers with dementia 




! 25 72 F P~ese~ted m~~~ tha~one week following injury i 
t············ 26 66 F 
..... -...... -... 
..... 
Fra~ture req~i~es internal fixation 
......... ~ .... -..... .-.... . ............................................ 
71 M I Non English speaking patient I 
! 28 I 55 F '6p~n' w~ist:f~~~hI~~sustained 
j ......................... J ....... Skel~tal m~t~stases fr~m pri~arYbreast: carcinoma both humeri , 29 ! 65 F 
229 
9.20APPENDIX 10 




43 60 F 
REASON FOR WITHDRAWAL 
Patient withdrew, not wishing to participate in trial follow up 
Patient developed dementia following further fall and subs~q~~~t hip 
fracture 
Patient withdrew, not coping with medication and not wishing to 
in trial follow up 
Patient developed significant cervical radiculopathy secondary to long 
56 77 F standing neck injury following wrist fracture 
----~,- ------.--~- --_!_-----------_ .. --.- --------'---,- -----------------------~----.-... ----,------------, .----. . ----.------------------------.------~---.----------.-----~.--
137 62 F Patient withdrew, not wishing to participate in trial follow up i 
--
151 83 F Patient withdrew, not wishing to participate in trial follow up 
--t------ ---------------------I-------------------~--------------------------------_ 




158 58 F Unable to contact patients and therefore lost to follow up 
-~--- - .---------------
165 S4 t F Unable to contact patients and therefore lost to follow up 




Patient withdrew, not wishing to participate in trial follow up 187 IF 
r ------------191 I 62 __ ~_ I U~able to -contact patients and therefore lost to follow up 
I 200 t 74 I F ! Unable to contact patIents and therefore lost to follow up __ l --------~-, --- ---r--r----1-----+ Pati~nt withdrew, ~nabt;t~ swallow medications and not wishing to 
I I I 
212 i 80 I F I participate in ~ial fOll~~_ up_ ___ ________ _ _ _ 
____ -l__ __ ______ -___ _ 
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9.21APPENDIX 11 
Patients excluded from study per protocol analysis 
r--'---' PtNo I Age Sex Reason 
<-----I 9 79 F Study medications not completed 
11 75 M Study medications not completed 
,,---------,- ... "-" ,~~-------~ •• .... ,,···~·~·· _______ N __ ' _____ _ •• 
13 80 F Study medications not completed 
14 79 Study medications not completed 
46 i 83 Study medications not completed 
--63 50 F Study medications not completed 
66 78 F --Study medications not completed 
-74 76 F Study medications not completed 
-i 79 71 • F Study medications not completed , j 1 : Significant medication break taken during trial period due to illness 
84 74 F (medications eventually completed) 
.. __ .... 
99 67 M Study medications not completed 
. 
112 73 I F Study medications not completed 
i 
146 81 ! F Study medications not completed 
.. _----, 
162 67 F Study medications not completed 
.. ,---.. ---~~-----.. -----.. 
186 64 F Study medications not completed 
.. -----.. _------,-_ .... _--_ ... 
-------,-----,---,--------""--
193 80 F Study medications not completed 
--- -- --- _.. ----------,----,,----
288 I 72 i F Study medications not completed 
297 • 72 I F displacement of fracture requiring internal fixation 
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9.22APPENDIX 12 
Effect of ascorbic acid on the features of complex regional pain syndrome 
Per protocol analysis 
Ascorbic acid Placebo Significance 
n=89 n=89 
Visual Analogue Scale n=89 n=89 U=3608.000 Mean (950/0 CI) 23.8 (18.4-29.9) 19.2 (14.4-24.3) Z=-1.096 
Range 0-98 0-88 p=0.274 
(max score = 100) 
Short form McGill pain score n=88 n=89 U=3633.500 
Mean (950/0 CI) 4.4 (3.2-5.7) 3.8 (2.6-5.0) Z=-0.894 
Range 0-27 0-27 p=0.372 
(max score = 39) 
Vasomotor Instability Score n=89 n=89 U=3813.500 
Mean (950/0 CI) 2.4 (1.9-3.0) 2.2 (1.7-2.9) Z=-0.439 
Range 0-10 0-10 p=0.662 
(max score = 11) 
Dolorimetry ratio n=89 n=89 U=3909.000 
Mean (950/0 CI) 0.88 (0.84-0.93) 0.88(0.84-0.91) Z=-O.lSO 
Range 0.38-1.30 0.20-1.35 p=0.882 
Abnormal dolorimetry ratio n=89 n=89 X2=0.417 
Yes 30(33.7%) 26(29.2%) p=0.628 
No 59(66.3%) 63(70.8%) 
Index finger circumference n=89 n=88 U=3694.000 
ratio Z=-0.6S0 
Mean (950/0 CI) 1.09 (1.04-1.15) 1.10 (1.06-1.15) p=0.517 
Range 0.65-1.88 0.71-1.69 
Abnormal index finger n-89 n 88 
circumference 
14(15.9%) Yes 14(15.7%) x2=0.001 
75(84.3%) 74(84.1%) p=1.000 No 
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Finger stiffness (degrees) n=89 n=89 (Cumulative ROM 
U=3812.000 difference) Z=-0.431 
Mean (950/0 CI) 
-5 8 (-7 6 to -41) 
-66 (-84 to -48) p=0.668 
Range 
-372 to 88 
-400 to 56 
Abnormal finger stiffness n=89 n=89 ;(=0.215 Yes 32(36.0%) 35(39.3%) p=0.757 
No 57(64.0%) 54(60.7%) 
Grip strength ratio n=89 n=89 
Mean (950/0 CI) 0.56 (0.52-0.60) 0.53 (0.49-0.57) t=0.775 
Range 0.15-1.17 0.13-1.07 p=O.439 
Abnormal grip strength n=89 n=89 
ratio X2=O.146 
Yes 69(77.5%) 71(79.8%) p=0.849 
No 18(22.5%) 16(20.2%) 
Abnormal hair growth n=88 n=89 
reported 
Yes 15(17.0%) 16(18.0%) X2=O.027 
No 73(83.0%) 73(82.0%) p=1.000 
Abnormal finger nail growth n=88 n=89 
reported 
Yes 23(26.1%) 36(40.4%) X2=4.079 
No 65(73.9%) 53(59.6%) p=O.056 
Fine motor control n=88 n=89 
dysfunction reported 
X2=0.302 Yes 34(38.6%) 38(42.7%) 
No 54(61.4%) 51(57.3%) p=0.647 
Tremor reported n=88 n=89 
Yes 17(19.3%) 10(11.2%) X2=2.236 
No 71(80.7%) 79(88.8%) p=O.149 
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Reported hand and finger symptoms following distal radial fracture 
Per protocol analysis 
Ascorbic acid Placebo Significance 
n=89 n=89 
Any reported pain 
Yes 47 (52.8%) 41 (46.1 %) X2=0.809 
No 42 (47.2%) 48 (53.9%) p=0.454 
Spontaneous pain 
Yes 27 (30.30/0) 24 (27.0%) X2=0.247 
No 62 (69.7%) 65 (73.0%) p=0.740 
Exercise induced pain 
Yes 42 (47.20/0) 34 (38.2%) X2=1.470 
No 47 (52.8%) 55 (61.8%) p=0.289 
Allodynia 
Yes 19 (21.30/0) 17 (19.1%) X2=0.139 
No 70 (78.7%) 72 (80.9%) p=0.852 
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Reported features of vasomotor instability 
Per protocol analysis 
Ascorbic acid 
n=89 





























The relationship of patient reported pain (Visual analogue score) and 
finger tenderness (dolorimetry ratio). 
Per protocol analysis 
Pearson's correlation coefficient 
Visual analogue score and 0.424 (95 0/ 0 CI 0.280-0.560) 
Dolorimetry ratio p=<O.OOOl 
The relationship of reported pain and abnormal finger tenderness 
(dolorimetry ratio <0.83) 
Per protocol analysis 
Abnormal Normal Significance 
dolorimetry Dolorimetry 
n=56 n=122 
Any pain symptoms 
Yes 39(69.6%) 49( 40.2%) X2=13.343 
No 17(30.4%) 73(59.8%) p=<O.OOOl 
Spontaneous pain 
Yes 23(41.1%) 28(23.0%) X2=6.165 
No 33(58.9%) 94(77.0%) p=0.02 
Pain on exercise 
only 
40(32.8%) X2=15.565 Yes 36(64.3%) 




17(13.9%) X2=9.510 Yes 19(33.9%) 
No 37 (66.1 %) 105(86.1 %) p=0.003 
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The relationship of patient reported swelling and index finger 
circumference. 
Per protocol analysis 
Abnormal index Normal index 






Yes 19(67.9%) 49(32.9%) )(2=12.184 
No 9(32.1%) 100(67.1%) p=0.001 
The relationship of patient reported finger stiffness and measured finger 
stiffness. 
Per protocol analysis 
Abnormal finger Normal finger 




Yes 48(72.7%) 35(31.5%) )(2=28.206 
No 18(27.3%) 76(68.5%) p=<0.0001 
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The relationship of measured index finger circumference and measured 
finger stiffness 
Per protocol analysis 
Abnormal finger Normal finger 






Yes 22(27.3%) 6(5.4%) X2=24.242 
No 44(72.7%) 105(94.6%) p=<O.OOOl 
The relationship between reported severe weakness and an abnormal grip 
strength ratio 
Per protocol analYSis 
Abnormal grip Normal grip Significance 




Yes 117(84.2%) 14(41.2%) X2 =27.471 
No 22(15.8%) 20( 48.8%) p=<O.OOOl 
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The relationship between reported and observed trophic changes in the 
affected hand. 
Per protocol analysis 
Abnormal Normal growth Significance 
growth observed observed 
Patient reported n=14 n=163 
abnormal finger 
nail growth X2=18.770 
p=<0.0001 
Yes 12(85.7%) 47(28.8%) Fisher's test 
No 2(14.30/0) 116(71.2%) p=<O.OOOl 
Patient reported n=30 n=147 
abnormal hair 
growth 
Yes 20(66.70/0) 11(7.5%) X2=60.409 
No 10(33.30/0) 136(92.5%) p=<O.OOOl 
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The relationship between the development of complex regional pain 
syndrome and patient demographic variables 
Per protocol analysis 
CRPS No CRPS Significance 
(n=25) (n=154) 
Gender 
Male 2(8.00/0) 75(49.3%) Fisher's test 
Female 23(92.0%) 77(50.7%) p=0.743 
Age (Years) 
Mean (950/0 CI) 66.2 (62.6-69.7) 69.5 (67.8-71.0) t=-1.517 
Range 51.0-83.0 50.0-92.0 p=0.131 
Smoking 
Yes 5(20.0%) 22(14.4%) X2=0.528 
No 20(80.0%) 131(85.6%) p=0.546 
Working status 
Working 10(40.0%) 42(27.5%) X2=1.636 
Not working 15(60.0%) 111(72.5%) p=0.237 
Side injured 
Left 12(48.0%) 94(61.4%) X2=1.611 
Right 13(52.0%) 59(38.6%) p=0.272 
Dominant arm 
Affected? 
Yes 13(52.0%) 62(40.5%) X2=1.161 
No 12(48.0%) 91(59.5%) p=0.383 
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CRPS No CRPS Significance 
(n=27) (n=169) 
Multivitamins 
Yes 5(20.0%) 16(10.5%) Fisher's test 
No 20(80.0%) 137(89.5%) p=0.183 
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The relationship between the development of complex regional pain 
syndrome and fracture management variables 
Per protocol analysis 




Yes 19(76.0%) 75(49.3%) X2=6.126 
No 6(24.0%) 77(50.7%) p=O.017 
Fracture 
remanipulated 
Yes 3(12.0%) 16(10.4%) Fisher's test 
No 22(88.0%) 137(89.6%) p=0.734 
No. of days 
immobilized 
U=1255.000 
Mean (950/0 CI) 42.4 (40.0-43.0) 39.3 (38.2-40.6) Z=-2.425 
Range 29-61 24-65 p=O.015 
Plaster problems 
reported 
Yes 7(28.0%) 23(15.0%) X2=2.579 




Yes 16(64.00/0) 46(30.1%) X2=10.902 
No 9(36.00/0) 107(69.9%) p=O.OOl 
242 
Demographic data 





Mean (950/0 CI) 69.5 (67.4-71.6) 
(Range) 50.0-91.0 
Sex n=89 
Male 11 (12.40/0) 
Female 78 (87.6%) 
Smoker n=89 
Yes 10 (11.2%) 
No 79 (88.8%) 
Employment n=89 
Retired 61 (68.50/0) 
Employed 26 (29.2%) 
Housewife 2 (2.2%) 
Fractured wrist n=89 
Dominant side? 
Yes 35 (39.3%) 






















40 (44.9%) p=0.544 
49 (55.1%) 
243 
Fracture management data 





Yes 41 (46.1%) 
No 48 (53.9%) 
Type of anaesthesia n=41 
used 
Biers block 23 (56.10/0) 
Haematoma block 7 (17.1%) 
Sedation 11 (26.8%) 
General anaesthetic o (0%) 
Fracture n=89 
remanipulated 
No 79 (88.8%) 
Yes 10 (11.2%) 
Time in plaster cast n=89 
(Days) 
Mean (95 O/oCI) 39.8 (38.2-41.4) 
Range 27-65 
Physiotherapy after n=89 
cast removal 
Yes 32 (36%) 















80 (89.9%) p=0.875 








30 (33.7%) p=0.875 
59 (66.30/0) 
Trial medicine data 
Per protocol analysis 
Days recruited post 
injury 









Bottles not returned 
Clinical assessment 
(Days post injury) 
Mean (95% CI) 
Range 
Ascorbic Acid Placebo 
n=89 n=89 
n=89 n=89 
2.9 (2.4-3.4) 3.6 (3.1-4.1) 
0-7 0-7 
n=89 n=89 
89 (100%) 89 (100%) 
0(0%) 0(0%) 
n=89 n=89 
70 (78.7%) 66 (74.2%) 
19 (21.3%) 23 (25.8%) 
n=89 n=89 





•• ~r""\, A r"'\'\..1 
54-156 
Significance 
U=3030.000 
Z=-2.055 
p=O.04** 
X2=<0.0001 
p=1.000 
X2=0.499 
p=0.597 
U=3801.000 
Z=-0.464 
p=0.644 
